Nicole Gray

2603 articles by Nicole Gray

• PhRMA: US remains vaccine R&D leader

  Aug. 19, 2016

• Roche, Eleven Bio eye the ocular market

  Aug. 19, 2016

• Nutrinia raises $30M for pediatric oral insulin

  Aug. 19, 2016

• Chinese/Indian manufacturing facilities facing repercussions

  Aug. 18, 2016

• Another Indian API facility added to EU's 'do not import' list

  Aug. 18, 2016

• FDA expedites Aspen's prostate drug ahead of merger

  Aug. 18, 2016

• Trek Therapeutics in-licenses Medivir hep C drug

  Aug. 18, 2016

• Rasna Therapeutics taps public market with merger

  Aug. 18, 2016

• GSK enters pay-for-performance deal for gene therapy

  Aug. 17, 2016

• Ipsen hopes to be David to Allergan's Goliath

  Aug. 17, 2016

• JAMA: PCSK9s should cost $4536, but don't

  Aug. 17, 2016

• Chiasma slashes staff as problems persist

  Aug. 16, 2016

• Boehringer seeks real-world data to support reversal agent

  Aug. 16, 2016

• Cynapsus proceeds after safety OK

  Aug. 16, 2016

• Aurinia succeeds, but safety concerns loom

  Aug. 16, 2016

• Allergan to consolidate operations in NJ

  Aug. 12, 2016

• Mallinckrodt plans regen med acquisition

  Aug. 12, 2016

• Gilead licenses bi-specific tech from Danish biotech Genmab

  Aug. 12, 2016

• Spark Therapeutics on track to file gene therapy in 2017

  Aug. 11, 2016

• Medivation bullish on Xtandi as PDUFA approaches

  Aug. 11, 2016

• AstraZeneca bolsters stake in Moderna by $140 million

  Aug. 11, 2016

• Shire launches new treatment for hereditary bleeding disorder

  Aug. 10, 2016

• AstraZeneca's lung cancer hopeful fails in Phase 3

  Aug. 10, 2016

• Novartis execs indicted in bribery scandal—this time in Korea

  Aug. 10, 2016

• BIO president defends Orphan Drug Act after op-ed criticism

  Aug. 9, 2016

• Swiss Helsinn picks up late-stage cancer drug from MEI Pharma

  Aug. 9, 2016

• Does MannKind have a shot at a successful Afrezza re-launch?

  Aug. 9, 2016

• Biosimilar battle heats up as AbbVie sues Amgen over Humira copy

  Aug. 8, 2016

• Experimental asthma pill from Novartis posts encouraging results

  Aug. 8, 2016

• Merck locks up another cancer approval for Keytruda

  Aug. 8, 2016

• Chinese drug manufacturer lies to FDA, promptly gets banned

  Aug. 4, 2016

• Keryx says Auryxia shortage 'imminent'

  Aug. 4, 2016

• FDA hits Adaptimmune with partial hold on T-cell therapy

  Aug. 4, 2016

• New poll suggests Big Pharma losing battle over CA pricing ballot

  Aug. 4, 2016

• UK court orders coverage of Gilead's HIV drug in England

  Aug. 3, 2016

• With new exclusions, payers draw line on pricing

  Aug. 3, 2016

• Big Pharma benefits more from breakthrough therapy designations: report

  Aug. 2, 2016

• Celgene facing charity-related kickback allegations

  Aug. 2, 2016

• Lymphoma drug from Takeda, Seattle Genetics beats out existing meds in late-stage trial

  Aug. 2, 2016

• Private equity firm Advent buys 50% stake in InVentiv

  Aug. 1, 2016

• Tokai cuts workforce by 60% after phase 3 failure with prostate cancer drug

  Aug. 1, 2016

• Bayer leans on partnering for new growth

  July 31, 2016

• Editas teams up with Italian gene therapy institute

  July 29, 2016

• US, UK pledge to combat antibiotic resistance through new alliance

  July 29, 2016

• Shnaghai Fosun to buy large stake in Gland Pharma for $1.4 billion

  July 28, 2016

• Pfizer may sell its stake in Latin America's largest manufacturer

  July 28, 2016

• Phase 1 trial reveals high efficacy for hemophilia A gene therapy

  July 28, 2016

• GSK enters $230 million licensing deal with Janssen

  July 28, 2016

• Janssen: Bristol-Myers' newest Opdivo combo research partner

  July 27, 2016

• J&J, Genmab line up second-line use for multiple myeloma med

  July 27, 2016

• Tokai Pharma tumbles after Phase 3 failure

  July 27, 2016

• FDA strengthens warnings on class of antibiotics

  July 26, 2016

• Celgene abandons plans for new Revlimid indication after trial disappointment

  July 26, 2016

• Regulators to expedite review of Merck's Ebola vaccine

  July 26, 2016

• Kite eyes off-the-shelf T-cell therapies with UCLA research deal

  July 26, 2016

• FDA delays decision on Merck's C. diff drug

  July 25, 2016

• Japanese government to set new controls on specialty drugs: report

  July 25, 2016

• After scandal, China begins vaccine inspections nationwide

  July 25, 2016

• Amgen, Allergan get biosimilar lift with positive data on Herceptin copy

  July 22, 2016

• Theranos expands compliance team with new execs, committee

  July 22, 2016

• Pfizer presses on with expansion of Irish manufacturing site

  July 21, 2016

• Merck KGaA building $115 million life science facility in MA

  July 21, 2016

• Novartis CEO sees more restrictive drug pricing to come in US

  July 21, 2016

• Mylan gets 'all clear' from EU regulators for $7.2 billion Meda deal

  July 21, 2016

• What's so scary about biosimilars?

  July 20, 2016

• Zafgen shuts down development of obesity drug, cuts staff

  July 20, 2016

• US, EU regulators to review Opdivo for new cancer indication

  July 19, 2016

• Teva raises $15 billion through bond sale

  July 19, 2016

• After phase 2 success, Brainstorm sees promise for ALS drug

  July 19, 2016

• FDA: Flood of orphan drug applications slowing review process

  July 19, 2016

• PDUFA 6 procedures will include patients, biomarkers for 2018-2022

  July 18, 2016

• Celgene picks up broader EU approval for key cancer drug

  July 18, 2016

• Samsung Bioepis continues biosimilar push with EU submission of Humira copy

  July 17, 2016

• Santhera hopes for accelerated approval of Duchenne drug dashed

  July 15, 2016

• Shkreli's securities fraud case set for June 2017

  July 15, 2016

• FDA bans imports from four Indian and Chinese drugmakers

  July 14, 2016

• Cipla invests $90 million in South African biosim plant

  July 14, 2016

• High-profile VC firm hires former Merck exec as chief medical officer

  July 14, 2016

• Two for two: FDA panel gives green light to Novartis' Enbrel biosim

  July 14, 2016

• Lilly, Boehringer enter R&D pact to test breast cancer combo

  July 14, 2016

• Amgen touts new dosing option for underperforming cholesterol drug

  July 13, 2016

• FDA approves broader use of Pfizer's pneumonia vaccine

  July 13, 2016

• FDA panel unanimously recommends approval of Amgen's Humira biosimilar

  July 13, 2016

• Increase in US cancer center ad spending fueled by single company

  July 12, 2016

• Nichi-Iko expands into US with $736 million Sagent buy

  July 12, 2016

• EMA says benefits of Gilead's Zydelig outweigh risks

  July 11, 2016

• Drug manufacturer Patheon plans major IPO to pay down debt

  July 11, 2016

• Canadian court overrules Alexion's efforts to avoid price caps

  July 11, 2016

• Gilead secures European approval for new hepatitis C drug

  July 11, 2016

• Medicines Patent Pool expands access to HIV, hepatitis C drugs with new deals

  July 11, 2016

• Pfizer's leukemia drug approved by UK cost watchdog after previous rejection

  July 8, 2016

• Democrats exhort FDA to approve generic versions of Crestor

  July 8, 2016

• Pfizer planning expansion of Irish manufacturing facility

  July 7, 2016

• 3-D drug firm Aprecia wins another $30 million in venture-funded debt

  July 7, 2016

• Moderna and Vertex partner to target cystic fibrosis with RNA therapies

  July 7, 2016

• Bial's Parkinson's drug wins approval in Europe

  July 7, 2016

• Pfizer, German Merck to test new combo against ovarian cancer

  July 7, 2016

• Valeant mulling sale of dermatology assets to Spanish Almirall: report

  July 6, 2016

• Japanese regulators approve PCSK9 drug from Sanofi, Regeneron

  July 6, 2016

• Another loss for J&J: Court sides with teenager in Risperdal case

  July 6, 2016

• Despite sluggish IPO market, biotechs continue to lead the way

  July 6, 2016

• Chinese biotech CStone raises $150 million in new financing

  July 5, 2016

• With insulin market set for shake-up, Novo Nordisk expands production plant

  July 5, 2016

• Pfizer makes bid for Bind after repayment woes

  July 5, 2016

• Patent Office accelerates patent review for cancer drugs in pilot program

  July 1, 2016

• J&J, AbbVie eye new indication for cancer drug Imbruvica

  July 1, 2016

• Boehringer continues to restructure, cuts 725 jobs in US

  July 1, 2016

• InVentiv Health comes on board as Pfizer's fourth CRO

  June 30, 2016

• Icagen to buy Sanofi lab, widening R&D reach

  June 30, 2016

• Two more Chinese drugmakers run afoul of FDA inspections

  June 30, 2016

• Pfizer's PCSK9 drug notches two Phase 3 wins

  June 30, 2016

• Shire's adult ADHD drug shows promise in late-stage study

  June 30, 2016

• Cancer Moonshot summit adds new partnerships to lofty goals

  June 30, 2016

• Roche eyes faster approval for multiple sclerosis drug

  June 29, 2016

• More generic drugs from India clearing FDA approval: report

  June 29, 2016

• Teva, Allergan sell off more drugs in quest for approval of generics deal

  June 29, 2016

• What does it take to succeed as a New York biotech startup?

  June 29, 2016

• Dr. Reddy's breaks off marketing partnership with Glaxo

  June 28, 2016

• Bristol-Myers eyes new indication as Opdivo nabs breakthrough tag in bladder cancer

  June 28, 2016

• Takeda hands back two developmental drugs to Amgen

  June 27, 2016

• FDA should be independent agency, former commissioners say

  June 26, 2016

• Industry group pushes back against proposed bill to reduce drug exclusivity

  June 26, 2016

• Study says Novartis heart med could prevent 28,000 US deaths per year

  June 24, 2016

• Eleven Bio slashes workforce after drug test failures

  June 23, 2016

• India targets drugmakers with wave of inspections

  June 23, 2016

• Opko wins approval for kidney drug after manufacturing snag

  June 23, 2016

• Selecta Biosciences raises $70 million in IPO, forges ahead with gout drug

  June 23, 2016

• Russian biosims company accuses Roche of undercutting its business

  June 23, 2016

• Celgene puts up $50 million to partner with four NCI cancer centers

  June 23, 2016

• Doctors who ate on pharma's dime prescribed drugs more often, study finds

  June 22, 2016

• Supreme Court asks for DOJ input on biosimilar case, delaying decision

  June 22, 2016

• Could label update for diabetes med Jardiance boost drug class?

  June 22, 2016

• Austin biotech Savara adds two lung drugs in deal for Serendex

  June 22, 2016

• Philips ad for lung device wins top honors at Cannes

  June 21, 2016

• Kite Pharma opens cell therapy plant as lead CAR-T candidate gathers steam

  June 21, 2016

• Incidence of Parkinson's may be increasing: Mayo Clinic study

  June 21, 2016

• Clinton racks up donations from pharma industry

  June 20, 2016

• NICE greenlights Bristol-Myers' combo drug for melanoma

  June 20, 2016

• Epizyme stock falls after mixed Phase 2 results for blood cancer drug

  June 20, 2016

• Hologic's Zika test can be used on emergency basis, FDA says

  June 20, 2016

• Why Novartis' new heart med could reverse slow start

  June 17, 2016

• Payer interest grows in outcomes-based drug deals: report

  June 17, 2016

• Roche's combo melanoma treatment turned down by UK cost watchdog

  June 17, 2016

• Venture funding for UK biotechs hits new high

  June 17, 2016

• EMA cites US-based Pii for manufacturing violations

  June 16, 2016

• Roche selling Spanish facility to CMO Famar

  June 16, 2016

• Lawmakers introduce bill to end REMS abuse, boost generic competition

  June 16, 2016

• Shkreli's stake in KaloBios cut after judge OK's bankruptcy plan

  June 16, 2016

• NYC-based Rgenix raises $33 million to advance cancer immunotherapy

  June 15, 2016

• Lilly and Boehringer's Jardiance sets new bar, shows kidney benefit

  June 15, 2016

• Teva hands back global rights for heart drug to Australian Mesoblast

  June 15, 2016

• Success rate for clinical trials climbed in recent years: study

  June 15, 2016

• Infinity Pharma to lay off one-fifth of staff in wake of phase 2 setback

  June 14, 2016

• Merck eyes US approval with positive data on Lantus copy

  June 14, 2016

• Novo's diabetes drug shown to decrease heart risks, boosting competitive edge

  June 14, 2016

• Dr. Reddy's snaps up eight generics from Teva for $350 million

  June 14, 2016

• Merck, Pfizer expand trial studying CV benefit of experimental diabetes drug

  June 13, 2016

• Valeant weighs sale of Egyptian drug company

  June 13, 2016

• FDA approves world's first single-dose cholera vaccine

  June 12, 2016

• Lilly presents solid long-term data for baricitinib in RA patients

  June 12, 2016

• GSK wants to replace drugs with tiny implants

  June 10, 2016

• Amgen's chronic migraine-prevention drug shows promise in midstage trials

  June 10, 2016

• FDA wants to suspend more than 4,000 illegal Rx sites

  June 10, 2016

• Alexandria Center for Life Sciences offers $25M in seed funding for small biotechs

  June 9, 2016

• Will the approval of Inflectra be a biosimilar adoption tipping point?

  June 9, 2016

• Sun Pharma selling off two more US facilities

  June 9, 2016

• Researchers discover 11 acute myeloid leukemia subtypes

  June 9, 2016

• Gene therapy CMO Brammer Bio moves HQ to Massachusetts

  June 9, 2016

• Study: Blood-based 'liquid biopsy' cancer testing works

  June 8, 2016

• Vermont becomes first state with drug pricing justification law

  June 8, 2016

• Kite, Juno anticipating 2017 approvals for T-cell therapy

  June 8, 2016

• Genentech/OSI fined $67 million for skewing cancer-drug survival data

  June 8, 2016

• FDA approves Allergan's fixed-dose combo for hyertension

  June 8, 2016

• Senators request pricing info from opioid-overdose drugmakers

  June 8, 2016

• ASCO update: Biden announces launch of cancer data-sharing system

  June 7, 2016

• Alexion's Soliris fails in late-stage myasthenia gravis trial

  June 7, 2016

• Study: Cancer drugs most expensive in US, least accessible in China, India

  June 6, 2016

• Regeneron/Sanofi's dupilumab shines in phase 3 eczema trial

  June 6, 2016

• Study: Bristol-Myers' immunotherapy combo boosts response in lung cancer

  June 6, 2016

• Roche positioning Tecentriq as first-line therapy in bladder cancer

  June 6, 2016

• Mylan's Herceptin biosim shows comparable efficacy/safety

  June 6, 2016

• AstraZeneca continues to shed rights to gout drug

  June 3, 2016

• Novartis cancer drug wins expanded indication in Europe

  June 2, 2016

• FDA approves liquid biopsy test from Roche

  June 2, 2016

• Sanofi Pasteur starts up vaccine production at new facility in India

  June 2, 2016

• Sun Pharma continues to feel effect of Halol plant problems

  June 2, 2016

• Swiss biotech AC Immune readies US IPO

  June 2, 2016

• Two San Diego biotechs merge to create new oncology-focused company

  June 2, 2016

• Report: Investors concerned Teva overpaid for Allergan generics unit

  June 2, 2016

• Kite Pharma rides CAR-T momentum into ASCO

  June 2, 2016

• AstraZeneca discontinues 'Take it From a Fish' ad campaign

  June 1, 2016

• Federal judge orders Washington state to cover hep C medications

  June 1, 2016

• Daiichi Sankyo halts late-stage study of lung cancer drug

  June 1, 2016

• Next-generation eczema drugs on pace for 2017 launch

  May 31, 2016

• FDA knocks back Teva drug for Huntingon's, requests more information

  May 31, 2016

• EMA recommends approval for hepatitis C meds from Gilead, Merck

  May 31, 2016

• Wellcome Trust scores with startup investment in diagnostic company

  May 31, 2016

• Multiple sclerosis drug from Biogen, AbbVie clears FDA review

  May 31, 2016

• Second biosimilar of J&J's blockbuster Remicade approved in Europe

  May 31, 2016

• Contract researcher BioClinica reportedly weighing sale

  May 27, 2016

• FDA approves first implanted buprenorphine for opioid dependence

  May 27, 2016

• Fate of Ionis drug in doubt after GSK decides against Phase 3 study

  May 27, 2016

• FDA reprimands German API supplier for manufacturing violations

  May 26, 2016

• MIT lab shrinks drug manufacturing process into a small prototype machine

  May 26, 2016

• Aiming to make living tissue, Israeli companies test 3-D stem cell printing

  May 26, 2016

• Novartis moves toward sale of $14 billion stake in Roche

  May 26, 2016

• Two states sue Johnson & Johnson over vaginal mesh device problems

  May 26, 2016

• Kevin Young to return to Gilead as COO

  May 26, 2016

• In unanimous vote, FDA panel recommends Novo diabetes drug

  May 25, 2016

• Sandoz's biosimilar rituximab gets regulatory review in EU

  May 25, 2016

• While advancing cancer pipeline, Halozyme builds up through pharma collaborations

  May 25, 2016

• EMA reportedly reviewing clinical guidelines in wake of fatal drug trial

  May 25, 2016

• New ad for Bristol's Opdivo highlights testing advantage over Keytruda

  May 24, 2016

• Arbor Pharma buys XenoPort for $467 million

  May 24, 2016

• Sanofi diabetes chief to leave company as US business struggles

  May 24, 2016

• Lilly hopes to catch rivals with abemaciclib data

  May 24, 2016

• Novartis faces new challenges as top executives leave

  May 24, 2016

• China slashes prices of top-selling cancer, hep B drugs

  May 23, 2016

• Novartis' Entresto gets boost from leading US cardiology groups

  May 23, 2016

• Oramed's oral insulin shines in mid-stage trials

  May 23, 2016

• Merck KGaA/Pfizer's PD-L1 skin cancer drug shows encouraging interim results

  May 20, 2016

• Novartis launches ambitious clinical program for Entresto

  May 19, 2016

• AbbVie takes on AD at new Cambridge research facility

  May 19, 2016

• In reversal, Braeburn Pharma will stay in NC despite controversial law

  May 19, 2016

• Capsugel subsidiary flagged by Swedish regulator for GMP failures

  May 19, 2016

• BMS completes $280 million biologics plant expansion in MA

  May 19, 2016

• Novartis breast cancer drug proves efficacy, trial stopped early

  May 19, 2016

• AstraZeneca's gastric cancer drug falls short in phase 3

  May 19, 2016

• Janssen ponies up $740 million for another MacroGenics cancer drug

  May 19, 2016

• As big pharma moves in, biotech Galectin looks to stake claim to NASH market

  May 18, 2016

• Everyday low price? Walmart teams with McKesson to source generics

  May 18, 2016

• Orexigen struggles to stay afloat as obesity market stagnates

  May 18, 2016

• Celgene expands partnership with Agios into immuno-oncology

  May 18, 2016

• FDA looks to ease burden for compassionate drug use

  May 17, 2016

• Roche continues generics battle with latest lawsuit over Avastin copies

  May 17, 2016

• Novartis debates how to crack sales code for CAR-T therapy

  May 17, 2016

• Editas forges $5 million CRISPR research deal with Cystic Fibrosis Foundation

  May 17, 2016

• Aduro's pancreatic immunotherapy fails phase 2, sending stock tumbling

  May 16, 2016

• Eisai's kidney drug wins expanded indication in the U.S.

  May 16, 2016

• AstraZeneca looks to DNA damage-response drugs for edge in oncology

  May 16, 2016

• New phase 3 data boosts Pfizer's meningitis vaccine

  May 15, 2016

• Valeant pressured on promise to provide heart drug discount

  May 13, 2016

• Regneron CEO counters criticism from ICER on pricing

  May 13, 2016

• Oracle founder Larry Ellison donates $200 million for USC cancer center

  May 12, 2016

• J&J expands JLABS into Canada with new Toronto site

  May 12, 2016

• NIH-funded malaria vaccine shows safety, efficacy in early trial

  May 12, 2016

• Cigna signs value-based pricing deals with Amgen, Sanofi for PCSK9 drugs

  May 12, 2016

• Sanofi R&D chief, ex-FDA head cite need to improve international regulatory coordination

  May 12, 2016

• Opko Health's quest to redefine treatment for secondary HPT

  May 12, 2016

• Updated survival data added to Imbruvica's label

  May 11, 2016

• GSK's lupus drug finally wins NICE backing, but only after discounts

  May 11, 2016

• Daiichi snaps up Japanese rights to CVD stem-cell therapy

  May 11, 2016

• Americans may have overspent billions on brand-name drugs, study finds

  May 11, 2016

• Pfizer planning first triple-drug immuno-oncology study

  May 11, 2016

• NewLink Genetics writes off pancreatic cancer immunotherapy after phase 3 failure

  May 10, 2016

• Pharma opposition to Brexit cites concern for UK patients, life sciences

  May 10, 2016

• Wave Life Sciences touts more effective Duchenne drug

  May 10, 2016

• Cellectis' T-cell therapy clears leukemia in second baby

  May 9, 2016

• U.K. cost agency recommends new PCSK9 drugs, but only after further discounts

  May 9, 2016

• ICER questions high prices of multiple myeloma meds

  May 9, 2016

• Clovis shuts down cancer drug, will reduce staff by 35%

  May 6, 2016

• Regeneron reports strong Q1, but key drug faces pressure

  May 6, 2016

• Pfizer bets on Wave with drug development deal

  May 6, 2016

• New Zealand pushes back on coverage for Merck's Keytruda

  May 5, 2016

• Bayer's Stivarga shows efficacy in liver cancer

  May 5, 2016

• India may require more clinical trials for Sanofi's dengue vaccine

  May 5, 2016

• J&J loses another talcum powder case, ordered to pay victim $55 million

  May 4, 2016

• FDA warns antipsychotic can cause uncontrollable urges to gamble, have sex

  May 4, 2016

• Bayer's Xarelto projected to become top-selling drug in Europe by 2022

  May 4, 2016

• Former Turing CEO Martin Shkreli could face new federal charges

  May 4, 2016

• Generic drug backlog persists as FDA slowly clears applications

  May 4, 2016

• How Aprecia Pharma hopes to tackle patient noncompliance with 3-D printed drug

  May 3, 2016

• Caught by repayment demand, cancer biotech Bind Therapeutics files for bankruptcy

  May 3, 2016

• Colombia reportedly set to override Novartis patent on a key cancer drug

  May 3, 2016

• Takeda renames antidepressant after name confusion leads to errors

  May 3, 2016

• Multiple sclerosis drug from Biogen, AbbVie clears regulatory hurdle in EU

  May 1, 2016

• Crestor tumbles off patent cliff as first generic copy approved in US

  May 1, 2016

• Acadia wins FDA approval for first drug to treat Parkinson's disease psychosis

  May 1, 2016

• Amid pharma lobbying, US trade rep keeps India on priority watch list

  April 29, 2016

• Canadian drugmaker tells CMS it can make cheaper version of cancer drug Xtandi

  April 29, 2016

• New Express Scripts program aims to react faster to spikes in drug prices

  April 29, 2016

• Alexion eyes new manufacturing investment in Ireland

  April 28, 2016

• Sanford Weill and wife donate $185 million to UCSF for neuroscience research

  April 28, 2016

• Novartis aims for $1 billion in savings from centralization plans

  April 28, 2016

• NantKwest's billionaire CEO pocketed $148 million in total compensation last year

  April 28, 2016

• UBS venture fund raises $471 million for early-stage cancer investments

  April 28, 2016

• Pfizer settles Wyeth Medicaid rebate case for $784.6 million

  April 28, 2016

• AstraZeneca debuts new tech along with approval of COPD inhaler

  April 27, 2016

• Biogen's 'active woman' Tecfidera ad will go off air soon

  April 27, 2016

• Keeping pace with rival Keytruda, Bristol-Myers' Opdivo wins new breakthrough designation

  April 27, 2016

• Why Inflectra may face greater challenges than Zarxio in winning over US docs

  April 27, 2016

• Non-profit urges big pharma to take responsibility for drug take back programs

  April 27, 2016

• AstraZeneca hands off Zurampic marketing rights to Ironwood for $100 million

  April 26, 2016

• Viiv Healthcare expands access to HIV drug through patent pooling

  April 26, 2016

• Novartis may divest $14B stake in Roche, could generate M&A funding

  April 26, 2016

• With CEO Papa headed to Valeant, Perrigo faces new challenges

  April 26, 2016

• Major study shows no increased suicide risk from smoking cessation drugs

  April 25, 2016

• Proton pump inhibitors linked to serious kidney diseases in study

  April 25, 2016

• Germany mulling changes to limit prices drugmakers can charge

  April 25, 2016

• Chinese FDA to expedite review of new hepatitis C meds

  April 25, 2016

• Actelion denies reports of takeover

  April 22, 2016

• FDA issues critical response to Sarepta's latest DMD drug data

  April 22, 2016

• Boosting pipeline, AbbVie inks two deals for preclinical cancer drugs

  April 22, 2016

• In $205 million deal, Recipharm buys Kemwell's US, India CDMO businesses

  April 21, 2016

• Sanofi to invest €300 million in Belgian biologics site

  April 21, 2016

• CRISPR-Cas9 editing technology gets a precision upgrade

  April 21, 2016

• Combo of J&J Ebola vaccine, Nordic Bavarian booster yields 100% success in small-scale tests

  April 21, 2016

• New survey finds consumers unlikely to act on drug ads

  April 21, 2016

• Biosimilar update: Zarxio one year later

  April 20, 2016

• New analysis boosts cost-effectiveness argument for Merck's Zepatier

  April 20, 2016

• Indian pharma companies ramp up R&D to expand reach in US

  April 20, 2016

• PhaseRX, Gemphire move forward with IPOs despite challenging market

  April 20, 2016

• Armed with genetic data, UK biotech revisits abandoned Roche cholesterol drug

  April 20, 2016

• Merck vs. Merck: Trademark suit over brand name heats up

  April 19, 2016

• Chiasma shares nosedive after FDA rejects acromegaly drug, asks for more data

  April 19, 2016

• Study finds long-term health gains, cost-effectiveness benefits to new HPV vaccine

  April 19, 2016

• Eli Lilly cuts ties with Transition, ends diabetes drug collaboration

  April 19, 2016

• EMA broadens scope of safety review for Hep C antivirals

  April 18, 2016

• Starboard presses on with proxy efforts against Depomed

  April 18, 2016

• AbbVie's experimental hep c combo proves highly effective across genotypes

  April 18, 2016

• EASL 2016: Merck's 'no patient left behind' approach to hepatitis C

  April 18, 2016

• Roche rules out quality problems with Avastin in India

  April 15, 2016

• Glaxo investigating alleged bribes to government officials in Yemen: report

  April 15, 2016

• Most cancer drug labels don't include patient experiences: study

  April 15, 2016

• Fallout from China vaccine scandal continues with arrests of officials

  April 14, 2016

• Two Indian generic companies bow to pressure, end appeal for compulsory licenses

  April 14, 2016

• In first, FDA approves Janssen's switch to continuous manufacturing for HIV drug

  April 14, 2016

• Horizon expects most sales to come later in the year, precipitating share's slide

  April 14, 2016

• UK antitrust regulators fine Pfizer over epilepsy drug price increase

  April 14, 2016

• Billionaire Sean Parker stakes $250 million on cancer immunotherapy research

  April 14, 2016

• ICER questions cost effectiveness of multiple myeloma therapies

  April 13, 2016

• Federal court reverses dismissal of class-action suit against Pfizer over pain drugs

  April 13, 2016

• PledPharma takes on chemo-induced neuropathy with an eye to US market

  April 13, 2016

• With Sanofi gone, Mannkind tries to reinvigorate Afrezza marketing

  April 12, 2016

• Alkermes' Vivitrol gets second chance as opioid crisis deepens

  April 12, 2016

• California lawmakers debate bill requiring pharma companies to report 10% price increases

  April 12, 2016

• Celgene snaps up $50 million option for select Juno CAR-T programs

  April 12, 2016

• With polio near eradication, global switch to a new vaccine set to begin

  April 11, 2016

• Juno aims to bring CAR-T therapy to China with new joint venture

  April 11, 2016

• Activist hedge fund targets Depomed board

  April 11, 2016

• Ahead of key meeting, FDA reviewers question efficacy of Clovis' lung cancer drug

  April 11, 2016

• Major NGO drops India's IPCA Labs as a source of anti-malarials

  April 8, 2016

• FDA advisory board unanimously supports approval of Intercept's liver drug

  April 8, 2016

• Relypsa reportedly reviewing buyout offers on renewed interest in hyperkalemia drug

  April 8, 2016

• FDA approves Medtronic's Micra, first wireless pacemaker in the U.S.

  April 7, 2016

• Inventiv Health sets up IPO to pay down debt

  April 7, 2016

• Lilly invests $40 million in Irish continuous manufacturing facility

  April 7, 2016

• In potential $450 million licensing deal, J&J to develop prostate cancer drug

  April 7, 2016

• Broad Institute offering cloud-based access to trove of genomic data

  April 7, 2016

• Federal judge dismisses hundreds of Zoloft birth defect lawsuits

  April 7, 2016

• Philippines launches world's first public immunization program against dengue

  April 6, 2016

• New data: Pharma magazine ad spending surpasses $1.5 billion in 2015

  April 6, 2016

• Key panel nears vote on OCA, Intercept's potential blockbuster liver therapy

  April 6, 2016

• FDA chastises Shionogi for misleading copay voucher

  April 6, 2016

• BIO Spring 2016: Immunovia's quest to make early-stage pancreatic diagnosis a clinical reality

  April 6, 2016

• FDA warns on heart failure risk associated with Onglyza, Nesina

  April 6, 2016

• Analysis shows pharma companies aggressively increased prices on widely used drugs

  April 5, 2016

• Federal government appoints blue-ribbon advisory panel for cancer moonshot

  April 5, 2016

• Nimbus liver drug bought by Gilead for $400M cash plus incentives

  April 5, 2016

• With a biosim in the wings, Samsung Bioepis sues AbbVie over patent defense of Humira

  April 4, 2016

• ACC 2016: Boehringer's Pradaxa 'antidote' passes real-world test

  April 4, 2016

• ACC 2016: Novartis' Entresto reduces risk of hospitalization in HF patients

  April 3, 2016

• Price of success: Medivation reportedly hires JP Morgan to help fend off deal-hungry buyers

  April 1, 2016

• Lilly's arthritis drug baricitinib notches another success

  April 1, 2016

• Federal inspection report reveals major problems at Theranos lab

  April 1, 2016

• Urging more robust FDA response, lawmakers warn of contaminated heparin

  March 31, 2016

• FDA allows use of Roche's experimental test for Zika virus in endemic areas

  March 31, 2016

• Shire boosts CEO Ornskov's pay in light of "exceptional performance"

  March 31, 2016

• In cancer moonshot push, Biden and Bloomberg highlight potential of immunotherapy

  March 31, 2016

• FDA approves Jazz's rare liver disorder drug

  March 31, 2016

• Could long-term "mortgages" help patients fund short-term curative treatments?

  March 30, 2016

• Xenoport sells US rights to psoriasis drug to Dr. Reddy's

  March 30, 2016

• Denmark-based Lundbeck emerges as top-ranked company in survey of US patient groups

  March 30, 2016

• In reversal, FDA denies cognitive dysfunction label expansion for Brintellix

  March 30, 2016

• Novartis allegedly paid bribes in Turkey to secure advantages for its drugs

  March 30, 2016

• Eagle Pharma's Bendeka denied orphan exclusivity

  March 29, 2016

• Emulate raises $28 million for organ-on-chip technology

  March 29, 2016

• As vaccine scandal continues, WHO urges China to more strictly police regulations

  March 29, 2016

• Shire prevails in Lialda patent case against Allergan

  March 29, 2016

• Theranos blood testing inconsistent with other labs, study shows

  March 29, 2016

• New poll finds widespread support for cancer research funding

  March 28, 2016

• US gov demands more information from Novartis on purported kickbacks

  March 28, 2016

• Amid safety concerns, FDA adcomm set to review Acadia's Parkinson's drug

  March 28, 2016

• Trial begins in federal court over $60 million heist of Lilly drugs

  March 24, 2016

• South Korean, US researchers develop diabetes skin patch

  March 24, 2016

• Growing anger in China as vaccine scandal comes to light

  March 24, 2016

• Valeant doubled price of physician-assisted suicide drug

  March 24, 2016

• Biotech IPOs continue as Corvus prices public listing

  March 24, 2016

• Philanthropist Paul Allen launches new $100 million bioscience research initiative

  March 24, 2016

• NICE reverses course, endorses expanded use of J&J's Zytiga

  March 23, 2016

• Brexit could complicate marketing status of drugs, new licenses

  March 23, 2016

• J&J and Genentech partnering in two cancer studies combining Darzalex with atezo

  March 23, 2016

• Denying recent reports, India government say it hasn't promised to restrict compulsory licensing

  March 23, 2016

• Why ViiV Healthcare leads the pharma industry in corporate reputation

  March 22, 2016

• 23andMe enabling iPhone users to share DNA data with medical researchers

  March 22, 2016

• BioMarin's PKU drug meets primary goal in phase 3, but falls short on secondary endpoints

  March 22, 2016

• Indian court temporarily blocks government ban on sales of FDCs

  March 22, 2016

• As FDA review approaches, Duchenne experts push for approval of Sarepta's eteplirsen

  March 22, 2016

• WHO suspends all TB products from India's Svizera Labs

  March 21, 2016

• Biden names corporate exec Greg Simon to lead Cancer Moonshot

  March 21, 2016

• EMA issues safety guidance for Gilead's Zydelig in wake of patient infections

  March 21, 2016

• OptumRx signs on with Walgreens Boots Alliance

  March 18, 2016

• Top Gilead cancer researcher has left company

  March 18, 2016

• Former Turing exec to Senate panel: We warned Shkreli about Daraprim price hike

  March 18, 2016

• Bayer planning new life sciences hub in Cambridge, MA

  March 17, 2016

• Cellectis and MabQuest team up to develop new class of anti-PD1 antibodies

  March 17, 2016

• Valeant's stock collapse triggers closer scrutiny

  March 17, 2016

• In limited study, NIH-developed dengue vaccine proves 100% effective

  March 17, 2016

• Despite promising clinical results, uptake challenges continue for Novartis' Entresto

  March 17, 2016

• Valeant acquires Orexigen's obesity drug, stock continues its slide

  March 16, 2016

• CDC issues new guidelines for prescribing opioids

  March 16, 2016

• Survey: Pharma advertising works—especially with millennials

  March 16, 2016

• EMA finalizes clinical trial redaction guidelines

  March 16, 2016

• Lilly changes endpoint for phase 3 Alzheimer's trial

  March 16, 2016

• Indian authorities withdraw alert on off-label use of Roche's Avastin

  March 15, 2016

• As U.S. biosim market grows, FDA's regulatory work has cost nearly $82 million

  March 15, 2016

• GW Pharma stock doubles after positive phase 3 cannabis drug results

  March 15, 2016

• Sanders proposes cash prize for development of lower-priced AIDS drugs

  March 15, 2016

• Allergan would pay $86M in 'golden parachute' taxes if senior execs dismissed

  March 15, 2016

• KaloBios sets up funding to clear bankruptcy, acquire Chagas drug

  March 14, 2016

• EU regulators investigating Gilead's Zydelig after infection deaths

  March 14, 2016

• Indian Health Ministry bans nearly 350 combo drugs

  March 14, 2016

• Boehringer turns to 'red fish' for Pradaxa boost

  March 14, 2016

• Sarepta's Duchenne drug gets a new date for FDA review

  March 11, 2016

• Bispecifics emerging as alternative cancer immunotherapy to CAR-T

  March 11, 2016

• Major opioid abuse bill passes 94 to 1 in Senate

  March 11, 2016

• Whistleblower sues Indian drug regulators for poor oversight

  March 10, 2016

• Merck names new manufacturing head, replacing 12-year veteran

  March 10, 2016

• French regulator halts manufacturing at HIV-focused biotech

  March 10, 2016

• Senate HELP Committee advances seven bills as counterpart to 21st Century Cures

  March 10, 2016

• Gilead and Merck lock horns in court over sofosbuvir patent

  March 10, 2016

• CRISPR patent battle begins, setting 'first to file' against 'first to invent'

  March 10, 2016

• Black box warning order clouds future for Bayer's Essure

  March 9, 2016

• Colombia health ministry recommends compulsory license for Novartis' Gleevec

  March 9, 2016

• FDA accepts new Keytruda data, opening door for wider indication

  March 9, 2016

• Kentucky Senate overwhelmingly passes biosimilar prescription bill

  March 9, 2016

• Senate HELP Committee to mark up 21st Century Cures legislation

  March 8, 2016

• Counterfeit Harvoni from India found in Israel

  March 8, 2016

• Industry groups, doctors ask CMS to withdraw proposed Part B experiment

  March 8, 2016

• Novartis' Cosentyx proves superior to Janssen's Stelara in head-to-head comparison

  March 7, 2016

• New study strengthens link between Zika and serious birth defects

  March 7, 2016

• GSK's asthma drug Nucala boosted by long-term safety study

  March 7, 2016

• Alaska Permanent Fund betting big on biotech startups

  March 4, 2016

• Endo to pay $200K penalty, overhaul marketing of opioid painkiller

  March 4, 2016

• FDA approves first Zika diagnostic for emergency use

  March 3, 2016

• In major expansion, Lupin subsidiary setting up plant in Japan

  March 3, 2016

• BMJ study: Single dose vials cost nearly $2B a year in wasted cancer drugs

  March 3, 2016

• Merck forges ahead with phase 3 trial of Humira biosimilar

  March 3, 2016

• Sanofi's generics divestment in the E.U. likely to be delayed

  March 3, 2016

• Amgen going after Novartis for Enbrel patent infringement

  March 3, 2016

• Bayer's Essure permanent birth control gets black-box warning

  March 2, 2016

• San Diego-based Conatus takes aim at unmet medical need in cirrhosis

  March 2, 2016

• AstraZeneca's mesothelioma drug fails monotherapy testing

  March 2, 2016

• Teva planning global rebrand as it works to close Allergan generics deal

  March 2, 2016

• Clinton ad lambastes Valeant for 'predatory' pricing

  March 2, 2016

• Federal investigation probing Horizon Pharma's patient assistance program

  March 2, 2016

• AstraZeneca sells off more 'non-core' assets, raising nearly $600M

  March 1, 2016

• AARP report: Average prescription drug cost rose by 10% in 2013

  March 1, 2016

• Roche's asthma drug stumbles on mixed phase 3 results

  March 1, 2016

• Boehringer/AbbVie reportedly in cancer-collaboration talks

  March 1, 2016

• Report: Pfizer attempting to dodge $35 billion in taxes through merger with Allergan

  Feb. 29, 2016

• Chinese Food and Drug Administration vows to expedite drug approvals

  Feb. 29, 2016

• CDC reports new cases of sexual transmission of Zika virus

  Feb. 29, 2016

• How the ambitious Cancer Moonshot hinges on the potential of immunotherapies

  Feb. 28, 2016

• Doctors Without Borders blasts $1700 price tag of Otsuka TB drug

  Feb. 26, 2016

• AZ's deal for Acerta already showing promise as cancer drug wins orphan nod

  Feb. 25, 2016

• Valeant's Pearson recovering, but timetable for return remains uncertain

  Feb. 25, 2016

• Sandoz issues major recall for hypertension drug made in India

  Feb. 25, 2016

• Banned Chinese supplier given exemption to ship chemotherapy drug to U.S.

  Feb. 25, 2016

• Merck's Zepatier holds its own in safety comparison to Gilead meds

  Feb. 25, 2016

• Lilly's lung cancer drug Portrazza wins EU approval as first-line biologic

  Feb. 25, 2016

• Novo Nordisk notches another phase 3 success for GLP-1 drug

  Feb. 25, 2016

• Merck CEO Frazier acknowledges pricing 'challenges,' need for new models

  Feb. 24, 2016

• Amgen's bone-building osteo drug dazzles in phase 3, but could face hefty competition

  Feb. 24, 2016

• IBM buys Truven for $2.6 billion, continues to build its big data focus in healthcare

  Feb. 24, 2016

• Alibaba under siege as Chinese regulators & pharmacies fight its e-drug tracking system

  Feb. 24, 2016

• Why uptake of new PCSK9 cholesterol meds has been so slow

  Feb. 24, 2016

• Do big name journals have a 'marketing trial' problem?

  Feb. 24, 2016

• Startup turns to 'video game' medical tech to address brain-based disorders

  Feb. 23, 2016

• Alzheimer's startup Chase plots $70M in 2016 funding

  Feb. 23, 2016

• AstraZeneca nabs two big European nods for gout & heart meds

  Feb. 23, 2016

• UK firm may have just revolutionized NSAID delivery with ibuprofen patch

  Feb. 23, 2016

• Allergan's Q4 earnings best expectations on back of US sales

  Feb. 23, 2016

• FDA approves new UCB drug to treat epilepsy-related seizures

  Feb. 22, 2016

• Startup AvroBio touts gene therapy candidates for blood cancer, Fabry disease

  Feb. 22, 2016

• The flip side of the T-cell hype: Experts urge caution on huge costs, safety concerns

  Feb. 21, 2016

• UPDATE: Teva to hawk $1 billion in assets to clear massive Allergan generics deal

  Feb. 19, 2016

• The next overdose crisis? Benzo-related deaths on the rise in US

  Feb. 19, 2016

• Celgene hitches wagon to Bluebird, doles out $10M as biotech launches 1st CAR-T trial

  Feb. 19, 2016

• New Zafgen data shows obesity med's promise in diabetics—but will FDA lift its clinical hold?

  Feb. 19, 2016

• Eight pharma suppliers band together to improve packaging testing, compatability

  Feb. 18, 2016

• Pfizer issues major recall of children's Advil in Canada

  Feb. 18, 2016

• Armed with strong new data, Regulus aims to defy skeptics of its hep C injectable

  Feb. 18, 2016

• AstraZeneca scores a clutch 'breakthrough' for major bladder cancer med

  Feb. 18, 2016

• AMD Awareness Month: For drugmakers, value is the name of the game

  Feb. 17, 2016

• Pfizer downgrades Q4 outlook after $785M DOJ settlement spurred by 'serial whistleblower'

  Feb. 17, 2016

• FDA expands Gilead's Harvoni label for advanced cirrhosis patients

  Feb. 17, 2016

• Express Scripts putting all Valeant scripts under the microscope amid pricing furor

  Feb. 17, 2016

• Amgen launches Kyprolis in the UK for multiple myeloma

  Feb. 16, 2016

• HHS chief mulling controversial 'march-in' to smack down patents & tackle drug prices

  Feb. 16, 2016

• New PCSK9s & heart meds face slow uptake, brush up against payer review requirements

  Feb. 16, 2016

• Global API market ballooning, will hit $186 billion by 2020: report

  Feb. 16, 2016

• UK regulator smacks Glaxo with $54.4 million fine over pay-for-delay deals

  Feb. 16, 2016

• UK High Court delivers heavy blow to Lilly in patent spat over blockbuster Alimta

  Feb. 16, 2016

• Struggling Clovis to once again chase FDA favor for would-be Tagrisso competitor

  Feb. 16, 2016

• China's next big move to bolster domestic drug industry: Market consolidation

  Feb. 16, 2016

• Dr. Reddy's Q3 earnings flat despite FDA woes

  Feb. 11, 2016

• Taiwan earthquake leaves drug API plants unscathed

  Feb. 11, 2016

• In search for specialists, Teva laying off factory workers at UK plant

  Feb. 11, 2016

• Biopharma giants Biogen & Sanofi buy into round A for Tony Coles' Yumanity

  Feb. 11, 2016

• Egypt facing major drug supply crisis fueled by weak currency & political turmoil

  Feb. 11, 2016

• Gene editing: The latest national security threat?

  Feb. 11, 2016

• Competition from Lilly's Trulicity weighs on Novo's otherwise solid Q4

  Feb. 10, 2016

• Breaking down Super Bowl 50's pharma ads: A bold moment for gut drugs

  Feb. 10, 2016

• Shire gets new PDUFA date for eye drug hopeful once spurned by FDA

  Feb. 10, 2016

• J&J, Viacyte team up on a potential stem cell therapy 'cure' for type 1 diabetes

  Feb. 10, 2016

• You've got InMail: Pharma ratcheting up use of LinkedIn for marketing

  Feb. 10, 2016

• Sanofi CEO wants to leverage Dengue vax success to expedite Zika vaccine development

  Feb. 10, 2016

• BIO CEO 2016: What it will take to achieve Cancer MoonShot 2020

  Feb. 10, 2016

• Clinics peddling unauthorized stem cell treatments face FDA heat

  Feb. 9, 2016

• A besieged drug industry launches major new ad campaign to woo lawmakers

  Feb. 9, 2016

• BIO CEO 2016: Purdue pursues deals, boosting the NIH, Schumer slams Shkreli, & more

  Feb. 9, 2016

• FDA staff sounds encouraging note on Celltrion's biosim of J&J blockbuster Remicade

  Feb. 7, 2016

• Supernus wins court victory over Allergan in epilepsy drug patent spat

  Feb. 7, 2016

• OncoGenex slashes workforce after phase 3 cancer med setbacks

  Feb. 7, 2016

• UPDATE: LifeSci Advisors apologizes for JPM party that stoked sexism critiques

  Feb. 5, 2016

• A bankrupt KaloBios may still buy Chagas drug that Shkreli wanted to acquire-and-hike

  Feb. 5, 2016

• Lundbeck wins key FDA backing for expanding depression drug Brintellix's label

  Feb. 5, 2016

• Agilent accuses Twist Bioscience CEO of stealing trade secrets

  Feb. 5, 2016

• Glaxo, Adaptimmune ratchet up cancer collab in $500 million deal

  Feb. 4, 2016

• Statisticians question methods used in deadly Bial study

  Feb. 4, 2016

• Allergan's Texas plant primed for expansion, possible job growth

  Feb. 4, 2016

• Pfizer, Merck, & other pharmas reviewing vaccine portfolios to address Zika emergency

  Feb. 4, 2016

• Martin Shkreli goes to Washington—and refuses to say anything to Congress

  Feb. 4, 2016

• From blunt force to electrical currents: Cancer treatment in the 21st century

  Feb. 3, 2016

• New study: Pfizer's Chantix no more effective than nicotine patches

  Feb. 3, 2016

• Old Novartis cancer flagship Gleevec heads to pharmacies as lower-cost generic

  Feb. 3, 2016

• J&J heads to court over alleged talcum powder, ovarian cancer link

  Feb. 3, 2016

• Insulin wars heat up as Novo's Tresiba bests Lantus in major safety outcomes trial

  Feb. 2, 2016

• 21st Century Cures progress may be hitting a partisan buzzsaw

  Feb. 2, 2016

• Appeals court upholds drug companies' right to manufacture generic OxyContin

  Feb. 2, 2016

• Obama seeks $755M for Cancer MoonShot, boosts to NIH & FDA

  Feb. 2, 2016

• Express Scripts ditches Valeant diabetes med as part of 2016 formulary shakeup

  Feb. 1, 2016

• A promising sign for 'Pfallergan' pipeline as Allergan depression med nabs 'breakthrough'

  Feb. 1, 2016

• Hep C market poised for pricing rumble as Merck's cheaper med approved

  Feb. 1, 2016

• How the brain disease model of addiction drives innovation in drug development

  Jan. 29, 2016

• Q4 update: Bristol-Myers outperforms and Celgene misses EPS estimates

  Jan. 29, 2016

• FDA alleges deleted files, hidden data at India's Wockhardt

  Jan. 28, 2016

• Eisai grabs an FDA approval for life-extending soft tissue cancer drug

  Jan. 28, 2016

• Catalent still in strategic acquisition mode after a slew of big deals

  Jan. 28, 2016

• Editas Medicine prepping for IPO even as biotech market struggles

  Jan. 28, 2016

• New study: Schizophrenia may be caused by gene-driven 'overpruning'

  Jan. 28, 2016

• Novartis blames slower-than-expected Entresto growth in US on insurer tardiness

  Jan. 28, 2016

• Top NCI scientist: 'Autologous' cell approach of firms like Kite, Juno will be main CAR-T focus

  Jan. 28, 2016

• Focus on Brazil: In pursuit of the Zika vaccine

  Jan. 27, 2016

• NEJM editor Drazen hit with big backlash over 'research parasites' comments

  Jan. 26, 2016

• DTC TV ad spending fell in December, but Pfizer topped peers

  Jan. 26, 2016

• Oxford Pharmascience hunting for a big pharma partner for painkiller marketing

  Jan. 26, 2016

• US temporarily halts enrollment in Cigna Medicare Advantage & drug plans

  Jan. 26, 2016

• Valeant CEO Pearson on the mend, but timing of return uncertain

  Jan. 26, 2016

• Judge amends Shkreli's bail to let him travel to DC for drug pricing hearing

  Jan. 26, 2016

• Roche investigating off-label Avastin use after 15 Indian patients hospitalized

  Jan. 26, 2016

• Zika vaccine quest begins as WHO warns of spread to most countries in the Americas

  Jan. 26, 2016

• Why 2 senators, including Sanders, just blocked a vote on Obama's FDA chief nominee

  Jan. 25, 2016

• OPDP warns Hospira about misleading YouTube video

  Jan. 25, 2016

• The biggest implications of ICJME's new clinical trial data sharing proposal

  Jan. 25, 2016

• Researchers probing links between Down syndrome and Alzheimer's

  Jan. 25, 2016

• Amgen wins big with Kyprolis expansion in US and Repatha approval in Japan

  Jan. 25, 2016

• Sanofi expected to slash jobs as diabetes franchise feels the squeeze

  Jan. 25, 2016

• Glaxo chief: Consumer unit can stand on its own—but don't expect a spinoff soon

  Jan. 22, 2016

• Novo Nordisk eyes the future, expands presence in Iran as sanctions lift

  Jan. 22, 2016

• Alkermes' depression drug flunks phase 3, shares nearly sliced in half

  Jan. 21, 2016

• Study: FDA scrutiny, other competition likely to eat into Indian pharma growth

  Jan. 21, 2016

• Drug firms like J&J cautious on FAAH inhibitors in wake of trial death in France

  Jan. 21, 2016

• Glaxo, Qualcomm reportedly mulling med tech joint venture

  Jan. 21, 2016

• Biden pushes Cancer MoonShot to corporate leaders in Davos, pitches faster approvals

  Jan. 21, 2016

• Express Scripts shares rocked by antitrust suit, Anthem breakup threat

  Jan. 20, 2016

• Nivalis grabs a key orphan designation for its cystic fibrosis drug

  Jan. 20, 2016

• Big data: The key to healthier patients, better margins, & making Cancer MoonShot 2020 a reality

  Jan. 20, 2016

• Off-label use of Avastin in India hospitalizes 15, sales halted in two states

  Jan. 19, 2016

• Taiwan election results buoy biotech sector, president-elect seen as major ally

  Jan. 19, 2016

• Eleven Bio shares fall off a cliff as ophthalmic drug fails second phase 3 trial

  Jan. 19, 2016

• Samsung Bioepis scores first-ever Enbrel biosim approval in EU

  Jan. 19, 2016

• FDA harshly criticizes Sarepta's Duchenne drug just one day after rejecting BioMarin's

  Jan. 15, 2016

• Cipla's pipeline bursting with more than 200 drugs

  Jan. 15, 2016

• Glaxo heading to court over generic Paxil claims in suicide case

  Jan. 15, 2016

• Behind the scenes at the FDA: Why they ultimately approved Addyi

  Jan. 15, 2016

• Analysts skeptical about Shire's Baxalta 'growth play' strategy

  Jan. 14, 2016

• ASCO: Reform the 'clinical pathways' approach to cancer

  Jan. 14, 2016

• Pay-for-delay deals continue to fall following FTC court victory

  Jan. 14, 2016

• Cancer MoonShot 2020: Independence Blue Cross to cover genome sequencing costs

  Jan. 13, 2016

• Pharma execs dismiss protests over drug pricing, focus on deal-making at JPM16

  Jan. 13, 2016

• Cervical Health Awareness Month: How far we've come since Nixon declared war on cancer

  Jan. 13, 2016

• Glaxo to stop paying physicians to promote its drugs

  Jan. 13, 2016

• Roche and AbbVie move promising CLL drug towards finish line

  Jan. 13, 2016

• Baxter again forced to recall IV solutions due to insect presence

  Jan. 12, 2016

• Allergan acquires Anterios to enhance neurotoxin delivery, bolsters Botox portfolio

  Jan. 12, 2016

• Study: PPIs for heartburn linked to increased risk of kidney disease

  Jan. 12, 2016

• Supreme Court rejects Janssen appeal over $124 million Risperdal fine

  Jan. 12, 2016

• Seres signs on with Nestlé Health Science in gut drug partnership

  Jan. 12, 2016

• Novartis CEO to unveil growth program for Alcon unit amidst falling sales

  Jan. 12, 2016

• Lawmakers urge NIH to combat high drug prices with patent overrides

  Jan. 12, 2016

• Walgreens' leadership defends unconventional Valeant deal

  Jan. 11, 2016

• Biotech Moderna partners with CRO to advance promising RNA therapies into trials

  Jan. 11, 2016

• FDA accepts Sanofi/Regeneron application for RA drug

  Jan. 11, 2016

• New year brings higher prices for 100 Pfizer drugs

  Jan. 11, 2016

• Positive hemophilia B gene-therapy results boost UniQure stock

  Jan. 8, 2016

• Medical marijuana clinics open in New York with strict restrictions

  Jan. 8, 2016

• Deal-hungry J&J partners with Chinese firm to focus on hep B breakthrough

  Jan. 8, 2016

• Zydus Cadila slapped with FDA GMP violation letter

  Jan. 7, 2016

• Large cancer database upgraded to provide 3D insights

  Jan. 7, 2016

• In efficiency bid, Novartis selling Alcon unit to Recipharm in $20M deal

  Jan. 7, 2016

• Brazil trims vaccine doses as recession deepens

  Jan. 7, 2016

• Biogen partners with Rodin on Alzheimer's research, possible buy-out opp

  Jan. 7, 2016

• Number of violation letters issued by FDA hits all-time low

  Jan. 7, 2016

• Global breast cancer treatment market forecast to hit $17.2 billion by 2021

  Jan. 6, 2016

• How one pharma marketing exec hit back at the AMA's call to ban DTC drug ads

  Jan. 6, 2016

• ACCME vs. PharmedOut: How credible is CME in the age of Addyi?

  Jan. 6, 2016

• A lesson in DTC: What happened when a Vogue contributor took Addyi for a test run

  Jan. 6, 2016

• Actelion lines up a $160,000 price tag for PAH orphan med Uptravi

  Jan. 6, 2016

• Major Chinese pharma firm plots a $3 billion IPO in Hong Kong

  Jan. 5, 2016

• Rat study finds link between neural tube defects and low PCSK9 levels

  Jan. 5, 2016

• Baxalta strikes a $1.6B immuno-oncology deal ahead of potential Shire deal

  Jan. 5, 2016

• Teva's MS hopeful takes another big hit in phase 3

  Jan. 4, 2016

• New UK program gave 500 melanoma patients early access to Merck's Keytruda

  Jan. 4, 2016

• Take two: Dr. Reddy's relaunches generic Nexium in new blue color

  Jan. 4, 2016

• The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

  Jan. 4, 2016

• FDA oncology chief Pazdur scrutinized over cancer drug approvals after wife's death

  Jan. 4, 2016

• Bill Ackman sells 14% of Valeant shares, citing tax purposes

  Jan. 4, 2016

• WellCare ditches UnitedHealth in PBM scuffle, opts for CVS

  Jan. 4, 2016

• Bionor Pharma's 'kick and kill' HIV therapy shows promise

  Dec. 23, 2015

• In unique Valeant-Walgreens distribution deal, drugmaker to retain titles to its therapies

  Dec. 23, 2015

• New CMS drug spending database reveals 7 drugs at least doubled in cost

  Dec. 23, 2015

• Actelion lines up 2016 launch for newly approved PAH orphan drug Uptravi

  Dec. 23, 2015

• Baxalta fielding buyout offers, but may land with Shire after all

  Dec. 23, 2015

• FDA approves 2015's 45th new drug, AstraZeneca's gout med

  Dec. 23, 2015

• 11 biopharma execs & experts look back on 2015: A record year for record-breaking

  Dec. 22, 2015

• Health regulators step in to investigate employee complaints against Theranos

  Dec. 22, 2015

• Bayer pumping 335 million euros into CRISPR Therapeutics gene-editing partnership

  Dec. 22, 2015

• ICER: Glaxo's new asthma drug massively overpriced, should cost 70% less

  Dec. 22, 2015

• For pharma reps, typical in-service fare includes burgers & fries—but not pizza

  Dec. 22, 2015

• UC Davis & Moffitt Cancer Center suspend KaloBios cancer trial after Shkreli debacle

  Dec. 22, 2015

• Employers turn to new tactics to rein in drug costs

  Dec. 21, 2015

• Sun Pharma's Halol plant gets FDA warning, shares slump 7%

  Dec. 21, 2015

• Isis Pharma ditches its terrorism-tainted name, will now be Ionis Pharmaceuticals

  Dec. 21, 2015

• Novartis CEO: Pharma needs to share both pain and gain with payers, providers

  Dec. 21, 2015

• AstraZeneca's hopes for major cancer hopeful durvalumab dim

  Dec. 21, 2015

• Fortune reporter offers apology for previous glowing coverage of Theranos

  Dec. 18, 2015

• Shire-Baxalta takeover drama barreling towards its final act

  Dec. 18, 2015

• University of California invests $250 million in biotech venture fund

  Dec. 18, 2015

• Chinese FDA's crackdown on poor-quality drugs shows no signs of easing up

  Dec. 18, 2015

• Gilead snags 15% stake in Galapagos 3 months after AbbVie backs out

  Dec. 18, 2015

• Narcan is just the beginning: Unleashing the power of opioid antagonism

  Dec. 18, 2015

• Why genetic testing could be coming to a workplace near you

  Dec. 17, 2015

• Novartis poaches a Harvard oncologist to head up immuno-oncology program

  Dec. 17, 2015

• With eye on the future, AstraZeneca to beef up manufacturing, R&D presence in China

  Dec. 17, 2015

• Glaxo's IL-6 antibody shows promise in rheumatoid arthritis

  Dec. 17, 2015

• Advaxis soars as FDA releases patient death-related clinical hold on its drugs

  Dec. 17, 2015

• Ted Cruz proposes controversial plan to expedite drug approvals through 'reciprocity'

  Dec. 16, 2015

• Mylan to Strides: Help us cover the tab for your noncompliant plants

  Dec. 16, 2015

• Amgen to snatch 3 drugs back from Glaxo in key int'l markets

  Dec. 16, 2015

• Pharma's 1st Amendment battle rages on as Pacira, FDA reach Exparel settlement

  Dec. 16, 2015

• Boehringer, Sanofi prepping complex asset swap of consumer, animal health units

  Dec. 15, 2015

• Reckitt Benckiser taking heat from Australian, British watchdogs for pain med ads

  Dec. 15, 2015

• Major research institutions fail transparency requirements, and pharma's not much better

  Dec. 15, 2015

• Akebia strikes $350 million deal with Mitsubishi Tanabe for next-gen anemia pill

  Dec. 15, 2015

• In surprising setback for Merck, FDA panel refuses to back broader Zetia indication

  Dec. 15, 2015

• New study: Antidepressants in pregnancy may be linked to autism

  Dec. 14, 2015

• FTC wants even more info from Walgreens & Rite Aid on proposed merger

  Dec. 14, 2015

• Lilly prices cancer med Portrazza at nearly 10 times docs' recommendation

  Dec. 14, 2015

• Valeant, in the hot seat, beefs up its legal and crisis management muscle

  Dec. 14, 2015

• UPDATE: AstraZeneca buys 55% stake in Acerta for $4 billion

  Dec. 14, 2015

• It's official: FDA shoots past 2014's new drugs record with Roche lung cancer med nod

  Dec. 14, 2015

• FDA approves first-of-its-kind chemo overdose antidote, Vistogard

  Dec. 14, 2015

• The new PCSK9 scorecard: Praluent favored by UnitedHealth, Repatha by CVS, both by Express Scripts

  Dec. 11, 2015

• New study: Too many factories, too few inspectors for India's pharma industry

  Dec. 11, 2015

• FDA AdComm recommends Teva asthma drug for adults—but not teens

  Dec. 11, 2015

• The 'Soliris-killer' cometh? Alnylam plans final 2017 trials to take on world's priciest drug

  Dec. 11, 2015

• A lead researcher and a Boehringer SVP on the drumbeat of innovation in oral anticoagulants

  Dec. 11, 2015

• WSJ details the painstaking process behind pricing a major Pfizer cancer med

  Dec. 10, 2015

• Sanofi scores landmark approval for world's 1st Dengue vaccine in Mexico

  Dec. 10, 2015

• 21st Century Cures orphan drug exclusivity measures could divide consumer and patients advocates

  Dec. 10, 2015

• EMA chief: Faster drug approvals can quell Rx sticker shock

  Dec. 10, 2015

• New analysis boosts Harvoni as 'safest' next-gen hep C option

  Dec. 10, 2015

• New study: Chemical castration doubles risk of Alzheimer's disease

  Dec. 9, 2015

• Flush with cash, Gilead chasing a mid-range deal like the one that gave it Sovaldi

  Dec. 9, 2015

• Alexion scores FDA nod for orphan drug derived from genetically engineered chickens

  Dec. 9, 2015

• FDA approves Baxalta's Vonvendi for von Willebrand bleeding disorder

  Dec. 9, 2015

• Obama FDA nominee under the microscope as regulators review pivotal Xarelto trial he ran

  Dec. 8, 2015

• Hillary Clinton to unveil 'exit tax' plan to combat inversion mergers like Pfizer/Allergan

  Dec. 8, 2015

• Laguna Pharma calls it quits after phase 3 CVD drug flop

  Dec. 8, 2015

• ASH15: Early-stage Keytruda trial shows unprecedented response in advanced multiple myeloma

  Dec. 8, 2015

• Merck & Samsung Bioepis nab 2nd major biosim approval in Korea

  Dec. 8, 2015

• Lilly's next-gen insulin hopes hit a buzzsaw as firm ditches late-stage diabetes candidate

  Dec. 7, 2015

• Merck's Keytruda gets presidential lift as Jimmy Carter announces he's cancer-free

  Dec. 7, 2015

• Mylan slapped with Justice Department subpoena over doxycycline pricing

  Dec. 7, 2015

• ASH15: J&J/AbbVie's Imbruvica cuts CLL death risk; Bluebird/Celgene buoyed by NIH myeloma data

  Dec. 7, 2015

• ASH15: Bluebird tanks 35% on gene therapy data; Novartis preps 2017 filing for blood cancer CAR-T

  Dec. 7, 2015

• Medtronic's inversion deal has already saved it more than $9 billion

  Dec. 4, 2015

• Inside the bold new fight for an HIV cure: An exclusive interview with amfAR CEO Kevin Robert Frost

  Dec. 4, 2015

• Experts at gene-editing summit warn against using CRISPR-Cas9 to cure embryos

  Dec. 4, 2015

• High specialty drug prices help drive renewed spike in 2014 healthcare spending

  Dec. 4, 2015

• Pfizer shutting down another UK R&D site, nixing more than 100 jobs

  Dec. 4, 2015

• Martin Shkreli's big regret: Not pricing Daraprim even higher

  Dec. 4, 2015

• Can Rich Heyman score a buyout hat-trick with prostate cancer drug startup ORIC?

  Dec. 3, 2015

• Pharma's PR problem: 53% of Americans blame pursuit of profits for high drug prices

  Dec. 2, 2015

• Game on: Amgen files biosimilar Humira, pulls ahead of the pack

  Dec. 2, 2015

• Pentagon official's emails demonstrate that Theranos concerns date back to 2012

  Dec. 2, 2015

• US Senate report slams Gilead over Sovaldi price, insinuates culture of profits over patients

  Dec. 2, 2015

• Adaptimmune heats up the immuno-oncology race & stares down Cellectis with Universal Cells deal

  Dec. 2, 2015

• Influential GOP lawmaker calls for tax overhaul in wake of Pfizer-Allergan inversion deal

  Dec. 2, 2015

• As Theranos deal fizzles, Safeway brings in Sonora Quest Labs for diagnostic tests

  Dec. 2, 2015

• Express Scripts banishes Turing from formulary, turns to compounder for generic Daraprim

  Dec. 2, 2015

• World AIDS Day: PrEP uptake main hurdle to 2030 eradication goal as Obama unleashes action plan

  Dec. 1, 2015

• FDA approves 3rd multiple myeloma med in a month, this time from Bristol-Myers & AbbVie

  Dec. 1, 2015

• World class panel of experts to tackle CRISPR, genome editing ethics during DC summit

  Dec. 1, 2015

• How China is getting serious about developing quality drugs right at home

  Dec. 1, 2015

• SCOTUS rejects Medtronic's patent-infringement restoration request against J&J

  Dec. 1, 2015

• New York Stem Cell Foundation doubling its footprint in Manhattan

  Dec. 1, 2015

• What's driving the rapid rise in dermatology drug prices?

  Nov. 30, 2015

• Roche severs 'superbug' antibiotic R&D pact with Polyphor

  Nov. 30, 2015

• Allergan beefs up its CNS portfolio ahead of Pfizer merger

  Nov. 30, 2015

• In rare setback, Bristol-Myers' Opdivo denied expanded melanoma label

  Nov. 30, 2015

• Could CRO revenues become a victim of the Pfizer-Allergan merger?

  Nov. 30, 2015

• UPDATE: BioMarin Duchenne drug appears destined for failure after brutal FDA meeting

  Nov. 25, 2015

• Defiant Ackman doubles down on stake in embattled Valeant

  Nov. 25, 2015

• Robots, sound waves, and software: How AZ is beefing up tech at its UK R&D hub

  Nov. 24, 2015

• After Pfizer-Allergan, few large inversion deal options for cash-rich companies

  Nov. 24, 2015

• America's favorite pharma stock is Israel's Teva

  Nov. 24, 2015

• Pricey hep C drugs found to be cost-effective in early disease and beyond

  Nov. 24, 2015

• Int'l experts reprimand WHO over Ebola crisis response

  Nov. 24, 2015

• In blow to Sanofi/Regeneron, CVS favors Amgen's competing PCSK9 med for its formulary

  Nov. 24, 2015

• Bristol-Myers' unstoppable Opdivo now approved for advanced kidney cancer

  Nov. 24, 2015

• Bristol-Myers, U.N. strike generic hep C drug production pact for poor nations

  Nov. 24, 2015

• Roche's immuno-oncology blockbuster hopeful shines in early melanoma trial

  Nov. 24, 2015

• How biopharma companies can thrive in the era of megamergers and shrinking budgets

  Nov. 24, 2015

• Horizon Pharma ditches $1 billion hostile bid for Depomed

  Nov. 23, 2015

• Samsung Bioepis close to major EU approval for Enbrel biosimilar

  Nov. 23, 2015

• FDA approves 3rd multiple myeloma med of 2015, Takeda's Ninlaro

  Nov. 23, 2015

• New data: Celldex brain cancer vaccine boosts long-term survival in advanced disease

  Nov. 23, 2015

• AstraZeneca, Sanofi strike massive compound-sharing open research pact

  Nov. 23, 2015

• KaloBios has been 'rescued' by Martin Shkreli—who is now its CEO

  Nov. 20, 2015

• Multidrug resistant bacteria now stronger than super-strength antibiotics

  Nov. 20, 2015

• Big pharma trying to quash CA drug price cap effort with massive campaign war chest

  Nov. 20, 2015

• FDA approves first-ever nasal spray to fight opioid overdose

  Nov. 20, 2015

• CAR-T companies scale up production with eye towards lowering costs

  Nov. 19, 2015

• IMS 2020 forecast: Drug spending will hit a whopping $1.4 trillion

  Nov. 19, 2015

• Sandoz chases 2-for-2 record as US biosim pioneer as FDA agrees to review copycat Neulasta

  Nov. 19, 2015

• Early scripts for female libido pill Addyi fall flat, Valeant left holding the bag

  Nov. 19, 2015

• In unexpected setback, UK cost regulators reject Amgen's PCSK9 drug

  Nov. 19, 2015

• Innovation update: Advancing the standard of care in rheumatoid arthritis

  Nov. 19, 2015

• Clovis Oncology's stock plummets on bad news about lung cancer drug

  Nov. 18, 2015

• Genmab's multiple myeloma drug gets FDA approval, boosts EU biotech sector

  Nov. 18, 2015

• Ex-Biogen exec presses ahead with new biotech

  Nov. 18, 2015

• Paris attack forces Isis Pharma to again consider name change

  Nov. 18, 2015

• AMA backs ban on direct-to-consumer pharma ads

  Nov. 18, 2015

• J&J nabs early approval for first-of-its-kind multiple myeloma med Darzalex

  Nov. 17, 2015

• Beyond trials: Real-world studies strengthen case for PrEP in HIV prevention

  Nov. 17, 2015

• Lucentis more effective than lasers for reversing diabetes-induced blindness in new study

  Nov. 17, 2015

• Senators to grill Obama's FDA commish nominee on pharma ties

  Nov. 17, 2015

• India's Sun Pharma reportedly plotting to snatch Japanese drug portfolio from Novartis

  Nov. 17, 2015

• Specialty pharma Irmat fights back, files suit against UnitedHealth Group in NY

  Nov. 16, 2015

• NEJM joins the fray in drug pricing debate as 2 thought leaders share divergent perspectives

  Nov. 16, 2015

• Billionaire Soon-Shiong's NantKwest forgoes R&D in favor of stock buyback

  Nov. 16, 2015

• Merck stands by its CETP inhibitor for heart disease even as others flop

  Nov. 15, 2015

• FDA approves Baxalta's longer-lasting hemophilia A drug

  Nov. 15, 2015

• In major victory, AstraZeneca wins FDA approval for potential $3B lung cancer med

  Nov. 15, 2015

• Roche to slash up to 1,200 jobs, shutter 4 plants in US and EU in major restructuring

  Nov. 13, 2015

• Bioethics group: Gilead, Sanofi flunk the clinical trial transparency test

  Nov. 13, 2015

• Merck's Cubicin protection efforts fail as appeals court invalidates 4 patents

  Nov. 13, 2015

• China FDA cracks down on pharmas in quality control effort

  Nov. 13, 2015

• Class-action suit alleges Endo birth control packaging errors led to unplanned pregnancies

  Nov. 13, 2015

• With an eye towards more collabs, Boehringer takes an axe to its R&D budget

  Nov. 12, 2015

• Google Life Sci, American Heart Association to pour $50M into heart research

  Nov. 12, 2015

• In potential mega-merger with Pfizer, Allergan chief Saunders could become CEO

  Nov. 12, 2015

• Horizon swipes back at Express Scripts as PBM cuts off drugmaker's specialty pharma

  Nov. 12, 2015

• WSJ: $350M Theranos-Safeway deal dissolving, adding to startup's recent woes

  Nov. 12, 2015

• Amgen flexes biologics muscle as Humira biosim nails an equivalence test for RA

  Nov. 11, 2015

• FDA approves Genentech's Cotellic as part of melanoma combo

  Nov. 11, 2015

• AstraZeneca may have a lupus blockbuster-in-waiting

  Nov. 11, 2015

• Sanofi intentionally slowed a drug approval to avoid a $708M payout, Genzyme shareholder suit alleges

  Nov. 11, 2015

• AHF: Gilead's new HIV med an attempt to evergreen, avoid patent expiration

  Nov. 11, 2015

• Researchers just discovered how to make blood stem cell genome editing a lot better

  Nov. 10, 2015

• Is Pfizer spinning its tax rate to justify a domicile-shifting merger with Allergan?

  Nov. 10, 2015

• Another heart failure hopeful: Cytokinetics/Amgen med shows phase 2 promise

  Nov. 10, 2015

• Allergan asks SCOTUS to take a hard look at pharma's controversial 'hard switch' tactic

  Nov. 10, 2015

• Advantage grows for Lilly's Jardiance with more stellar heart failure data

  Nov. 10, 2015

• AstraZeneca leapfrogs Actelion with $2.7B deal for ZS Pharma

  Nov. 9, 2015

• Payers: Forget specialty drug costs—generic prices are crushing our budgets, too

  Nov. 9, 2015

• 23andMe redux? Startup DNA4Life gets FDA warning letter on DTC genetic testing kit

  Nov. 9, 2015

• Novo's Victoza fails the 'Jardiance test,' doesn't improve heart outcomes in trial

  Nov. 9, 2015

• Armed with FDA panel nod, Merck hopes long-languishing sugammadex will finally win approval

  Nov. 9, 2015

• Insys Therapeutics under investigation for pushing powerful pain drug

  Nov. 6, 2015

• Celgene takes M&A-related hit and posts Q3 loss, but optimistic about full year

  Nov. 6, 2015

• Sanofi tries to reclaim diabetes momentum with $4.2B deal with Korean drug maker

  Nov. 6, 2015

• Hello, Genvoya: Gilead does it again with approval of single-dose, once-daily HIV pill

  Nov. 6, 2015

• A huge untapped opportunity for pharma marketing: Social media engagement with doctors

  Nov. 6, 2015

• Why biotech darling Bluebird crashed on Thursday despite solid gene therapy data

  Nov. 6, 2015

• Harvard study: Americans' prescription med use may be ballooning along with their waistlines

  Nov. 5, 2015

• Pfizer late to immunotherapy game, teaming up with Merck for lung cancer treatment

  Nov. 5, 2015

• The Jardiance effect: Novo hopes Victoza will show heart benefit, but wary of CV study design

  Nov. 5, 2015

• How Roche is applying immunotherapy techniques to fight bacterial infections

  Nov. 5, 2015

• AstraZeneca & Teva's Cephalon to pay feds, states $54M for alleged rebate fraud

  Nov. 5, 2015

• As generic drug savings reach all-time high, experts ponder biosims' long-term impact

  Nov. 5, 2015

• Walgreens, Mylan act to avoid antitrust violations as they pursue mega-deals

  Nov. 4, 2015

• Doctors' 'do-not-see' policies for pharma reps may be declining—here's why

  Nov. 4, 2015

• Bristol-Myers to snatch Cardioxyl for $2B, aiming for a novel heart failure med

  Nov. 4, 2015

• With Philidor out, Valeant lays out new derm program for patients

  Nov. 4, 2015

• Glaxo lays out ambitious plans for 20 new drugs by 2020, market shrugs

  Nov. 4, 2015

• Shire snatches rare disease firm Dyax for $5.9B, won't take eyes off Baxalta prize

  Nov. 3, 2015

• Why Mylan is taking its Perrigo pursuit to Tel Aviv's stock exchange

  Nov. 3, 2015

• Why has uptake of Novartis' expected sales superstar Entresto been so slow?

  Nov. 3, 2015

• AstraZeneca to generics makers: Back off our 'purple pill'

  Nov. 3, 2015

• Express Scripts to put specialty pharmas under the microscope, focusing on Teva & AbbVie

  Nov. 3, 2015

• FDA alleges major violations, use of old ingredients at Chinese Pfizer plant

  Nov. 2, 2015

• Activist investor Ackman holds marathon call defending embattled Valeant

  Nov. 2, 2015

• Merck chief Frazier's R&D-based drug price defense a tough sell for pharma

  Nov. 2, 2015

• Can Novartis take on Boehringer and Glaxo with its new COPD combo?

  Nov. 2, 2015

• The next challenge for CAR-T: Large-scale production

  Nov. 2, 2015

• Valeant severs ties with controversial specialty pharma after mass PBM exodus

  Oct. 30, 2015

• Sanofi, Novo forecasts dim prospects for insulin's unchallenged dominance

  Oct. 30, 2015

• CA residents to vote on major drug price cap referendum in 2016

  Oct. 30, 2015

• Vertex inches closer to profitability as CF drug sales smash estimates

  Oct. 30, 2015

• Meet Baxter's new CEO: Covidien vet José Almeida

  Oct. 30, 2015

• Hep C and long-term costs: Why safety is suddenly part of the value equation

  Oct. 30, 2015

• Merck lowers cost of Remicade in UK as biosimilars enter market

  Oct. 29, 2015

• Senate efforts to advance 21st Century Cures aims appear stymied

  Oct. 29, 2015

• FDA approves Amgen's first-in-class oncolytic viral therapy

  Oct. 29, 2015

• Despite concerns, Express Scripts sticks with AbbVie's hep C therapy

  Oct. 29, 2015

• Theranos filed $200M stock offer days before critical news report

  Oct. 29, 2015

• Gilead beats Q3 estimates substantially, shares slide anyways

  Oct. 28, 2015

• A 1st gen Pfizer Alzheimer's drug may help keep patients out of the nursing home

  Oct. 28, 2015

• How 2 biotechs are chasing a pioneering peanut allergy med

  Oct. 28, 2015

• Glaxo faces another cardio R&D failure for a lead candidate

  Oct. 28, 2015

• FDA inspection calls Theranos 'nanotainers' uncleared devices, cites quality assurance problems

  Oct. 27, 2015

• A mixed bag for Merck despite data showing Keytruda extends lung cancer survival

  Oct. 27, 2015

• Drug shortages & patent expiration: Authorized generics as more than a lifecycle strategy

  Oct. 27, 2015

• Vertex, CRISPR Therapeutics strike gene editing pact worth up to $2.6B

  Oct. 27, 2015

• Amgen reviewing privacy policy for Repatha patient assistance program

  Oct. 27, 2015

• Alexion shocks with lower-than-expected price for just-approved orphan drug

  Oct. 26, 2015

• Decade-old Novartis Parkinson's drug redeemed as FDA sees no CVD risk

  Oct. 26, 2015

• Walgreens puts expansion of Theranos presence on hold

  Oct. 26, 2015

• WHO: Introduction of first malaria vaccine should be delayed

  Oct. 25, 2015

• FDA cautiously recommends approval of AZ's gout drug

  Oct. 25, 2015

• ICER: US drug prices should align with value

  Oct. 25, 2015

• Bristol-Myers' new HIV drug shines in mid-stage trials

  Oct. 25, 2015

• GNC stock plunges as Oregon sues company, alleging drug-spiked supplements

  Oct. 23, 2015

• Ouch: PhRMA SVP says Valeant isn't 'innovative,' acts more like a hedge fund

  Oct. 22, 2015

• San Diego-based compounder to offer $1 alternative to Turing's Daraprim

  Oct. 22, 2015

• Moderna launches yet another startup, Caperna, to develop cancer vaccines

  Oct. 22, 2015

• FDA approves a new pancreatic cancer drug, Merrimack's Onivyde

  Oct. 22, 2015

• Michigan governor urges Perrigo shareholders to reject Mylan deal

  Oct. 22, 2015

• FDA questions AstraZeneca about safety of phase 3 gout drug

  Oct. 22, 2015

• Novartis expands its immuno-oncology portfolio via M&A, partnerships

  Oct. 22, 2015

• Biogen cutting 11% of workforce, betting big on Alzheimer's R&D

  Oct. 22, 2015

• Theranos CEO goes to the lion's den, refutes accusations at WSJ Live conference

  Oct. 22, 2015

• REPORT: American man in India illegally exported execution drugs to Nebraska, other states

  Oct. 21, 2015

• The Amarin effect? FDA removes warning letter aimed at Pacira from web site

  Oct. 21, 2015

• Merck plans to enter hep C market, take on Gilead & AbbVie with faster-acting combo drug

  Oct. 21, 2015

• Valeant trading at 52-week low on report alleging 'phantom pharmacies' & fake sales

  Oct. 21, 2015

• Actelion: We're interested in ZS Pharma, but not dependent on M&A

  Oct. 21, 2015

• US, Saudia Arabia may collaborate on MERS vaccine

  Oct. 21, 2015

• A Boehringer SVP and BioSig's CEO dish on the 'heart' of innovation

  Oct. 20, 2015

• Daiichi Sankyo laying off more than 1,000 US workers

  Oct. 20, 2015

• Bluebird stock plunges after patient treated with company's gene therapy relapses

  Oct. 20, 2015

• Lilly's unconventional launch for Trulicity's consumer campaign

  Oct. 20, 2015

• J&J's psoriasis star Stelara found effective for Crohn's patients in phase 3

  Oct. 20, 2015

• Novartis cancer med Tasigna may hold promise for Parkinson's patients

  Oct. 19, 2015

• FDA tells Theranos to stop using its tech except for approved herpes test

  Oct. 19, 2015

• Shire's case for a Baxalta takeover dims as FDA spurns lead eye drug

  Oct. 19, 2015

• FDA approves first-ever Pradaxa 'antidote,' BI's Praxbind

  Oct. 19, 2015

• Bristol-Myers, Novartis score big in major blood cancer drug cost-benefit analysis

  Oct. 19, 2015

• Pfizer chief Read: Lackluster insurance driving pharma's pricing woes

  Oct. 16, 2015

• Breast Cancer Awareness Month: A look at recent innovations in breast cancer

  Oct. 16, 2015

• Judge sides with PhRMA, rules orphan drugs not covered by 340B discount program

  Oct. 16, 2015

• FDA schedules separate meetings to review BioMarin, Sarepta Duchenne drugs

  Oct. 15, 2015

• Bristol-Myers, Five Prime forge $1.75B immuno-oncology development deal

  Oct. 15, 2015

• Bombshell report puts Theranos in the hot seat, alleges blood test inaccuracies & false claims

  Oct. 15, 2015

• J&J bullish that its own SGLT2 diabetes med will show Jardiance-like CV benefit

  Oct. 15, 2015

• September DTC TV ad spending for pharma hits $231 million

  Oct. 15, 2015

• Chinese firm plans large-scale production of Ebola vaccine

  Oct. 15, 2015

• 23andMe nabs $115M in new financing and a $1.1B valuation

  Oct. 15, 2015

• The curious case of Zafgen's stock and a phase 3 patient death

  Oct. 15, 2015

• Diabetes therapeutics: A hotbed of innovation and reservoir of pharma progress

  Oct. 14, 2015

• NY Attorney General probing Turing, Shkreli over antitrust concerns

  Oct. 14, 2015

• Why Bernie Sanders' opposition to Califf's FDA nomination is misguided

  Oct. 14, 2015

• Lilly to collaborate with ImaginAB on T-cell therapies for cancer

  Oct. 14, 2015

• Researchers: Bowel cancer can be categorized into four diseases

  Oct. 13, 2015

• FDA delays decision on Collegium's painkiller

  Oct. 13, 2015

• What Lilly's CVD drug failure means for other pharmas

  Oct. 13, 2015

• J&J bests Q3 estimates, announces $10B buyback; Earnings dogged by strong dollar

  Oct. 13, 2015

• Big pharmas to meet police chief who published CEOs' numbers over opioid crisis

  Oct. 13, 2015

• Good news on the horizon for Indian pharma as FDA ramps up approvals

  Oct. 13, 2015

• Reuters: Prices for top drugs in US 3 times higher than in UK

  Oct. 13, 2015

• Controversy erupts over pediatric OxyContin guidance

  Oct. 13, 2015

• AstraZeneca hits the brakes on 2 lung cancer trials after safety concerns

  Oct. 12, 2015

• Cigna eliminates mail-order requirement for HIV drugs

  Oct. 12, 2015

• Novartis pours another $15M into Israeli stem cell company

  Oct. 12, 2015

• Bristol-Myers' Opdivo nabs expanded lung cancer indication

  Oct. 12, 2015

• Senators propose adding nurses, physician assistants to Open Payments database

  Oct. 9, 2015

• Neurocrine's movement disorder drug shows promise, has blockbuster potential

  Oct. 9, 2015

• Could 'pay-for-performance' be coming to a prescription drug near you?

  Oct. 9, 2015

• Allergan, Valeant rethink 'acquire-and-hike' pricing strategy amid Shkreli-driven anger

  Oct. 9, 2015

• Roche MS drug shows big promise in harder-to-treat form of disease

  Oct. 9, 2015

• An inside look at Lilly's NYC expansion & focus on cancer immunotherapy

  Oct. 9, 2015

• Ireland-based Horizon plans big expansion, hiring spree in Chicago suburbs

  Oct. 8, 2015

• Pharma loves priority review vouchers—The FDA? Not so much

  Oct. 8, 2015

• FDA halts Advaxis immuno-oncology trials after patient death

  Oct. 8, 2015

• An innovation challenge: Using pharma R&D as a tool for social change

  Oct. 8, 2015

• FDA commish-in-waiting removes name from papers criticizing agency

  Oct. 8, 2015

• Study: Merck hep C combo effective in kidney disease patients

  Oct. 7, 2015

• Roche looks to Cotellic melanoma combo to boost Zelboraf sales

  Oct. 7, 2015

• Feds lose dietary supplement case against Bayer

  Oct. 6, 2015

• Valeant fights back against drug pricing criticism as stock tumbles

  Oct. 6, 2015

• The bubble burst cometh? Biotech stocks down 21% since July

  Oct. 6, 2015

• Alkermes generic for blockbuster schizophrenia med Abilify bags FDA nod

  Oct. 6, 2015

• Bristol-Myers settles SEC charges over China bribery scandal for $14.2M

  Oct. 6, 2015

• Spark inches closer to a pioneering US gene therapy approval

  Oct. 6, 2015

• Indian foreign secretary: EU ban on generic drugs 'unwarranted'

  Oct. 6, 2015

• CA governor signs controversial medication-assisted suicide bill

  Oct. 6, 2015

• Almost half of UK doctors have negative view of pharma industry

  Oct. 5, 2015

• TPP trade deal reached, BIO & PhRMA unhappy with drug patent compromise

  Oct. 5, 2015

• Amicus delays regulatory submission for Fabry drug

  Oct. 5, 2015

• Where are the women in HIV drug trials?

  Oct. 5, 2015

• Merck's Keytruda wins lung cancer indication—but it's not as broad as Opdivo's

  Oct. 5, 2015

• Sarepta's new strategy for winning a landmark Duchenne drug approval

  Oct. 2, 2015

• FTC asks Court of Appeals to reexamine Doryx 'product-hopping' case

  Oct. 2, 2015

• EMA nominates Guido Rasi as executive director—again

  Oct. 2, 2015

• TPP trade talks stuck in the mud over US drug exclusivity demands

  Oct. 2, 2015

• Bristol-Myers' Opdivo/Yervoy combo wins FDA approval, will cost $256,000

  Oct. 2, 2015

• Chasing a ghost: Why is FDA guidance on biosim interchangeability taking so long?

  Oct. 2, 2015

• Private artificial intelligence firm to help data mine for UK genomics project

  Oct. 1, 2015

• Teva exec: Pharma needs to face its pricing demons head-on

  Oct. 1, 2015

• WHO pushes for far more aggressive worldwide use of HIV meds

  Oct. 1, 2015

• Clovis set for showdown with AZ as it wins fast-track for lung cancer drug

  Oct. 1, 2015

• Global standoff looms between US, developing nations over WTO waiver extension

  Oct. 1, 2015

• Sanofi hopes to broaden diabetes portfolio as FDA accepts lixisenatide submission

  Sept. 30, 2015

• Can Lilly & Incyte elbow their way into a crowded market with promising RA drug?

  Sept. 30, 2015

• Pioneering Novavax RSV vaccine passes protection to newborns, wins $89M from Gates Foundation

  Sept. 30, 2015

• Aiming to cure blindness, UK team implants embryonic retinal cells in AMD patient

  Sept. 30, 2015

• Allergan riding high with 10% increase in branded product revenues

  Sept. 29, 2015

• Novartis backs graphic novel featuring a teen with a rare disease—and his dog

  Sept. 29, 2015

• Kyle Bass escapes USPTO sanctions on drug patent challenges, BIO balks

  Sept. 29, 2015

• Lilly settles Sanofi dispute, plans 2016 launch for biosim Lantus

  Sept. 29, 2015

• House Dems demand Valeant CEO testify on price hikes with Shkreli, stock plunges

  Sept. 29, 2015

• FDA approves Bayer's autoinjector for MS drug

  Sept. 28, 2015

• Glaxo shutting down French research lab, laying off 70 employees

  Sept. 28, 2015

• FDA revokes Sun Pharma's approval for epilepsy drug after compliance concerns

  Sept. 28, 2015

• Bristol-Myers' Opdivo boosts kidney cancer survival, Roche PD-L1 hopeful shrinks tumors

  Sept. 28, 2015

• The diabetes king? Novo finally gets its Tresiba long-acting insulin approval

  Sept. 28, 2015

• FDA warns Pathway Genomics cancer blood test 'may harm the public health'

  Sept. 25, 2015

• After bad news on Breo, Glaxo's monthly asthma drug wins an EU rec

  Sept. 25, 2015

• Arrowhead hep B treatment shows early promise, sends shares flying

  Sept. 25, 2015

• Novartis to tackle chronic diseases in poor countries with new program

  Sept. 25, 2015

• Top US cardiologists push to limit PCSK9 drug patient pool

  Sept. 24, 2015

• Nestlé partners with AC Immune to expand into Alzheimer's diagnostics

  Sept. 24, 2015

• Amgen-Allergan's Avastin biosimilar shows promise in lung cancer trials

  Sept. 24, 2015

• Are the EU's steep biosim discounts the ghost of US biosimilars' future?

  Sept. 24, 2015

• FDA approves Taiho Oncology's pill for metastatic colorectal cancer

  Sept. 24, 2015

• How the FDA is trying to demystify clinical trial data

  Sept. 24, 2015

• Has the era of the super successful pharma sales rep really come to an end?

  Sept. 23, 2015

• A 'reverse Turing?' Nonprofit reacquires TB drug, rolls back massive price hike

  Sept. 23, 2015

• Report: J&J had plan to block more FDA restrictions on Tylenol

  Sept. 23, 2015

• AZ using crowdsourcing to find effective cancer drug combos

  Sept. 23, 2015

• India's Serum Institute chases fast-track approval for dengue treatment as cases spike

  Sept. 23, 2015

• Study: Cancer drugs in US cost up to 6,000% of production cost

  Sept. 23, 2015

• UPDATE: Shkreli backtracks on 5,000% price hike after outrage, doesn't specify new cost

  Sept. 22, 2015

• Clinton calls out Turing & Shkreli on wild price hike, releases pharma cost cap plan

  Sept. 22, 2015

• Bristol-Myers' immuno-oncology star Opdivo nabs kidney cancer priority review

  Sept. 22, 2015

• Shire's once-daily extended-release ADHD drug now approved in Europe

  Sept. 22, 2015

• Mass. police chief lists big pharma CEO phone numbers as part of opioid addiction fight

  Sept. 22, 2015

• After Harvoni: A pangenotype hep C combo could be Gilead's next breakthrough

  Sept. 22, 2015

• Merck's antibody-in-development reduces risk of C. difficile re-infection

  Sept. 21, 2015

• 2nd time's the charm for Allergan, Richter antipsychotic drug

  Sept. 21, 2015

• Obama's FDA chief nominee received more than $200K in industry fees

  Sept. 21, 2015

• Lilly/BI's Jardiance found to be first diabetes med to cut CV deaths in study

  Sept. 21, 2015

• Aerie Pharma's glaucoma eye drop shows promise in late-stage trial

  Sept. 17, 2015

• Another big pharma exec leaves for a biotech—from Glaxo to Celyad

  Sept. 17, 2015

• AstraZeneca forges partnership with BARDA to develop powerful antibiotics

  Sept. 17, 2015

• Report: Glaxo withheld critical data on antidepressant Seroxat

  Sept. 17, 2015

• Why several FDA reviewers recommended not approving female libido med Addyi

  Sept. 17, 2015

• An update on first-ever US biosim Zarxio 2 weeks after its debut

  Sept. 17, 2015

• Merck's once-weekly diabetes med as effective as daily Januvia in study

  Sept. 17, 2015

• Amgen snaps up Dutch biotech Dezima for $1.55 billion

  Sept. 16, 2015

• Intra-Cellular shares fly as schizophrenia drug shown effective at higher doses

  Sept. 16, 2015

• Veteran NIMH director leaving agency to join Google Life Sciences

  Sept. 16, 2015

• Meet Travis McCready, the next head of the MA Life Sciences Center

  Sept. 16, 2015

• AbbVie, Janssen chase first-line approval of Imbruvica for CLL

  Sept. 16, 2015

• Xenoport shares dive as psoriasis drug shows serious GI side effects

  Sept. 16, 2015

• The gender gap is especially severe in biotech lab funding

  Sept. 16, 2015

• The next hope for GW Pharma's cannabis med: Schizophrenia treatment

  Sept. 16, 2015

• Steve Brill unleashing 15-part exposé on J&J, Risperdal: 'America's Most Admired Lawbreaker'

  Sept. 16, 2015

• Reputation matters: Why the rift between pharma and patients is ballooning

  Sept. 15, 2015

• Shire may be upping the ante in pursuit of Baxalta—with faster cash

  Sept. 15, 2015

• Acacia planning $232 million IPO in London market

  Sept. 15, 2015

• Takeda floats conditional $100M boost to $2.3 billion Actos settlement

  Sept. 15, 2015

• 10th Indian pharma plant this year makes FDA's do-not-import list

  Sept. 15, 2015

• UPDATE: Mylan officially takes $27B hostile bid to Perrigo shareholders

  Sept. 15, 2015

• Federal task force narrows aspirin use guidelines, suggests cancer benefit

  Sept. 15, 2015

• Lilly boosting size of Kendall Square innovation center

  Sept. 14, 2015

• A tale of two painkillers: Collegium gets FDA panel rec that eludes Purdue

  Sept. 14, 2015

• 2 new studies show Gilead's Truvada extremely effective for HIV prevention

  Sept. 14, 2015

• Amgen goes after once-monthly dosing option for Repatha

  Sept. 14, 2015

• Express Scripts CEO Paz to retire next May, leaving legacy of price pushbacks

  Sept. 11, 2015

• Another biotech M&A? Actelion, ZS Pharma in 'strategic transaction' talks

  Sept. 11, 2015

• Pfizer loses major Lyrica patent case in UK, leaving door for generics wide open

  Sept. 11, 2015

• Gilead raises $10 billion, stoking fresh rumors of a monster acquisition

  Sept. 11, 2015

• Georgia opens $14M bioscience training center next to Baxalta plant

  Sept. 11, 2015

• How to stop a biopharma compliance breach before it happens

  Sept. 10, 2015

• FDA concerned about dosing risk with Collegium's opioid painkiller

  Sept. 10, 2015

• Russia's Putin reiterates commitment to 90% domestic drug-making by 2020

  Sept. 10, 2015

• Africa's largest generic drug maker is on the hunt for acquisitions

  Sept. 10, 2015

• ICER report says $14,000 PCSK9 meds should actually cost 70% less

  Sept. 10, 2015

• Biogen strikes $544M deal with Mitsubishi Tanabe for late-stage autoimmune drug

  Sept. 10, 2015

• PayPal co-founder Peter Thiel pours $200M into cancer stem cell biotech

  Sept. 9, 2015

• Merck/Samsung Bioepis win their 1st biosim approval in Korea—for copycat Enbrel

  Sept. 9, 2015

• Roche CEO slams 'stupid,' 'arbitrary' UK decision to cut 17 cancer meds' funding

  Sept. 9, 2015

• Glaxo takes a big blow as 'son of Advair' fails to extend COPD patients' lives

  Sept. 9, 2015

• New study claims Pfizer's Chantix not linked to depression, heart attacks after all

  Sept. 8, 2015

• A big win for AZ as FDA clears Brilinta for long-term use

  Sept. 8, 2015

• Former Hospira chief's platinum parachute: $91 million in cash

  Sept. 8, 2015

• Bristol-Myers is testing out a dual-threat Opdivo/Yervoy lung cancer combo

  Sept. 8, 2015

• Experimental treatment offers hope for CAR-T leukemia patients

  Sept. 4, 2015

• World's largest public stem cell bank now open in CA

  Sept. 4, 2015

• Valeant partners with AZ on psoriasis drug

  Sept. 4, 2015

• More than half of doctors have 'no access' policies for reps

  Sept. 4, 2015

• Moody's upgrades financial outlook for biopharma industry

  Sept. 4, 2015

• Regeneron scientists score rare disease breakthrough with excess bone growth discovery

  Sept. 3, 2015

• The key facts to know about the FDA's new 340B drug discount guidance

  Sept. 3, 2015

• Amgen launching PCSK9 med Repatha in Europe at steep discount to US price

  Sept. 2, 2015

• How 2014 became a banner year for biotech job growth in MA

  Sept. 2, 2015

• US biosimilar era officially dawns as Novartis' Zarxio launches Thursday

  Sept. 2, 2015

• Biosimilars Council chief answers 6 key questions about biosims in the US

  Sept. 2, 2015

• Pharma takes major offense to French law promoting off-label Avastin use

  Sept. 2, 2015

• Alexion wins EU nod for newly acquired enzyme-replacement drug

  Sept. 2, 2015

• Pharma lobbies Congress for big—and expensive—changes to patent rules

  Sept. 2, 2015

• Novartis and Amgen team up to take on Alzheimer's, migraines

  Sept. 2, 2015

• 2 major insurers draw lines in the sand for pricey PCSK9 coverage

  Sept. 2, 2015

• Baxalta may have a new M&A-based strategy for spurning Shire

  Sept. 1, 2015

• Bristol-Myers sets sights on a Jakafi competitor with $1.25B fibrosis firm deal

  Sept. 1, 2015

• How do you solve a problem like drug shortages?

  Aug. 31, 2015

• Bayer lines up a phase III trial for its dual-threat heart failure hopeful

  Aug. 31, 2015

• Asterias stem cell therapy shows promise in spinal cord injury patients

  Aug. 31, 2015

• Novo Nordisk acquiring 2 US biotechs, Calibrium and MB2

  Aug. 31, 2015

• Oncologists question Lilly lung cancer hopeful's pricing in growing trend

  Aug. 31, 2015

• Stem cell researcher at major Swedish research hub cleared of misconduct

  Aug. 31, 2015

• FDA warns: DPP-4 inhibiting diabetes meds may cause severe joint pain

  Aug. 31, 2015

• An experimental anti-cholesterol drug could outperform approved PCSK9 meds

  Aug. 31, 2015

• Macro-level innovation: A Q&A with Bain & Company's healthcare guru

  Aug. 28, 2015

• FDA's new draft guidance on naming biosimilars already drawing pushback

  Aug. 28, 2015

• Lilly/BI snag another FDA approval for a diabetes drug—Synjardy

  Aug. 28, 2015

• FDA demands another study for uniQure's ultra-pricey gene therapy

  Aug. 27, 2015

• J&J/Genmab unveil promising data for a potential multiple myeloma superstar

  Aug. 27, 2015

• Massachusetts leads states' war on high drug prices

  Aug. 27, 2015

• FTC to FDA: Ramp up oversight on homeopathic drug makers

  Aug. 27, 2015

• Pfenex at the forefront: How a different biosim approach is becoming a disruptive force

  Aug. 27, 2015

• Novo jumping into phase III trials for major oral diabetes candidate

  Aug. 27, 2015

• In big win for pharma, advocates urge WH to push broader Medicaid hep C coverage

  Aug. 26, 2015

• Novo Nordisk planning $1.2 billion US expansion, bringing 700 jobs to NC

  Aug. 26, 2015

• Sarepta wins priority review for hotly anticipated Duchenne drug

  Aug. 26, 2015

• How Japan is trying to beef up its pharmaceutical industry

  Aug. 26, 2015

• Bristol-Myers, Sanofi prevail in Plavix false claims case

  Aug. 26, 2015

• UK's NHS commissions new TB drugs for first time in 50 years

  Aug. 26, 2015

• Controversial fund manager Kyle Bass loses first major pharma patent battle

  Aug. 26, 2015

• Could an aspirin a day keep colon cancer away?

  Aug. 26, 2015

• Why Gilead's hep C scripts are slowing down in Q3

  Aug. 25, 2015

• In huge victory for generics, court invalidates Takeda's Velcade patent

  Aug. 25, 2015

• Study: Common beta blockers can extend ovarian cancer patients' lives

  Aug. 25, 2015

• AZ poaches Genentech cancer vet Bohen, appoints him as new CMO

  Aug. 25, 2015

• Why BioMarin hawked a phase III cancer drug to Medivation for $570M

  Aug. 25, 2015

• US Army testing drug to protect soldiers' hearing

  Aug. 24, 2015

• Excitement over Jardiance may come at Merck's expense

  Aug. 24, 2015

• New tool aims to simplify cancer treatment cost/benefit analysis

  Aug. 24, 2015

• Sarepta, Biomarin vie for DMD approval, priority review voucher

  Aug. 24, 2015

• Novartis snaps up MS indication for Glaxo's Arzerra

  Aug. 24, 2015

• Rare disease companies' existential challenge: Patient enrollment

  Aug. 21, 2015

• Baxalta CEO touts new R&D model with a focus on development

  Aug. 21, 2015

• Biosim behemoth? Partners Samsung and Biogen will float a $1 billion IPO

  Aug. 21, 2015

• Jimmy Carter has cancer, and his treatment regimen includes Merck's Keytruda

  Aug. 21, 2015

• Lilly/BI's Jardiance could be the first diabetes med to cut heart attack, stroke risk

  Aug. 21, 2015

• How Addyi will change the way we talk about sex—and what it means for marketers

  Aug. 21, 2015

• Lundbeck shredding 1,000 jobs, 17% of workforce—and its stock is up big

  Aug. 19, 2015

• AbbVie snaps up priority review voucher from United Therapeutics for $350M

  Aug. 19, 2015

• Intarcia's diabetes pump bests Merck's Januvia in head-to-head trial

  Aug. 19, 2015

• Merck chief Frazier touts extra day off for workers, union not impressed

  Aug. 19, 2015

• Moving beyong licensing, gene therapy firm ReGenX plans $100 million IPO

  Aug. 19, 2015

• Tables turned: Mylan cited by FDA for quality violations at Indian plants

  Aug. 19, 2015

• Biogen & Columbia team up to unlock ALS genetics, with some 'Ice Bucket' cash

  Aug. 19, 2015

• Concordia and Par settle FTC's anti-competition charges

  Aug. 19, 2015

• Merck star Keytruda nabs priority review for first-line treatment of metastatic melanoma

  Aug. 18, 2015

• UPDATE: Sprout plots hiring binge after controversial female libido drug approval

  Aug. 18, 2015

• Retrophin sues outspoken founder Shkreli for $65M over alleged misuse of funds

  Aug. 18, 2015

• Kite Pharma does damage control, quashes drug-induced patient death rumors

  Aug. 18, 2015

• Roche's immunotherapy hopeful keeps rolling, this time in phase II lung cancer trial

  Aug. 18, 2015

• The next viruses in Gilead's crosshairs: HIV and hep B

  Aug. 18, 2015

• Genmab receives $2 million from Novo Nordisk for DuoBody platform

  Aug. 17, 2015

• Big win for Endo: Court rules against Actavis in generic painkiller patent spat

  Aug. 17, 2015

• Lawmakers set their sights on Valeant and its steep heart drug price hikes

  Aug. 17, 2015

• FDA approves OxyContin use in some children

  Aug. 17, 2015

• In Mylan-Perrigo hostile takeover drama, it's proxy firm vs. proxy firm

  Aug. 17, 2015

• Mylan reports a solid Q2, outpaces analysts' expectations

  Aug. 10, 2015

• The challenges of China for Western drug makers

  Aug. 10, 2015

• Where biotech is booming: From Boston, to Raleigh, and beyond

  Aug. 7, 2015

• AZ, Heptares heading into immuno-oncology partnership

  Aug. 7, 2015

• Novo reports stronger-than-expected Q2, raises full-year forecast

  Aug. 7, 2015

• Novo's chief medical officer dishes on innovation in diabetes drug development

  Aug. 7, 2015

• Armed with stronger label, can Sanofi's Toujeo perform better in the UK?

  Aug. 6, 2015

• Express Scripts' 2016 formulary: Who's in, who's out, & how did they decide?

  Aug. 6, 2015

• CNS-focused US cannabis patch company raises $42M in IPO

  Aug. 6, 2015

• Shire's pursuit of Baxalta stymied by strong takeover defenses

  Aug. 6, 2015

• India cancels EU trade talk meeting over widespread drug ban

  Aug. 6, 2015

• FDA to update Novartis' Gilenya label with brain-infection risk warning

  Aug. 5, 2015

• Bayer, Berkeley-based biotech labor union settle 4-year contract

  Aug. 5, 2015

• Bevy of factors to lift pharma sales to $1.3 trillion by 2018: Thomson Reuters

  Aug. 5, 2015

• Akorn accused of infringing Allergan's Lumigan patents

  Aug. 5, 2015

• Pfizer gains EU antitrust approval for Hospira acqusition

  Aug. 5, 2015

• A rare case: Young woman with Duchenne's waiting for a cure

  Aug. 4, 2015

• Shire buying Foresight Biotherapeutics and its pink eye drug for $300M

  Aug. 4, 2015

• AZ & Isis Pharma expanding collaborative gene therapy R&D

  Aug. 4, 2015

• Merck's hep C positioning strategy: Target toughest-to-treat patients

  Aug. 4, 2015

• Aprecia's Spritam becomes first FDA-approved 3D printed medication

  Aug. 4, 2015

• Sanofi, riding high from a strong Q2, may put its crosshairs on acquisitions

  Aug. 3, 2015

• All-in? AstraZeneca soldiers forward with psoriasis hopeful despite suicide link

  Aug. 3, 2015

• Big federal funding for vets' hep C treatments sneaked into highway bill

  Aug. 3, 2015

• FDA: Hospira infusion system vulnerable to hackers

  Aug. 2, 2015

• Biologic patent life emerges as sticking point in failed TPP talks

  Aug. 2, 2015

• Amgen raises full-year outlook on strong Q2 earnings

  July 31, 2015

• Is there a link between Teva's bribery probe and a former employee's firing?

  July 31, 2015

• Afrezza sales still underperforming, but MannKind remains optimistic

  July 31, 2015

• Kaiser CEO pens powerful op-ed on drug costs, calls for new pricing model

  July 31, 2015

• From Glaxo to Parexel—and now, unemployed

  July 30, 2015

• The Teva-Allergan deal and the power of the 'focus factor'

  July 30, 2015

• Uh-oh: Glaxo facing new corruption charges—this time, in Romania

  July 30, 2015

• Sanofi's LixiLan aces a late-stage trial, setting up diabetes showdown with Novo

  July 30, 2015

• Largest US benefits manager warns PCSK9 meds will 'wreak havoc' on payers

  July 30, 2015

• Novartis gets on risk-sharing bandwagon, spins off 3 pipeline drugs into new biotech

  July 30, 2015

• Why Pfizer is abandoning its OTC Lipitor program

  July 30, 2015

• Hospira's painkiller recall is ballooning—Is Pfizer getting nervous?

  July 29, 2015

• Want a better placebo effect? Stick to needles over pills

  July 29, 2015

• Welcome to the club: Regeneron, Sanofi to team up, join cancer immunotherapy fray

  July 29, 2015

• Soon-Shiong's NantKwest has a record-setting IPO and zero approved drugs

  July 29, 2015

• Stellar hep C sales help Gilead smash Q2 earnings estimates

  July 29, 2015

• Aegerion CEO resigns amid tensions with institutional investors

  July 28, 2015

• Could Sanofi's dengue vaccine become a game-changer?

  July 28, 2015

• UCSD wins legal spat against USC over control of landmark Alzheimer's project

  July 28, 2015

• Report finds pharma doesn't always report serious side effects to FDA in time

  July 28, 2015

• EU upholds massive drug ban over alleged CRO data manipulation

  July 28, 2015

• World Hepatitis Day: The transformation and enduring struggles of HCV treatment

  July 27, 2015

• Sandoz closing three German and Indian factories

  July 27, 2015

• AbbVie reports disappointing Q2 sales, better-than-expected profits

  July 27, 2015

• Biogen's comeback strategy after $18B market value loss: More acquisitions

  July 27, 2015

• Allergan buys Naurex for $560 million, nabs 2 antidepressants

  July 27, 2015

• Teva to snap up Allergan's generics unit for $40.5B, become Big Pharma behemoth

  July 27, 2015

• What's the most 'efficient' biopharma company of 2014?

  July 24, 2015

• 2nd gen radiotracers and Alzheimer's diagnosis in the age of early-intervention trials

  July 24, 2015

• European regulators just announced a massive overhaul of pediatric waivers

  July 24, 2015

• Eli Lilly stacking scientists in San Diego as part of R&D growth spurt

  July 24, 2015

• US appeals court: Pharmacy responsibilities trump religious beliefs

  July 24, 2015

• BMS and Exelixis make headway against Novartis in kidney cancer

  July 23, 2015

• The FDA wants to figure out DTC ad claims' effect on consumers

  July 23, 2015

• A tough setback for AZ as major eye cancer hopeful flunks phase III

  July 23, 2015

• Roche renews commitment to R&D of two AD drugs

  July 23, 2015

• Why Abbott's profits outperformed Q2 expectations

  July 23, 2015

• Promising stem-cell clinical trial results for rare lung disease

  July 22, 2015

• Amgen's Repatha becomes world's first approved PCSK9 inhibitor

  July 22, 2015

• Q2 earnings update: Novartis sales slump on strong dollar, weak Alcon

  July 22, 2015

• FDA chastises Vista Pharma for not paying generic drug user fees

  July 21, 2015

• Tekmira to become Arbutus, shift focus to hep B

  July 21, 2015

• An Alzheimer's update: New drugs, new insights, new hope

  July 21, 2015

• NEJM: Early HIV therapy delays AIDS-related events & death

  July 21, 2015

• Researchers are about to launch the largest AIDS treatment trial ever

  July 20, 2015

• Bristol-Myers' rock star Opdivo continues to roll, this time in kidney cancer

  July 20, 2015

• Novogen gets FDA approval for Anisina orphan drug status

  July 20, 2015

• FDA grants AbbVie's anti-tau drug orphan status

  July 20, 2015

• Amgen's leukemia drug excels in phase II for new indication

  July 20, 2015

• NICE recommends Daiichi Sankyo's oral blood thinner

  July 20, 2015

• WHO prequalifies Novartis' Coartem for malaria

  July 20, 2015

• Innovation vs. access: The big drug battle in Trans-Pacific Partnership negotiations

  July 17, 2015

• FDA huddles with Google to improve adverse-event reporting

  July 17, 2015

• Teva gets FDA OK to market generic Axert

  July 16, 2015

• Stem cell breakthrough for Salk Institute researchers

  July 16, 2015

• BMS nabs EU approval for once-daily HIV combo pill

  July 16, 2015

• Sun Pharma slashing Ranbaxy's contract manufacturing unit

  July 16, 2015

• Sandoz closing plant in India

  July 16, 2015

• Sanofi restructuring business to drive growth

  July 16, 2015

• Why some new drugs are truly earning the 'innovative' label

  July 16, 2015

• ASCO scorecard upgrades rating for Lilly's Alimta

  July 16, 2015

• Allergan faces lost sales as Namenda generics hit market

  July 16, 2015

• J&J/Bavarian Nordic launching phase II Ebola vaccine trial

  July 16, 2015

• J&J could reopen closed factory, revive OTC business

  July 15, 2015

• New depression treatment approach could provide relief within hours

  July 15, 2015

• NHS Scotland approves funding for five new drugs

  July 15, 2015

• Celgene buying Receptos for $7.2 billion

  July 15, 2015

• EU agency to investigate HPV vaccine safety

  July 15, 2015

• FDA approves AZ's Iressa for lung cancer

  July 14, 2015

• Roche's PD-L1 drug slows bladder cancer growth in trials

  July 13, 2015

• Study: Type 2 diabetes linked with cognitive decline

  July 13, 2015

• Amgen awaiting FDA decision on cancer drug Kyprolis

  July 13, 2015

• Janssen-Cilag's Imbruvica approved in EU to treat rare blood cancer

  July 13, 2015

• Analysts back Biomarin's stock as it reaches new high

  July 12, 2015

• R&D head leaving Biogen for startup

  July 12, 2015

• In reversal, NHS making Takeda's Entyvio available to Crohn's patients

  July 12, 2015

• FDA approves Otsuka/Lundbeck drug for both depression and schizophrenia

  July 12, 2015

• Study: Off-label use of antipsychotics growing in teens/young adults

  July 12, 2015

• A 21st century diabetes option: Will Oramed be first to market with oral insulin?

  July 10, 2015

• What Glaxo's strategy guru thinks the future holds for HIV markets

  July 10, 2015

• Walgreens taps Pessina as permanent CEO after besting Q3 expectations

  July 10, 2015

• Will public pressure drive the FDA to approve a so-so female libido drug?

  July 10, 2015

• FDA support for Lilly cancer drug comes down to unmet needs vs side effects

  July 10, 2015

• AstraZeneca divests gastro drug for $215 million

  July 10, 2015

• Insurers are getting bigger—What does that mean for pharma's pricing power?

  July 9, 2015

• Senior congressman joins chorus calling for heroin antidote price cut

  July 9, 2015

• One big change bolstering gene therapy enthusiasm? Better viral delivery systems

  July 9, 2015

• Novartis files leukemia drug Arzerra in the EU

  July 9, 2015

• UCSD calls out USC for alleged unethical recruiting of its Alzheimer's researchers

  July 9, 2015

• CF Foundation gains massive windfall from Vertex's Kalydeco

  July 8, 2015

• CVS Health quit tobacco—and now it's quitting the Chamber of Commerce

  July 8, 2015

• Another Indian CRO in hot water, this time with the WHO

  July 8, 2015

• Lilly's lung cancer drug seen as risky by FDA—but will that matter?

  July 8, 2015

• Horizon Pharma in hostile pursuit of Depomed for $3 billion

  July 8, 2015

• Sanofi, Gilead get boosts in Japan with new Lantus & Harvoni approvals

  July 7, 2015

• Biogen pursuing AGTC's ophthalmology gene therapy—for up to $1 billion

  July 7, 2015

• Pharma's newest adversaries on CME funding are... Hotel workers?

  July 7, 2015

• Pharma flings accusations, dire predictions in wake of Greek financial crisis

  July 7, 2015

• Will Vertex finally become profitable after FDA approval for CF drug Orkambi?

  July 6, 2015

• J&J moves HIV vax to human trials after 50% protection rate in monkeys

  July 6, 2015

• Another Roche Alzheimer's drug disappoints

  July 6, 2015

• Promise, and caution, as gene therapy shows potential for cystic fibrosis

  July 6, 2015

• Big deal for biosims? Major French hospital group opts for Hospira's Remicade copy

  July 6, 2015

• In rare move, Purdue pulls out of abuse-deterrent OxyContin meeting with FDA

  July 2, 2015

• Drug makers warn EU over troubled Greece: Medicine supply 'may be in jeopardy'

  July 2, 2015

• FDA gives pharmacies grace period to implement 'track and trace'

  July 2, 2015

• New study: Glaxo flu vax linked to increased narcolepsy risk

  July 2, 2015

• Novo to halt Tresiba sales in Germany over pricing conflict

  July 2, 2015

• 'Innovation' is everywhere in biopharma—but what does that actually mean?

  July 2, 2015

• Roche impresses with strong phase III data for MS drug candidate

  July 1, 2015

• DOJ wants to fine Novartis a staggering $3.35 billion for kickbacks

  July 1, 2015

• California governor signs mandatory vaccination bill into law

  July 1, 2015

• Open Payments: Docs got $6.5 billion from drug/device industries in 2014

  July 1, 2015

• Sanofi/MannKind might be facing a major flop with Afrezza inhaled insulin

  July 1, 2015

• Generics update: FDA releases new bioequivalence guidance

  June 30, 2015

• Novartis back in the pain game with $700M deal for Australia's Spinifex

  June 30, 2015

• Health advocacy groups sue FDA for Gilead's hep C data

  June 30, 2015

• Samsung Bioepis eyes NASDAQ IPO to fuel big name biosim R&D

  June 30, 2015

• Celgene & Juno just struck a blockbuster $1B collab deal—but does it make sense?

  June 30, 2015

• Parexel axing 850 jobs in big reorg

  June 29, 2015

• Pfizer goes to court in UK to fight for Lyrica patent integrity

  June 29, 2015

• Lilly's data mining may pay off with nearly-abandoned Alzheimer's drug

  June 29, 2015

• Bristol-Myers going all-in on biotech hub Cambridge for R&D

  June 29, 2015

• Is this the end of the line for Celladon after its gene therapy flop?

  June 29, 2015

• EMA validates BioMarin's Duchenne Muscular Dystrophy treatment

  June 26, 2015

• How Novartis' CEO wants to tackle an ever-aging world

  June 26, 2015

• The cost of 'Cures': FDA bill's rare disease provisions to cost $869 million

  June 26, 2015

• Bristol-Myers calls it quits on any new virology R&D programs

  June 26, 2015

• Take your medicine: CA lawmakers approve mandatory vax bill for children

  June 26, 2015

• REMS reform, round 2: Will the FAST Generics Act speed past the finish line this year?

  June 26, 2015

• Study: Combo Rx regimen can treat bipolar depression

  June 25, 2015

• Report: It pays big to focus on diabetes drugs

  June 25, 2015

• Federal panel decides meningitis B vaccination not mandatory

  June 25, 2015

• Alcobra flops as placebo beats its drug in phase II

  June 25, 2015

• Second top AstraZeneca exec heads for the exits

  June 25, 2015

• Takeda's CFO to swap industries, become Nestle's CFO

  June 24, 2015

• Will the TIPP trade agreement force the FDA & EMA to harmonize?

  June 24, 2015

• New generics-positive bill aims to end REMS abuse

  June 24, 2015

• The early winners and losers in ASCO's highly anticipated cancer drug scorecard

  June 24, 2015

• Google X unveils health-tracking wristband for clinical trials, research

  June 24, 2015

• Study: Australian gov't wasting $320 million per year on drug subsidies

  June 23, 2015

• Dutch or American? In takeover drama, Mylan seems to want it both ways

  June 23, 2015

• Pay attention: Adults now main ADHD treatment target

  June 23, 2015

• Immuno-oncology upstart Conkwest going public in $172.5M IPO

  June 23, 2015

• FDA approves Medicines Co's antiplatelet drug

  June 23, 2015

• Strike 2 for Teva's Copaxone in US appeals court

  June 22, 2015

• China rejects Gilead's hep C drug patent

  June 22, 2015

• Lilly, Teva to present late-stage migraine drug data

  June 22, 2015

• Bayer beefs up R&D investment to $4.5 billion this year

  June 22, 2015

• Tekmira's Ebola trials halted over efficacy concerns

  June 22, 2015

• Merging pains: Sun Pharma says goodbye to 18 major Ranbaxy execs

  June 19, 2015

• More than 1,000 online drug sites under FDA scrutiny

  June 19, 2015

• Amgen's colorectal cancer drug shines in phase III

  June 19, 2015

• Teva completes Mylan share purchases, official takeover bid could come any day

  June 19, 2015

• BioMarin's childhood dwarfism drug nails it in phase II

  June 19, 2015

• BIO2015 & 21st Century Cures: Why value matters more than ever

  June 19, 2015

• Report: Global Rx drug sales to reach nearly $1 trillion by 2020

  June 18, 2015

• Ebola vaccines require greater speed in trials

  June 18, 2015

• New drug compound may beat malaria with single $1 dose

  June 18, 2015

• Synergy Pharma shares soar from constipation drug study

  June 18, 2015

• Despite insider sale, Receptos stock surges on takeover rumors

  June 18, 2015

• GSK's decision to cast off now-valuable drugs raises questions

  June 17, 2015

• Bayer, Johns Hopkins team up for eye disease R&D

  June 17, 2015

• FDA to review Teva asthma biologic

  June 17, 2015

• Abbott gets involved in M&A drama, backs Perrigo buy

  June 17, 2015

• Study: Biopharma's pipeline-by-merger strategy isn't working

  June 17, 2015

• Largest US drug testing lab negotiating settlement with feds for over-testing

  June 16, 2015

• Biotech is booming—but is big pharma waning?

  June 16, 2015

• CVS further widens reach with $1.9B deal for Target's pharmacies

  June 16, 2015

• Avalanche gene therapy safe, modestly effective in AMD patients

  June 16, 2015

• Goodbye, Actavis—hello, Allergan

  June 16, 2015

• Study: Drug makers stay coy about FDA rejections & criticisms in their press releases

  June 15, 2015

• The curious case of Lilly's share price and its Alzheimer's hopeful data

  June 15, 2015

• 1st sickle cell patient treated with Bluebird's pioneering gene therapy doing well

  June 15, 2015

• FDA approves Brio's brain implant for Parkinson's

  June 15, 2015

• How did Axovant raise $315M with one asset and no clinical data?

  June 15, 2015

• FDA committee endorses Glaxo's severe asthma drug

  June 12, 2015

• Pfizer wins another Zoloft-birth defects lawsuit

  June 12, 2015

• LA county to finally distribute preventive Truvada

  June 12, 2015

• Glaxo, Sanofi slammed with regulatory fines in India over vaccines

  June 12, 2015

• FDA blunders labeling for Vanda sleep drug

  June 12, 2015

• How 21st Century Cures could change communications between biopharma, providers, & patients

  June 11, 2015

• Pennsylvania's Melior wins a Parkinson's patent

  June 11, 2015

• GlobeImmune decimating its workforce after hep B drug flop

  June 11, 2015

• Massive study: Merck's diabetes mega-blockbuster doesn't increase heart failure risk

  June 11, 2015

• Panasonic Healthcare to snap up Bayer diabetes unit for $1.1 billion

  June 11, 2015

• AZ chief med officer abruptly quits, CEO Soriot to oversee late-stage R&D

  June 11, 2015

• FDA and Amarin wrangle over free speech lawsuit

  June 10, 2015

• PCSK9 anti-cholesterol drug prices: How much is too much?

  June 10, 2015

• Sanofi diabetes drug ready to take on FDA with safety study in the rearview

  June 10, 2015

• Lilly stock soars on animal health spinoff inquiry

  June 10, 2015

• FDA finally responds to demand for Duchenne Muscular Dystrophy guidance

  June 10, 2015

• UPDATED: Sanofi/Regeneron's PCSK9 blockbuster-in-waiting gets prelim FDA nod

  June 9, 2015

• Lilly's Trulicity and Novo's IDegLira best Lantus in trials

  June 9, 2015

• Lilly's Lantus biosimilar will finally launch in Europe in Q3

  June 9, 2015

• Massive new study: The statin-memory lapse connection may be unfounded

  June 9, 2015

• Merck, New England Patriots boss part of investment team for ABX start up

  June 9, 2015

• Report: Pfizer scientist warned management about Zoloft-birth defects link last year

  June 9, 2015

• NIH halts drug production for pharma trials after FDA finds fungus

  June 8, 2015

• Amgen subpoenas journalist in fight against shareholder suit

  June 8, 2015

• Orexigen, Takeda take Actavis to court over obesity med Contrave generic

  June 8, 2015

• Amazon, Google battle to become 'e-warehouse' of choice for genomics data

  June 8, 2015

• Genzyme nabs breakthrough designation for rare enzyme disorder

  June 5, 2015

• Australia to big pharma: Pay more taxes

  June 5, 2015

• EU votes not to abolish animal testing despite rising advocate pressure

  June 5, 2015

• Report: Metformin decreases glaucoma risk in older adults

  June 5, 2015

• Vertex shareholders say 'no' to sky-high exec bonuses

  June 5, 2015

• UPDATE: FDA panel recommends women's libido drug despite safety concerns

  June 4, 2015

• How social media analytics can help get drugs to the right places during epidemics

  June 4, 2015

• AstraZeneca chief slams UK over NICE's Lynparza decision

  June 4, 2015

• Report: Many heart attack patients neglect to take their meds afterwards

  June 4, 2015

• PillPack just got a $50 million infusion—could it become the Amazon of pharmacies?

  June 4, 2015

• Amgen, Novartis duke it out in court over landmark Neupogen biosimilar

  June 4, 2015

• Why pay-to-delay arrangements can actually be good for consumers, too

  June 4, 2015

• FDA panel to review Lilly's lung cancer combo drug

  June 3, 2015

• Why did Regulus Therapeutics CEO Xanthopoulos suddenly quit?

  June 3, 2015

• White House meeting focuses on reducing use of antibiotics

  June 3, 2015

• UPDATE: Defiant Teva to buy even more Mylan shares, setting up potential legal showdown

  June 3, 2015

• NCI launching largest-ever personalized medicine study for cancer drugs

  June 3, 2015

• NICE says no to AZ's Lynparza

  June 2, 2015

• Ex-Obama administration official joins Sanofi

  June 2, 2015

• AstraZeneca may continue R&D of drug linked to suicidal thoughts

  June 2, 2015

• Could new FDA compounding guidelines stop Avastin use in AMD?

  June 2, 2015

• WHO calls for report on vaccine pricing and access

  June 1, 2015

• Bristol-Myers sues former immunotherapy exec for allegedly violating non-compete

  June 1, 2015

• US orders major review as suspect anthrax samples found in multiple labs

  June 1, 2015

• Report: Public health threat lurking at biolabs nationwide

  May 29, 2015

• Biopharma execs have big presence among top-paid CEOs

  May 29, 2015

• Gilead on R&D hiring spree

  May 29, 2015

• New evidence-based consensus: Start HIV treatment at diagnosis

  May 29, 2015

• Otsuka's efforts to block generic Abilify fail

  May 29, 2015

• Merck submits NDA for new 2-in-1 hepatitis C treatment

  May 29, 2015

• Supreme Court: Pharma companies must finance drug take-back programs

  May 28, 2015

• Juno to use Editas gene-editing platform for CAR-T cancer R&D

  May 28, 2015

• Express Scripts pushes 'pay-for-performance' drug policy in latest challenge to pharma

  May 28, 2015

• Retrophin sells Sanofi priority review voucher for $245m

  May 28, 2015

• Report: Greece owes pharma companies more than $1.2 billion in debts

  May 28, 2015

• CEO of cancer vax rising star Bavarian Nordic: We are not for sale

  May 27, 2015

• Boehringer Ingelheim nabs US approval for COPD combo

  May 27, 2015

• Vertex CEO gets called out over huge $45.8 million pay package

  May 27, 2015

• Disadvantage, Amgen? Dosing could be deciding factor in PCSK9 marketing battle

  May 27, 2015

• White House: Human germline editing 'a line that should not be crossed'

  May 27, 2015

• Trouble for AZ as Amgen quits psoriasis blockbuster hopeful collab over suicide risk

  May 26, 2015

• Bayer CEO: G7 will see creation of multinational antibiotic R&D fund

  May 26, 2015

• Sanofi prostate drug chief's exit latest in firm's oncology exodus

  May 26, 2015

• 'Hard switch' gets a hard no: Actavis must keep older Namenda on the market

  May 26, 2015

• Hypertension drug from India no longer banned in EU—but 100s of others still are

  May 26, 2015

• Word on the street: A massive Pfizer deal is coming

  May 22, 2015

• Otonomy's inner-ear drug flops in trials

  May 22, 2015

• Valeant chief latest pharma CEO to question M&A mania, calls it a 'bit of a bubble'

  May 22, 2015

• Sanofi/Regeneron's arthritis drug nails it in phase III

  May 22, 2015

• ProPublica opens up the Advair vault, raises safety and marketing ethics questions

  May 22, 2015

• UPDATE: Amgen's PCSK9 cholesterol med beats Sanofi's to an EU recommendation

  May 22, 2015

• J&J, Achillion strike $225 million hep C drug development pact

  May 21, 2015

• Study: Tylenol use during pregnancy may lower testosterone in male offspring

  May 21, 2015

• AbbVie, other pharma companies dominate list of 'most meaningful' places to work in US

  May 21, 2015

• J&J's ambitious plan: 10 new potential blockbusters filed by 2019

  May 21, 2015

• Valeant reportedly in acquisition talks with big Egyptian pharma

  May 21, 2015

• GW Pharma moves CEO to US to lay groundwork for cannabis-epilepsy med approval

  May 20, 2015

• Sanofi/Regeneron reports glowing phase 2b results for versatile asthma hopeful

  May 20, 2015

• Compounding pharmacy linked to meningitis outbreak to pay $200M to victims

  May 20, 2015

• Why biosimilars may not be the huge cost-saver people hope

  May 20, 2015

• Endo to scoop up rival Par Pharma for $8B in bid to expand generics portfolio

  May 19, 2015

• Unregulated stem cell clinics doing big business in the US

  May 19, 2015

• WHO plays hardball with Novartis & Roche, favors cheaper Avastin over Lucentis

  May 19, 2015

• AstraZeneca bets big on biotech with large new Swedish plant

  May 19, 2015

• Perrigo CEO changes tune, would consider Mylan merger—at right price

  May 19, 2015

• A rare win for US pharma: Indian court stops Glenmark sales of Merck diabetes copycats

  May 18, 2015

• Niger meningitis cases triple in 2 weeks amid dearth of vaccines

  May 18, 2015

• Amgen boasts promising phase II results for migraine drug

  May 18, 2015

• FDA sued by ADHD generics maker for revoking drug's Concerta bioequivalence

  May 18, 2015

• FDA warns popular Lilly, AZ, J&J, Boehringer diabetes meds could cause ketoacidosis

  May 18, 2015

• Why are analysts still optimistic about Orexigen's stock after the Contrave imbroglio?

  May 15, 2015

• One more potential Teva-related challenge for Mylan's shareholders: A huge tax bill

  May 15, 2015

• US class action against India's Ranbaxy cites dishonesty, manipulation of FDA rules

  May 15, 2015

• Hotly anticipated AZ lung cancer combo effective, but side effects remain a problem

  May 15, 2015

• A preview of the new lung cancer data Roche will debut at ASCO

  May 15, 2015

• VT senator to Veterans Affairs: Break Gilead's Sovaldi patents

  May 14, 2015

• Belgian biotech harnessing antibodies from... llamas?

  May 14, 2015

• Sanofi moving forward on Celiac disease immunotherapy development

  May 14, 2015

• How pharma is amping up R&D with gene sequencing

  May 14, 2015

• Rapid diagnostics emerging for Chagas disease

  May 14, 2015

• MannKind: Marketing glitches, delays explain slow Afrezza uptake

  May 13, 2015

• Glaxo CEO skeptical about pharma's M&A frenzy

  May 13, 2015

• Analysts answer: How long will it take the first Copaxone generics to gain market share?

  May 13, 2015

• How do you test an Ebola vaccine when almost no one has Ebola?

  May 13, 2015

• Challenges ahead for Vertex's controversial Kalydeco combo despite FDA panel nod

  May 13, 2015

• Drug-resistant typhoid 'superbug' becoming global problem

  May 12, 2015

• Alexion planning major expansion in Ireland

  May 12, 2015

• 4 drugmakers dismissed from Chicago opioid lawsuit

  May 12, 2015

• 7 drugs get SMC backing

  May 12, 2015

• HIV cure, not just treatment, is goal of Glaxo-UNC partnership

  May 12, 2015

• CA justices rule against pharma in first appellate court 'pay-for-delay' suit

  May 11, 2015

• What the Tories' election victory means for the NHS and UK pharma

  May 11, 2015

• FDA staff raises red flags over new Vertex cystic fibrosis med's cost

  May 11, 2015

• In challenge to pricey Gilead meds, WHO adds hep C drugs to 'essentials' list

  May 11, 2015

• Liberia declared Ebola-free

  May 11, 2015

• M&A mayhem: Q1 biopharma deal values surpass 2014's total

  May 8, 2015

• AbbVie, Roche nab FDA breakthrough designation for top leukemia prospect

  May 8, 2015

• Study: Measles vax may protect against other infections

  May 8, 2015

• Sheer power of CAR-T therapies leads drug makers to develop an 'off' switch

  May 8, 2015

• Mark your calendars: FDA will hold public meeting on off-label use this summer

  May 8, 2015

• Former Novo exec Schultz will become a CEO after all—just at another pharma

  May 7, 2015

• Glaxo reverses course, won't spinoff lucrative ViiV Healthcare HIV unit

  May 7, 2015

• An update on Tekmira: From Ebola promise to a strong hep B focus

  May 7, 2015

• Glaxo hoping for the best, prepping for the worst on Advair generics

  May 7, 2015

• Congress calls for gender equity in clinical trials

  May 7, 2015

• 7 questions you might have about biosimilarity, answered

  May 6, 2015

• New report: Digoxin risky for certain patients

  May 6, 2015

• Sanofi shareholders slam big pay packages for chiefs Viehbacher, Brandicourt

  May 6, 2015

• DaVita settles $450 million Medicare fraud lawsuit

  May 6, 2015

• IMS: Global cancer drug spending soared past $100 billion in 2014

  May 6, 2015

• UN: New Ebola cases fall to lowest level since mid-2014

  May 6, 2015

• Study: FDA bends over backwards to accommodate orphan drug developers

  May 5, 2015

• Bayer buys rights to Isis anti-clotting drug in $155M deal

  May 5, 2015

• The new Medicare Part D drug spending report only tells part of the story

  May 5, 2015

• Vyvanse binge eating push, NPS acquisition drives steady Q1 sales for Shire

  May 5, 2015

• Glaxo becomes first big pharma to file for a gene therapy approval

  May 5, 2015

• Why did Novo's supposed CEO-in-waiting suddenly leave the firm?

  May 4, 2015

• Viagra bucks global slowdown trend in China, sales soar 47%

  May 4, 2015

• Amgen successfully defends melanoma hopeful T-Vec, gets positive FDA feedback

  May 4, 2015

• 21st Century Cures changes would loosen Sunshine Act's CME disclosure rules

  May 4, 2015

• Novartis kickback case settlement will cost Express Scripts $60 million

  May 4, 2015

• Gilead dazzles, profits double in Q1 on strong hep C sales

  May 1, 2015

• Oklahoma gov OKs marijuana derivative for epilepsy clinical trial

  May 1, 2015

• FDA approves Glaxo's asthma drug Breo Ellipta for adults

  May 1, 2015

• Experts: Polio on the verge of global eradication thanks to vax campaigns

  May 1, 2015

• Pfizer emerges as mystery bidder for rare disease firm Swedish Orphan

  May 1, 2015

• Merck antibiotic combo Zerbaxa shows efficacy in complicated infections

  April 30, 2015

• Perrigo rejects Mylan's third takeover offer

  April 30, 2015

• FDA approves Kythera's double-chin injection

  April 30, 2015

• Amgen hiring staff for Cambridge and SF sites

  April 30, 2015

• Valeant CFO to resign; company beats expectations for quarter

  April 30, 2015

• Can the new FDA guidance on biosimilarity expedite development and approval?

  April 30, 2015

• Q1 reports: Dollar dogs Pfizer, cancer immunotherapies buoy Bristol-Myers, Merck

  April 29, 2015

• Game on: FDA approves first generics of blockbuster antipsychotic Abilify

  April 29, 2015

• FDA officially reject's Merck's Bridion—again

  April 29, 2015

• Merck gains advantage over AZ, Takeda as top diabetes med determined heart safe

  April 29, 2015

• Controversy ahead: HHS inspector general encourages more Part D drug rebates

  April 29, 2015

• Bristol-Myers, Gilead hep C combo shines in late-stage trial

  April 28, 2015

• Snap up a rival, then hike its drugs' prices—is this pharma's new normal?

  April 28, 2015

• Why tech transfer could be key to growing pharma in Africa

  April 28, 2015

• Good news for Lilly: Cyramza nabs yet another FDA approval

  April 28, 2015

• Report: Multiple sclerosis drug prices skyrocketing—even for older meds

  April 27, 2015

• Workers wanted: Seattle Genetics experiencing a growth spurt

  April 27, 2015

• Biogen ups the phase III ante on Alzheimer's breakthrough hopeful

  April 27, 2015

• Rare disease firm Swedish Orphan flies on mystery takeover offer

  April 27, 2015

• A tale of 2 takeover bids: Teva-Mylan-Perrigo M&A drama goes hostile

  April 27, 2015

• New study: Alcoholic hepatitis drugs not effective

  April 24, 2015

• Novartis chief: We're actively looking for $2-$5 billion acquisitions

  April 24, 2015

• Mapp Biopharma nabs federal liability protection for Ebola drug

  April 24, 2015

• Merck, Gilead duke it out with next-gen hep-C combos

  April 24, 2015

• More Q1 earnings: Novartis flies, Humira keeps AbbVie afloat, AZ feels patent sting

  April 24, 2015

• What biopharma needs to know about CAR-T cancer therapies

  April 24, 2015

• Milestone: Chinese researchers genetically modify human embryos

  April 23, 2015

• Are steady generic drug price hikes coming to an end?

  April 23, 2015

• Abbott's Mylan deal paying off big as M&A speculation sends shares soaring

  April 23, 2015

• Earnings roundup: Lilly bests estimates on new drugs, Abbott racks up $2.29B earnings

  April 23, 2015

• Inside Gilead's ambitious new hep C elimination project in Georgia

  April 23, 2015

• Research links poor quality medicines and potential global pandemic

  April 22, 2015

• Scientists to provide real-time genomic sequencing data on Ebola, MERS

  April 22, 2015

• Bernstein analyst to Gilead: 'Pull the trigger' and buy Vertex

  April 22, 2015

• How Amgen achieved its stellar Q1 earnings

  April 22, 2015

• US, Cuban research firms forge historic pact on lung cancer vax development

  April 22, 2015

• UPDATE: Teva scores a takeover talking point as Perrigo board rejects Mylan bid

  April 21, 2015

• Wave of the future: The Ebola crisis as a tipping point for pharmaceutical R&D

  April 21, 2015

• Glaxo uncovers quadrivalent flu vax potency problems, pulls it from market

  April 21, 2015

• Allergan laying off 577 more workers in Orange County

  April 21, 2015

• Teva to pay whopping $512 million fine in Provigil pay-to-delay suit

  April 21, 2015

• Small, early Novartis CAR-T trial shows promise in solid tumors

  April 21, 2015

• Sun Pharma tanks as Daiichi starts divesting $3.6B in stakes

  April 21, 2015

• EU's first-ever gene therapy bumps up against renewed regulatory scrutiny

  April 20, 2015

• Pfizer notches key victory in first of many Zoloft birth-defect cases

  April 20, 2015

• Merck files Keytruda for lung cancer, drug bests Bristol-Myers' Yervoy in melanoma

  April 20, 2015

• WHO promises reforms after 'slow and insufficient' Ebola response

  April 20, 2015

• Benefits manager warns Vertex's cystic fibrosis Kalydeco combo too pricey

  April 17, 2015

• Otsuka pulling out all the stops to deter copycats of blockbuster Abilify

  April 17, 2015

• Sandoz wins first FDA nod for generic of Teva MS flagship Copaxone

  April 17, 2015

• Bayer pumping $100M into new hemophilia-focused Berkeley testing facility

  April 17, 2015

• Study: Common heartburn meds linked with kidney failure risk in elderly

  April 17, 2015

• Star Scientific 2.0 falters in drug dev efforts after Va. gov corruption scandal

  April 17, 2015

• Ibrance late-stage trial stopped early amid impressive results

  April 16, 2015

• FDA approves first major new heart failure drug in a decade

  April 16, 2015

• The blood cancer boom: Nearly 250 meds in development, but plenty left to do

  April 15, 2015

• GW Pharma's cannabis-based epilepsy drug cuts seizure rates by 50%

  April 15, 2015

• Why did Rx drug spending in the US reach an all-time high in 2014?

  April 15, 2015

• FDA panel endorses new heart failure warnings for key AZ diabetes med

  April 15, 2015

• WHO calls for universal clinical trial transparency

  April 15, 2015

• J&J Q1 earnings highlight rising dollar's tumultuous effect on global pharmas

  April 15, 2015

• How NewLink Genetics defied its location and put Iowa on biotech's map

  April 14, 2015

• What a Celgene stake in Mesoblast means for the stem cell firm's prospects

  April 14, 2015

• Ichor, J&J to collaborate in $85M hep B immunotherapy deal

  April 14, 2015

• Roche's aggressive 2015 goal: 11 cancer immunotherapy drugs in late-stage trials

  April 14, 2015

• Glaxo to tweak unique US sales rep compensation plan amid complaints

  April 14, 2015

• Angelina Jolie-driven surge in pricey genetic test requests has payers on edge

  April 13, 2015

• Ebola phase III studies underpopulated as epidemic wanes

  April 13, 2015

• Water under the bridge: Allergan, Ackman drop hostile takeover lawsuits

  April 13, 2015

• Eisai plans big US layoffs in reorg

  April 13, 2015

• Mylan's $29B Perrigo bid seen as defensive play against M&A threat

  April 13, 2015

• Lawusit claims Pfizer knew about Zoloft birth defect risks

  April 10, 2015

• Billionaire Fidelity CEO betting big on cancer companies with personal money

  April 10, 2015

• Alzheon CEO calls out Biogen, says his firm will be 1st to Alzheimer's finish line

  April 10, 2015

• Politicians still going after Actavis for its Namenda hard-switch

  April 10, 2015

• Shire nabs priority review for potential blockbuster dry eye drug

  April 10, 2015

• Mid-cap biotechs best larger companies to emerge as 2014's growth kings

  April 9, 2015

• Merck's HCV drug candiate gets another breakthrough therapy designation

  April 9, 2015

• Silence Therapeutics raises $58 million to advance R&D

  April 9, 2015

• Report questions acetaminophen's efficacy in lower back, joint pain

  April 9, 2015

• Inside the FDA labeling fight that could upend the generics market

  April 8, 2015

• Report: Viagra most effective ED treatment, but has more side effects

  April 8, 2015

• VBI Vaccines, Sanofi Pasteur to collaborate on vaccine R&D

  April 8, 2015

• Hospira gets yet another FDA warning letter before Pfizer buyout

  April 7, 2015

• Shire bullish on 2017 approval of new, longer-lasting ADHD pill

  April 7, 2015

• Valeant commences its post-Salix deal job cuts

  April 7, 2015

• Targacept merger in jeopardy as Pfizer ends deal with buyer Catalyst

  April 7, 2015

• Hedge fund activist Bass takes aim at pricey Shire, Jazz drug patents

  April 7, 2015

• MorphoSys CEO stays bullish on cancer drug despite Celgene split

  April 7, 2015

• Juno, Novartis settle cancer patent spat for $12 million

  April 7, 2015

• Amgen CEO scores big pay package on record profits

  April 7, 2015

• Glaxo's post-Novartis vax deal reorg could uproot hundreds of jobs

  April 6, 2015

• Did Novartis try to sabotage Avastin ophthalmic trials?

  April 6, 2015

• Scientists milk snakes to make more stable broad spectrum anti-venom

  April 6, 2015

• UK scientists push back against animal testing critics

  April 6, 2015

• Big bonus bonanza coming up at Actavis

  April 2, 2015

• Partners wanted: Roche seeking collaborators in cancer immunotherapy

  April 2, 2015

• FDA issues final guidance on abuse-deterrent opioids

  April 2, 2015

• Amgen loses Neupogen biosimilar battle—again

  April 1, 2015

• Provocative: Analyst says hot new PD-1 cancer drugs are massively overrated

  April 1, 2015

• Report claims FDA is behind the times on employees' free speech

  April 1, 2015

• PETA hawks animal testing alternatives to CROs in San Diego

  March 31, 2015

• Merck Serono and Intrexon initiate $941 million CAR-T deal

  March 31, 2015

• UK opposition leader gives pharma a pass on his profit margin cap proposal

  March 31, 2015

• What UnitedHealth's $12.8B Catamaran deal means for pharma's pricing war

  March 31, 2015

• Glaxo settles J&J suit over allergy med advertisement claims

  March 31, 2015

• Alibaba, other e-retailers may foray into Rx drugs in China

  March 30, 2015

• In final speech, outgoing FDA chief defends US drug approvals record

  March 30, 2015

• Glaxo finally strikes UK deal for Bexsero that eluded Novartis

  March 30, 2015

• Confirmed: Sanofi's Toujeo launches in US Monday, setting up diabetes race

  March 30, 2015

• Novo to try for US Tresiba approval once again

  March 27, 2015

• J&J moving forward in China despite regulatory crackdowns

  March 27, 2015

• MorphoSys and Celgene call it quits

  March 27, 2015

• How PCSK9 cholesterol drugs will shift pharma's pricing trends

  March 25, 2015

• Guinea becomes focus of Merck Ebola vaccination study

  March 25, 2015

• Treatment for inhalational anthrax wins US approval

  March 25, 2015

• Regeneron's Eylea nabs yet another FDA approval for expanded label

  March 25, 2015

• FDA's rare disease pediatric voucher program could become permanent

  March 25, 2015

• RA drug that caused 'elephant man' side effect gets another chance

  March 25, 2015

• Merck's Keytruda bests Yervoy, shows promise as first-line melanoma med

  March 25, 2015

• CAR-T biotech Cellectis boosts IPO 50% to $197 million

  March 25, 2015

• FDA to reconsider homeopathy regulatory framework after 25 years

  March 25, 2015

• U of Minnesota called out for clinical trial practices—again

  March 24, 2015

• Regeneron CEO riding high with $42M salary, but with fewer perks

  March 24, 2015

• The Biogen ripple effect: Analyst recommends Genworth as proxy buy

  March 24, 2015

• FDA won't relabel Lilly's schizophrenia injectable after patient deaths

  March 24, 2015

• Paper: SSRIs impact teens' sexual function, too

  March 24, 2015

• 3D printing debuts in pharma

  March 23, 2015

• Gilead warns against Sovaldi, heart drug combo after patient death

  March 23, 2015

• J&J's Janssen gets a mixed bag in 2nd Risperdal case

  March 23, 2015

• Here comes the blockbuster: Novartis' Cosentyx bests Stelara in psoriasis trials

  March 23, 2015

• Congress wants to make it easier to get EU-approved drugs to the US

  March 23, 2015

• Namenda antitrust suit heats up in NY court

  March 20, 2015

• 9 important things to know about PCSK9 cholesterol drugs

  March 20, 2015

• Judge refuses to block Novartis biosimilar of Amgen drug

  March 20, 2015

• MannKind has a $100 million debt problem, and the clock is ticking

  March 19, 2015

• FDA approves first-ever med for rare bile disorder

  March 19, 2015

• MSF: Sovaldi profit protection measures squeeze out patients in poor nations

  March 18, 2015

• FDA advisory committee to talk Tekmira, Mapp Ebola vaccines in May

  March 18, 2015

• Celgene emerges as biotech partnering king of 2014

  March 18, 2015

• Glaxo's combo respiratory drug deemed safe by FDA staff

  March 18, 2015

• New obesity drugs jockey for market uptake

  March 18, 2015

• How Novo Nordisk plans to keep its eyes on the diabetes prize

  March 18, 2015

• US Novartis arm smacked with $110 million gender discrimination class action

  March 18, 2015

• Allergan CEO Pyott heading for the exits as Actavis finalizes buyout

  March 18, 2015

• Meet the Biogen vet who's about to become Chiasma's new CEO

  March 17, 2015

• Scientists may have uncovered next powerhouse antibiotic in horse dung

  March 17, 2015

• FDA panel: Pharmacyclics' Imbruvica cancer data strong enough to unblind

  March 17, 2015

• Novartis slapped with $12.6M fine for fuzzy Medicare pricing math

  March 17, 2015

• Could Biogen's Alzheimer's therapy become a breakthrough?

  March 17, 2015

• Why China's drug approval backlog spiked last year

  March 17, 2015

• US District Judge says FDA can revoke Ranbaxy drug approvals

  March 16, 2015

• Study: AZ's Brilinta shows promise, but comes with risks

  March 16, 2015

• Merck's anesthesia reversal drug faces 3rd likely FDA rejection

  March 16, 2015

• Neuralstem shares tank on discouraging ALS stem cell therapy data

  March 13, 2015

• The unlikely vaccine that's boosting immunooncology efforts

  March 13, 2015

• Bill & Melinda Gates Foundation bets big on CureVac's mRNA platform

  March 13, 2015

• Gilead, Vertex balk as SEC upholds shareholders' voting rights

  March 13, 2015

• 23andMe's next big ambition: Drug development

  March 13, 2015

• Zogenix selling painkiller Zohydro to Pernix in huge deal

  March 12, 2015

• J&J's CEO nabbed a hefty raise in 2014

  March 12, 2015

• Public Citizen to FDA: Don't let sales reps distribute data downplaying drug risks

  March 12, 2015

• Will Pradaxa reversibility be the final death knell for warfarin?

  March 12, 2015

• J&J to pay $25 million to settle children's Tylenol, Motrin contamination case

  March 12, 2015

• India denies patent protection to Bayer, BI blockbusters

  March 12, 2015

• Concordia acquiring Covis assets for $1.2 billion

  March 11, 2015

• Apple's new ResearchKit raises hopes, questions for medical studies

  March 11, 2015

• Why CNS drug maker Acadia's shares soared on Tuesday

  March 11, 2015

• More black box grief for Pfizer's Chantix as FDA adds alcohol, seizure warnings

  March 11, 2015

• United Therapeutics nabs priority review voucher, approval for rare pediatric cancer drug

  March 11, 2015

• Novartis CEO: Watch out for more cost-cutting on the horizon

  March 10, 2015

• Is that clinical trial doc getting pharma money? Patients want to know

  March 10, 2015

• What's next for Kythera after unanimous FDA rec for its double-chin injection?

  March 10, 2015

• Ackman becomes Valeant's 5th largest shareholder with $3.3B gamble

  March 9, 2015

• Amgen: The biotech that's getting on the biosimilar R&D bandwagon

  March 9, 2015

• Bangladeshi pharma launches $10 version of Sovaldi

  March 9, 2015

• Bribery scandal still dogging Glaxo as pharma giant axes 110 jobs in China

  March 9, 2015

• Astellas nabs FDA approval for new antifungal

  March 9, 2015

• Merck to start hacking away at Cubist's workforce with 128 R&D layoffs

  March 9, 2015

• In latest blow to Lilly, German court clears Actavis generics of lung cancer blockbuster

  March 9, 2015

• Dawn of a new era: FDA approves first-ever biosimilar, Novartis/Sandoz's Zarxio

  March 6, 2015

• Flu vax committee picks next year's virus strains after 2014 debacle

  March 6, 2015

• FDA to pharma: Watch out for unapproved Facebook claims

  March 6, 2015

• Vanda's atopic dermatitis drug fall flat in mid-stage trial

  March 6, 2015

• UPDATE: Shire's Boston move involves 'mass layoff' of up to 600 employees

  March 6, 2015

• FDA launches first drug-shortages mobile app

  March 5, 2015

• AstraZeneca to spin off antibiotics R&D for $40 million

  March 5, 2015

• Genentech denies knowledge of distribution-related problems

  March 5, 2015

• Akorn latest to reject use of its drugs for lethal injection

  March 5, 2015

• 21st Century Cures: Making Breakthrough Therapy designations more effective

  March 5, 2015

• BMS' Opdivo wins lung cancer indication more than 3 months before PDUFA date

  March 4, 2015

• The post-acquisition cuts begin: Valeant lays off 77 Dendreon employees

  March 4, 2015

• BI files its Pradaxa 'antidote' in North America, EU

  March 4, 2015

• Could Sangamo's gene therapy 'cure' HIV?

  March 4, 2015

• FDA clamps down on testosterone labeling rules

  March 4, 2015

• Orexigen shoots itself in foot with early disclosure of positive Contrave heart data

  March 4, 2015

• Celgene's Abraxane approved in EU for first-line treatement of NSCLC

  March 3, 2015

• AZ board to CEO Soriot: Want that big bonus? Show us the money

  March 3, 2015

• US lawmakers push Amphastar for answers on naloxone prices

  March 3, 2015

• Survey: New Genentech distribution policy delaying cancer patients' care

  March 3, 2015

• Gilead seals generic Sovaldi deal with Natco, NICE rec for Harvoni in UK

  March 3, 2015

• Sanofi's Toujeo nabs EU rec and efficacy shoutout on heels of FDA blessing

  March 2, 2015

• Indian advisory board proposes waiving phase III for certain drugs

  March 2, 2015

• A biotech is bringing a new IUD to market—but the company's a nonprofit

  March 2, 2015

• Ousted Sanofi chief Chris Viebacher lands at PureTech

  March 2, 2015

• Positive phase II Provenge data a good early sign for ambitious Valeant

  Feb. 27, 2015

• EU approves first new chemical entity for Parkinson's in a decade

  Feb. 27, 2015

• A booming Bayer projects 10% pharma-driven growth in 2015

  Feb. 27, 2015

• Gilead raking in billions off of foreign tax laws

  Feb. 27, 2015

• GSK's CEO faces another pay cut—and it's a big one

  Feb. 27, 2015

• How 23andMe used rigorous clinical trials to win a landmark FDA authorization

  Feb. 26, 2015

• Pharmacyclics surges on news of potential sale to J&J, Novartis

  Feb. 26, 2015

• Shire puts binge-eating disorder on the medical map

  Feb. 26, 2015

• Federal judge strikes down Maine's controversial prescription drug import law

  Feb. 26, 2015

• It's been a good year: Juno's top management nabs big bonuses

  Feb. 26, 2015

• CA lawmaker to pharma: Show us, with numbers, why drugs cost so much

  Feb. 26, 2015

• Merck, MPP team up to provide low-cost HIV pediatric meds in poor countries

  Feb. 25, 2015

• French government slams Sanofi over new CEO's pay

  Feb. 25, 2015

• Public Citizen requests FDA ban on certain antifungal meds

  Feb. 25, 2015

• Shire keeps acquisition train rolling with $70M Meritage Pharma deal

  Feb. 25, 2015

• Platinum parachute? Allergan CEO Pyott could get $100M exit fee

  Feb. 25, 2015

• Toronto Star retracts piece suggesting injuries linked to Merck's Gardasil

  Feb. 24, 2015

• BMS strengthens oncology pipeline with two big deals worth $1.6B

  Feb. 24, 2015

• Novartis' Farydak wins FDA approval for multiple myeloma

  Feb. 24, 2015

• Duchenne, orphan drug maker PTC Therapeutics fielding takeover bids

  Feb. 24, 2015

• Lilly's long-acting insulin not ready for prime time

  Feb. 24, 2015

• Is there still a place for the mighty pharmaceutical sales force?

  Feb. 23, 2015

• Compounding pharmacies chafe at FDA's disciplinary actions

  Feb. 23, 2015

• Corgenix's 15-minute Ebola test approved by WHO

  Feb. 23, 2015

• FDA to review Pfizer's rare lung disease drug for women

  Feb. 23, 2015

• Holoclar makes history: Europe approves West's first stem-cell therapy

  Feb. 23, 2015

• Cellectis files $115M IPO to fund unique CAR-T program

  Feb. 22, 2015

• Ohio seeks its own deal with Amphastar for heroin antidote

  Feb. 20, 2015

• New Jersey residents' parting gift to Roche: A lawsuit

  Feb. 20, 2015

• NewLink wins $20 million Ebola vaccine milestone from Merck

  Feb. 20, 2015

• New company, new name: Actavis to rebrand as Allergan post-buyout

  Feb. 20, 2015

• Biogen, academic collaborators discover new ALS gene

  Feb. 20, 2015

• UPDATE: Bayer HealthCare chief Brandicourt named Sanofi's next CEO

  Feb. 19, 2015

• Why so little uptake of preventive Truvada in the at-risk gay community?

  Feb. 19, 2015

• Team of rivals? Scientist nominated for AZ board has history of dinging pharma

  Feb. 19, 2015

• Gilead's Harvoni supplants Sovaldi as top-selling launch drug

  Feb. 19, 2015

• Why FDA's label expansion for Celgene's Revlimid could foretell a global sales surge

  Feb. 19, 2015

• Biotech battle: Regeneron's Eylea bests Genenetch's Lucentis in head-to-head

  Feb. 19, 2015

• Shanghai official to serve 19 years over GSK bribery case

  Feb. 18, 2015

• The more, the merrier? Endo also pursuing Salix Pharma bid

  Feb. 18, 2015

• CVS fires controversial warning shot in opening salvo of PCSK9 price wars

  Feb. 18, 2015

• Sprout Pharma submits 'women's Viagra' for approval once again

  Feb. 18, 2015

• FDA reopens conversation about controversial generic labeling rules

  Feb. 17, 2015

• Profits fall for India's largest drug maker

  Feb. 17, 2015

• Can AZ finally solidify a deal for its anti-infectives unit?

  Feb. 17, 2015

• GSK replaces US pharma ops head Connelly amid struggles

  Feb. 17, 2015

• NAFTA patent spat rages on between Canada and Lilly

  Feb. 17, 2015

• How ViiV Healthcare became a pharma favorite for patient groups

  Feb. 13, 2015

• Valeant arranges financing for potential Salix Pharma bid

  Feb. 13, 2015

• Indian pharma giants scuffle to snap up injectables maker Claris

  Feb. 13, 2015

• AZ to settle Nexium kickback case for $7.9M

  Feb. 13, 2015

• Teva's internal probe turns up 'likely' corruption

  Feb. 12, 2015

• Shire raises 2015 forecast on NPS acquisition

  Feb. 12, 2015

• EMA defends data black-out policy for AbbVie's Humira

  Feb. 12, 2015

• Riken stem cell saga continues as Obokata and other scientists face reprimands

  Feb. 12, 2015

• GSK broadens vax portfolio with $190M GlycoVaxyn deal

  Feb. 12, 2015

• Former Merck financial analyst to plead guilty to insider trading

  Feb. 11, 2015

• Nanotrending: FDA adopts another nanotech standard

  Feb. 11, 2015

• Another one bites the dust: FDA to revoke breakthrough status for BMS hep C med, too

  Feb. 11, 2015

• Former MN gov demands more trial transparency at UMN in wake of '04 suicide

  Feb. 11, 2015

• Patient groups rank ViiV Healthcare #1 in corporate reputation survey, again

  Feb. 11, 2015

• Juno forges ahead with novel cancer therapy, opens manufacturing facility

  Feb. 10, 2015

• Merck fights back after BC Health Ministry drops diabetes drug

  Feb. 10, 2015

• ICYMI: Sanofi undertakes major sales reorg of US diabetes business

  Feb. 10, 2015

• New research: Could Novartis CVD game-changer increase dementia risk?

  Feb. 10, 2015

• BIO survey finds more series A VC funding for fewer recipients

  Feb. 10, 2015

• Roche's blockbuster Lucentis nabs fourth FDA approval

  Feb. 9, 2015

• FDA warning for blockbuster hopeful edoxaban hits Daiichi where it hurts

  Feb. 9, 2015

• Pfizer may still be hungry after Hospira deal

  Feb. 9, 2015

• FDA proposes new consumer-friendly print drug ad guidance

  Feb. 9, 2015

• Arkansas settles Vertex Medicaid suit over pricey Kalydeco

  Feb. 9, 2015

• Isis earns $10 million milestone from Biogen Idec

  Feb. 6, 2015

• Why the FDA wants to double inspectors at Indian manufacturing facilities

  Feb. 6, 2015

• FDA simplifies compassionate use process in a big way

  Feb. 6, 2015

• NY Attorney General nabs price reduction for heroin-fighting naloxone

  Feb. 6, 2015

• Q4: Allergan soars past estimates, again

  Feb. 6, 2015

• Passing the torch: Ralph Neas' tenure at the Generic Pharmaceutical Association

  Feb. 5, 2015

• Promising Roche Parkinson's med causes lung toxicity in monkey trials

  Feb. 5, 2015

• Study: Drug makers fail to meet adverse-event reporting requirements

  Feb. 5, 2015

• Trans-Pacific Partnership trade talks fail to resolve patent & IP issues

  Feb. 5, 2015

• Pfizer on fire with early FDA nod for blockbuster Ibrance, $15B Hospira buyout

  Feb. 5, 2015

• Merck's hep C treatment loses FDA breakthrough status

  Feb. 5, 2015

• Another FDA warning letter for India-based Apotex

  Feb. 4, 2015

• Moody's: Patent-cliff challenges will continue to dog big pharma

  Feb. 4, 2015

• Merck's Belsomra for insomnia now available in US

  Feb. 4, 2015

• US to launch large-scale universal flu shot testing in 2016

  Feb. 4, 2015

• Valeant reportedly considering Salix acquisition

  Feb. 4, 2015

• FTC: Ranbaxy must sell acne drug to Torrent Pharma before Sun takeover

  Feb. 3, 2015

• FDA approves new Zohydro ER pankiller formulation

  Feb. 3, 2015

• Chimerix shifts from Ebola focus to adenoviruses, CMV as outbreak wanes

  Feb. 3, 2015

• Ireland threatens to cap drug prices

  Feb. 3, 2015

• Pro-life groups blame Merck, in part, for surging measles cases

  Feb. 2, 2015

• Valeant to make $296M 'stalking horse' bid on Seattle-based Dendreon

  Feb. 2, 2015

• Shire's Vyvanse nabs FDA approval for binge-eating disorder

  Feb. 2, 2015

• Roche's Tamiflu vindicated in new analysis of data

  Feb. 2, 2015

• What will the new federal budget mean for pharmaceutical R&D tax credits?

  Feb. 1, 2015

• Alexion COO Hallal named company's next CEO

  Jan. 30, 2015

• J&J's Imbruvica gets expanded label for rare blood cancer treatment

  Jan. 30, 2015

• Some UK cystic fibrosis patients being denied breakthough treatment

  Jan. 30, 2015

• J&J under continued scrutiny for off-label pediatric use of Risperdal

  Jan. 30, 2015

• Biogen Idec re-enters gene therapy R&D with hemophilia focus

  Jan. 30, 2015

• Study: Parkinson's patients' response doubles with 'expensive' placebo

  Jan. 29, 2015

• Pfizer dodges class-action trial with $400 million settlement

  Jan. 29, 2015

• Express Scripts claims it's saved US healthcare $4B through hep C deals

  Jan. 29, 2015

• Earnings update: Roche plateaus, Amgen stock slides despite solid performance

  Jan. 29, 2015

• Largest US health insurer latest to give Harvoni preferred hep C drug status

  Jan. 29, 2015

• Gilead to launch generic Sovaldi in India this summer

  Jan. 28, 2015

• E. coli-sniffing One Codex search platform scores CDC cash prize

  Jan. 28, 2015

• Actavis to buy Auden McKenzie for $465M

  Jan. 28, 2015

• Google, Biogen Idec partnering to study causes of multiple sclerosis

  Jan. 28, 2015

• NIH to launch Down syndrome research portal

  Jan. 28, 2015

• Counterfeit Roche cancer drug smuggler gets 30 months in jail

  Jan. 27, 2015

• Novo deploys 500 rep army to take Saxenda message to MDs

  Jan. 27, 2015

• Average Rx drug prices spiked 10.9% last year

  Jan. 27, 2015

• Rumor mill churns as Duke's Dr. Robert Califf appointed FDA deputy commish

  Jan. 27, 2015

• UPDATE: Pfizer gives poor nations modest discount after vax price blowback

  Jan. 27, 2015

• Teva wins big as FDA approves its generic Nexium

  Jan. 27, 2015

• GSK denies reports of imminent job cuts in China

  Jan. 26, 2015

• Shire pleased as NPS Pharma wins Natpara approval

  Jan. 26, 2015

• Sanofi tops new index that measures pharma's commitment to infectious diseases

  Jan. 26, 2015

• EMA suspending almost 50 drugs over flawed CRO clinical studies

  Jan. 26, 2015

• Novartis nabs FDA nod for group B meningitis vaccine Bexsero

  Jan. 26, 2015

• Hindsight: Valeant CEO admits mistakes in approach to Allergan bid

  Jan. 23, 2015

• Digital dawn: Online interactions with MDs leading to more prescripts

  Jan. 23, 2015

• EU approves Genzyme's Cerdelga for type 1 Gaucher patients

  Jan. 23, 2015

• Express Scripts determined to influence prices for cancer drugs

  Jan. 23, 2015

• Regulators get creative on Ebola vaccine testing as infections decline

  Jan. 23, 2015

• The M.D. perspective: Who stands to benefit from clinical trial transparency?

  Jan. 22, 2015

• J&J: Regulatory delays in China are stymying drug approvals

  Jan. 22, 2015

• UN Ebola chief requests one last $1 billion in funding to fight outbreak

  Jan. 22, 2015

• Chasing transparency in the pharmaceutical industry: How much is enough?

  Jan. 22, 2015

• Out with the old: Merck discontinues US sales of hep C med Victrelis

  Jan. 22, 2015

• Plaintiffs wanted: Law firms seek shareholders to launch a Sanofi kickback suit

  Jan. 22, 2015

• Salix Pharma reportedly exploring options, considering sale

  Jan. 22, 2015

• Teva wins Copaxone patent protection suit in US Supreme Court

  Jan. 21, 2015

• Ambitious RNA biotech Alnylam raising $450M, looking for acquisitions

  Jan. 21, 2015

• Colorado-based ViroCyt raises $3.5M to market its Virus Counter

  Jan. 21, 2015

• J&J's Q4 earnings: A solid 2014

  Jan. 21, 2015

• One more push: Senators reintroduce bill to expedite antibiotic approval

  Jan. 20, 2015

• China FDA to reverse course, allow online Rx drug sales

  Jan. 20, 2015

• Hospira closes North Carolina plant over cost concerns

  Jan. 20, 2015

• AbbVie strikes hep C discount deal with US state-based AIDS programs

  Jan. 20, 2015

• UPDATED: Yet another major insurance company strikes hep C deal with Gilead

  Jan. 16, 2015

• Pfizer warns UK MDs: Lyrica is still on patent for pain

  Jan. 16, 2015

• J&J: Women were inappropriately pressured to file pelvic mesh suits

  Jan. 16, 2015

• Pharma stocks plunge as Switzerland discontinues fixed-price peg to euro

  Jan. 16, 2015

• Blast from the past: Roche's dalcetrapib, HDL-raising meds could work for some patients

  Jan. 15, 2015

• Flu vaccine only 23% effective this season

  Jan. 15, 2015

• Intrexon, Ziopharma invest $100M in MD Anderson cancer immunotherapy tech

  Jan. 15, 2015

• UPDATED: Gilead to appeal India's rejection of Sovaldi patent protection

  Jan. 15, 2015

• FDA approves novel weight-loss device

  Jan. 15, 2015

• Johnson & Johnson to release trial data

  Jan. 15, 2015

• New Brilinta data supports extending use beyond one year

  Jan. 15, 2015

• BMJ physicians urge reexamination of widespread hep C screening

  Jan. 14, 2015

• Digital marketing slowly gaining traction with US doctors

  Jan. 14, 2015

• Actavis betting on conversion to new Namenda

  Jan. 14, 2015

• J&J licensing IBD drug from microbiome specialist Vedanta

  Jan. 14, 2015

• Merck invests $50 million in Moderna

  Jan. 14, 2015

• Mersana Therapeutics expands $300M R&D pact with Takeda

  Jan. 13, 2015

• UK's Cancer Drugs Fund gets cash infusion, but loses 16 drugs

  Jan. 13, 2015

• Merck goes after non-small cell lung cancer indication for Keytruda

  Jan. 13, 2015

• Mylan's REMS lawsuit against Celgene gaining traction

  Jan. 13, 2015

• Roche buys majority stake in Foundation Medicine for $1.03B

  Jan. 13, 2015

• Cempra announces $100M stock sale after antibiotic impresses in pneumonia trials

  Jan. 12, 2015

• Biogen Idec, Columbia University forge $30 million genetics research pact

  Jan. 12, 2015

• Done deal: Shire acquires NPS Pharma for $5.2 billion

  Jan. 12, 2015

• Daiichi Sankyo, DOJ reach $39 million settlement in kickback suit

  Jan. 12, 2015

• Novartis seeks FDA approval for two smoker's cough drugs

  Jan. 9, 2015

• How one hedge fund manager plans to take on big pharma patents

  Jan. 9, 2015

• Tensions with pharma run high as UK's Cancer Drugs Fund cuts expenses

  Jan. 9, 2015

• Finally approved: FDA says 'yes' to Impax's Parkinson's drug

  Jan. 9, 2015

• Biogen Idec's novel optical nerve repair therapy shows promise, but only some

  Jan. 9, 2015

• Siga ordered to pay $113M to PharmaAthene in smallpox case

  Jan. 8, 2015

• Novartis OTC advertising under fire after Pfizer complaint

  Jan. 8, 2015

• Namenda controversy continues as Actavis awaits court decision

  Jan. 8, 2015

• Study reveals no Gardasil-MS link

  Jan. 8, 2015

• The first groundbreaking antibiotic in 25 years may literally come out of the ground

  Jan. 8, 2015

• UPDATE: Novartis Neupogen biosimilar takes yet another step toward FDA approval

  Jan. 8, 2015

• AZ taps new immuno-oncology leader as two valued veterans depart

  Jan. 7, 2015

• Gilead acquires Phenex's FXR liver drugs in $470 million deal

  Jan. 7, 2015

• FDA grants drug makers 'track and trace' reprieve until May

  Jan. 7, 2015

• Billionaire Mark Cuban to host first Pediatric Health Pitch Day at SXSW arts fest

  Jan. 7, 2015

• Pharma companies unite to fight CA drug take-back program

  Jan. 7, 2015

• Minnesota Investment Board will not support Medtronic-Covidien inversion deal

  Jan. 6, 2015

• Moderna raises record $450M from investors with groundbreaking RNA tech

  Jan. 6, 2015

• NIH awards $28 million in grants to unlock mysteries of gene regulation

  Jan. 6, 2015

• J&J and Isis strike $835 million co-development deal

  Jan. 6, 2015

• Massachusetts mulls legal action over marketing practices for pain drugs

  Jan. 5, 2015

• Out with the old: Novartis completes Lilly animal health sale as part of overhaul

  Jan. 5, 2015

• ICYMI: 9 big biopharma predictions for 2015, according to industry experts

  Jan. 5, 2015

• Chiasma raising $56M to develop acromegaly drug—without Roche

  Jan. 5, 2015

• An 18-year record: FDA approved 41 drugs in 2014

  Jan. 5, 2015

• Japan first nation to approve potential Novartis blockbuster Cosentyx

  Jan. 5, 2015

• Neuroderm stock surges, then plunges, after positive Parkinson's data

  Jan. 1, 2015

• It's over: Teva and OncoGenex dissolve custirsen cancer partnership

  Dec. 31, 2014

• J&J investing $125M up front for MacroGenics' blood cancer drug

  Dec. 23, 2014

• Disgraced Japanese scientist fails to replicate stem-cell breakthrough results

  Dec. 23, 2014

• Vanda, Novartis reach settlement in schizophrenia drug licensing spat

  Dec. 23, 2014

• Tekmira, Oxford University team up to test new investigational Ebola therapy

  Dec. 23, 2014

• HHS's BARDA grants $30M Ebola vax development contract to NewLink

  Dec. 23, 2014

• Actavis considering Almirall acquisition to expand European foothold

  Dec. 22, 2014

• FDA approves Cubist's novel antibiotic Zerbaxa for complicated infections

  Dec. 22, 2014

• FDA unexpectedly approves AZ's Lynparza for advanced ovarian cancer

  Dec. 22, 2014

• 2014's 9 biggest biopharma game-changers, according to industry experts

  Dec. 19, 2014

• AbbVie pins hopes for first major approval in 10 years on hep C drug

  Dec. 19, 2014

• GSK shingles vax shows major promise, could challenge Merck's Zostavax

  Dec. 19, 2014

• Glaxo assures shareholders: Dividend payout secure despite sluggish sales

  Dec. 19, 2014

• Amgen leukemia drug Blincyto's massive price tag: $178,000

  Dec. 19, 2014

• Controversial pay-to-delay deals on the decline in the EU

  Dec. 19, 2014

• 14 pharmacy execs arrested, 2 charged with murder over 2012 meningitis deaths

  Dec. 18, 2014

• Actavis reveals post-merger management plans: Saunders to stay as CEO

  Dec. 18, 2014

• Will this Pfizer orphan drug emerge as the Duchenne victor?

  Dec. 18, 2014

• Report: Shire still hunting for a deal, maybe with NPS Pharma

  Dec. 18, 2014

• FDA approves Novartis/Alcon's Xtoro for swimmer's ear

  Dec. 18, 2014

• Google Ventures ventures more aggressively into healthcare, life sciences

  Dec. 17, 2014

• The US Patent Office just gave a big gift to biopharma companies

  Dec. 17, 2014

• Sanofi/Regeneron's opening move on PCSK9 marketing: 'Cholesterol Counts' campaign

  Dec. 17, 2014

• FDA forces Pfizer to put another warning on antipsychotic Geodon

  Dec. 17, 2014

• Former Onyx CEO tackles hard-to-treat CNS diseases with new biotech

  Dec. 17, 2014

• FDA approves two new plasma-based tests, expands use of a third

  Dec. 16, 2014

• Pfizer, OPKO reach growth hormone drug pact worth up to $570M

  Dec. 16, 2014

• The other victims of scuttled AbbVie-Shire deal? Big banks

  Dec. 16, 2014

• Senate bill would give 15 years' data exclusivity to drugs for unmet needs

  Dec. 16, 2014

• How Teva's CEO is preparing for a 2015 of patent expirations

  Dec. 16, 2014

• Abbott closes Veropharm deal amidst US-Russia political tension

  Dec. 15, 2014

• Indian Supreme Court rejects Bayer's bid to block cheap cancer generic

  Dec. 15, 2014

• Federal judge: Actavis must keep selling older version of Alzheimer's drug

  Dec. 15, 2014

• Jazz pushing potential $1B rare disease drug through rolling NDA

  Dec. 15, 2014

• Novartis psoriasis drug bests J&J's Stelara in head-to-head trial

  Dec. 15, 2014

• Lawmakers propose new antibiotics pathway to combat superbugs

  Dec. 12, 2014

• Gavi pledges $300M to get Ebola vaccines to hard-hit countries

  Dec. 12, 2014

• Compromise: Branded biologics, biosimilar firms reach hard-won agreement

  Dec. 12, 2014

• Philly transit authority launches class action against Gilead over Sovaldi price

  Dec. 12, 2014

• Teva 2015 revenue forecast $1 billion lower than expected

  Dec. 12, 2014

• Brave new world of digital pharma marketing has privacy advocates balking

  Dec. 11, 2014

• 'Audition' for a job? Pfizer gets creative in its hiring approach in Sweden

  Dec. 11, 2014

• Mylan to foot $20M tax penalty for top execs after inversion merger

  Dec. 11, 2014

• Teva launches generic of Pfizer's arthritis med Celebrex in the US

  Dec. 11, 2014

• FDA approves new HPV super-vaccine, Merck's Gardasil 9

  Dec. 11, 2014

• After failed Allergan offensive, Valeant finally taking break from M&A focus

  Dec. 10, 2014

• HHS extends legal immunity to Ebola vaccine makers

  Dec. 10, 2014

• A $3B case of bad timing? Merck defends Cubist deal after judge invalidates patents

  Dec. 10, 2014

• Bluebird shares skyrocket on promising gene therapy-blood disorder data

  Dec. 10, 2014

• Feds refuse to hear Sandoz case related to biosimilar development efforts

  Dec. 10, 2014

• ICYMI: AARP and GPhA on what to do about generic drug price hikes

  Dec. 10, 2014

• Feds drop wire fraud charges against former Lilly scientists

  Dec. 9, 2014

• France, Germany, other EU countries suspend Indian generics approvals

  Dec. 9, 2014

• Pfizer creating gene therapy platform to expand rare disease efforts

  Dec. 9, 2014

• Microsoft co-founder Allen donates $100M to unlock mysteries of the human cell

  Dec. 9, 2014

• FDA: A defined biosimlar pathway is coming—soon

  Dec. 8, 2014

• Some more firsts for Incyte: Jakafi approved for chronic bone marrow disease

  Dec. 8, 2014

• Merck, BMS PD-1 drugs continue to roll, show promise for Hodgkin's lymphoma

  Dec. 8, 2014

• Why CRO employee turnover is still so high

  Dec. 8, 2014

• Merck to buy antibiotics powerhouse Cubist for $9.5 billion

  Dec. 8, 2014

• Big pharma meets medical marijuana? Dutch firm to build cannabinoid gum factory

  Dec. 5, 2014

• Google's secretive Calico looking to hire bioinformatics pro

  Dec. 5, 2014

• The FDA's new effort to make it easier to create generics of risky drugs

  Dec. 5, 2014

• GSK reverses course, retracts plan to sell older drugs

  Dec. 5, 2014

• Whistleblower: Sanofi, ex-CEO Viehbacher paid out $34M in kickback scheme

  Dec. 4, 2014

• FDA OKs Amgen's Blincyto to treat rare form of acute lymphoblastic leukemia

  Dec. 4, 2014

• Mice infused with human brain cells shed light on cognitive function

  Dec. 4, 2014

• Beyond ABC: FDA finalizes labeling rules for pregnant, lactating women

  Dec. 4, 2014

• Actavis to lay off 200 workers in California

  Dec. 4, 2014

• ICYMI: Are low-cost generic drugs a thing of the past?

  Dec. 3, 2014

• Security firm: Hackers trying to manipulate global markets by stealing pharma emails

  Dec. 3, 2014

• Patent cliff ahead: Otsuka to buy Avanir for $3.5B and a slate of new products

  Dec. 3, 2014

• A $945 million breakup: J&J, Astellas call off major rheumatoid arthritis deal

  Dec. 3, 2014

• Promising Biogen Alzheimer's drug leapfrogs from phase I to phase III

  Dec. 3, 2014

• Puma Biotech plummets in after hours trading after delaying breast cancer NDA

  Dec. 3, 2014

• Meet the healthcare and pharma industry vet who will be Teva's next chairman

  Dec. 2, 2014

• Mylan strikes deal to make Gilead's HIV drugs more accessible to poor nations

  Dec. 2, 2014

• Done deal: Pfizer completes acquistion of Baxter's vaccines

  Dec. 2, 2014

• Why BMS is getting ready to slash up to 1,000 jobs in China

  Dec. 2, 2014

• Despite deaths, Italian regulators declare Novartis flu vaccine safe—for now

  Dec. 2, 2014

• Report: China considering large-scale eradication of drug price caps

  Dec. 1, 2014

• The key to successful clinical trial recruitment? Patient empowerment

  Dec. 1, 2014

• EU green lights BI's Vargatef for advanced lung cancer

  Dec. 1, 2014

• Job cuts ahead: GSK plans US workforce restructuring

  Dec. 1, 2014

• Glaxo/NIH Ebola vaccine elicits immune response in human trials

  Dec. 1, 2014

• Generic drug price hikes move Congress to consider consumer relief measures

  Nov. 26, 2014

• Trouble for J&J? Amgen/AZ plaque psoriasis drug bests Stelara in phase III

  Nov. 26, 2014

• Lilly's once-weekly diabetes drug approved in EU

  Nov. 26, 2014

• FDA: No decision on Novartis' troubled panobinostat for 3 months

  Nov. 26, 2014

• Takeda US CEO leaving after 22 years

  Nov. 26, 2014

• A lead investigator reveals how Baxter's Hyqvia got its hard-won approval

  Nov. 25, 2014

• Top UK fund manager to launch major new biotech fund in 2015

  Nov. 25, 2014

• 3 compounding pharmacies sue Express Scripts over blocked coverage

  Nov. 25, 2014

• Lundbeck CEO resigns after serious conduct breaches

  Nov. 25, 2014

• Novartis scientist who fabricated data fired and banned from receiving funding

  Nov. 25, 2014

• In search of new opportunities, Bayer considers selling $2.5B diabetes unit

  Nov. 25, 2014

• UK life sciences minister: Hospitals must aid in clinical trial process

  Nov. 24, 2014

• Hep C wars heat up as AbbVie scores likely EU approval for Harvoni challenger

  Nov. 24, 2014

• EU regulators weigh in on hotly debated testosterone, heart attack link

  Nov. 24, 2014

• AZ to ramp up biologics production with new plant, jobs in MD

  Nov. 24, 2014

• Merck, NewLink strike exclusive deal to scale up Ebola vaccine production

  Nov. 24, 2014

• Sacré bleu! Sovaldi to cost 38.8% less in France than in US

  Nov. 21, 2014

• EMA's updated conflict of interest policy reflects pragmatism, flexibility

  Nov. 21, 2014

• Judge refuses to block Ranbaxy's generic competitors

  Nov. 21, 2014

• Sanofi can't shake its diabetes business blues—and investors aren't happy

  Nov. 21, 2014

• Purdue joins burgeoning abuse-deterrent pain pill field with Hysingla approval

  Nov. 21, 2014

• Another first: Gilead spends $125M on priority review voucher for mystery drug

  Nov. 20, 2014

• These execs are on Sanofi's CEO short list

  Nov. 20, 2014

• In massive transparency effort, feds push for failed clinical trial data reporting

  Nov. 20, 2014

• Goodbye Philly, hello Boston: Shire moves US HQ, 500 jobs

  Nov. 20, 2014

• Novartis aims to put more 'tech' in biotech

  Nov. 20, 2014

• ICYMI: Inside Indian pharma's push to reform and modernize

  Nov. 19, 2014

• GSK, Clovis team up to study treamtents for mutant form of lung cancer

  Nov. 19, 2014

• Regeneron/Sanofi PCSK9 inhibitor could become cholesterol top dog

  Nov. 19, 2014

• India's Ranbaxy sues FDA for yanking Nexium, Valcyte generics approval

  Nov. 19, 2014

• Rainmaker: Gilead's Harvoni approved in the EU

  Nov. 19, 2014

• Has the price of developing drugs really doubled in the last 11 years?

  Nov. 19, 2014

• Plot twist: Controversial Merck cholesterol drugs Zetia, Vytorin work

  Nov. 18, 2014

• Docs breathe sigh of relief as Actavis buyout ends Valeant-Allergan drama

  Nov. 18, 2014

• Merck dances: Keytruda more than doubles PFS in some melanoma patients

  Nov. 18, 2014

• How pharma has improved patients' access to drugs since 2012

  Nov. 18, 2014

• FDA commish to talk drug safety at China regulatory chief confab

  Nov. 18, 2014

• 2 DRG analysts dish on the 'unprecedented' Valeant-Allergan struggle

  Nov. 17, 2014

• Another big win for Roche as Avastin nabs FDA ovarian cancer indication

  Nov. 17, 2014

• Finally: FDA reverses course, OKs Sanofi's Lemtrada for MS

  Nov. 17, 2014

• EU's top drug regulator forced out by EMA panel

  Nov. 16, 2014

• Japanese transparency data raises eyebrows about pharma spending

  Nov. 14, 2014

• AstraZeneca in preclinical development for Brilinta reversal agent

  Nov. 14, 2014

• Apollo Global Manangement joins bidding wars for GSK's mature drugs

  Nov. 14, 2014

• FDA approves new Invega indication for schizoaffective disorder

  Nov. 14, 2014

• FDA has concerns over bioequivalence of two Concerta generics

  Nov. 14, 2014

• Pfizer, Gates Foundation team up to get injectable contraceptives to poor countries

  Nov. 14, 2014

• ICYMI: India's fixed-dose combo problem: Too much of a good thing?

  Nov. 14, 2014

• Let's make a deal: Allergan, Actavis talk $60 billion merger

  Nov. 13, 2014

• Indian pharma really feeling the pain of lagging US generic approvals

  Nov. 13, 2014

• Advaxis wants to investigate a compound for head & neck HPV-related cancers

  Nov. 13, 2014

• GSK applying for expanded Revolade indication in the EU

  Nov. 13, 2014

• No more half measures: Senate to add Ebola to priority review program

  Nov. 13, 2014

• Gilead, AbbVie hep C drugs score 97% cure rates, Regulus gets cold shoulder

  Nov. 12, 2014

• 10 major hospitals ask Congress to scrutinize Genentech distribution changes

  Nov. 12, 2014

• Shire CEO: The future looks bright—who needs AbbVie?

  Nov. 12, 2014

• GE Healthcare and Takeda to take on liver disease R&D together

  Nov. 12, 2014

• Does a common 'algae virus' found in humans really make them dumb?

  Nov. 12, 2014

• Swing and a miss: Merck's ambitious 4-week hep C regimen fails

  Nov. 11, 2014

• Cigna responds to discrimination claims with cheaper HIV meds in Florida

  Nov. 11, 2014

• Pfizer: Nothing shady about our relationship with Missouri Attorney General

  Nov. 11, 2014

• Amgen gets PDUFA date for hotly anticipated PCSK9 anti-cholesterol drug

  Nov. 11, 2014

• Decisions, decisions: UCB to sell its generic unit to private equity firms

  Nov. 10, 2014

• Isis Pharma wins $10M neurodegeneration treatment milestone from Biogen

  Nov. 10, 2014

• Political unrest in Russia nixes deal with German pharma company

  Nov. 10, 2014

• Salix Pharmaceuticals' inventory woes ruined potential Allergan buyout

  Nov. 10, 2014

• The cost of a cure: $188B to treat all US hep C patients with pricey new drugs

  Nov. 10, 2014

• FDA sends Sciecure Pharma rare, scathing letter over insomnia drug sales aid

  Nov. 7, 2014

• This billionaire hedge fund manager may sue over busted AbbVie-Shire deal

  Nov. 7, 2014

• Allergan, Actavis talk merger while Valeant gets the cold shoulder

  Nov. 7, 2014

• Ranbaxy loses $250M while US consumers lose a Nexium generic

  Nov. 7, 2014

• FDA approves JNJ's Olysio in combo with Sovadi for hep C treatment

  Nov. 7, 2014

• Largest US pharma benefits manager may seek alcohol/tobacco-free network

  Nov. 6, 2014

• AZ's $2B ovarian cancer drug-in-development could be a 2-for-1 deal

  Nov. 6, 2014

• UPDATED: Novartis cancer hopeful panobinostat not on track for FDA approval

  Nov. 6, 2014

• Why GSK's promising hep C vaccine is good news for its Ebola drug

  Nov. 6, 2014

• FDA presents novel plan for testing and fast-tracking Ebola drugs

  Nov. 6, 2014

• Innovation in fixed-dose combos: HIV/AIDS therapeutics edition

  Nov. 5, 2014

• Some payments exempt from Sunshine Act pharma database reporting

  Nov. 5, 2014

• Bayer injects $25 million cash into biotech venture capital fund

  Nov. 4, 2014

• Allergan-Valeant standoff rages on as Allergan loses in court

  Nov. 4, 2014

• Regeneron posts solid Q3 on Eylea strength

  Nov. 4, 2014

• Lundbeck's schizophrenia drug wallops competition in novel head-to-head trial

  Nov. 4, 2014

• One-fifth of all drug sales in 2020 could be for pricey, specialty orphan meds

  Nov. 4, 2014

• India-based Wockhardt's profits plummet as it faces continued FDA export ban

  Nov. 4, 2014

• Diagnostics giant LabCorp buys CRO Covance for $6.1 billion

  Nov. 4, 2014

• BMS gets heat from advocates over pricing plan for its hep C drug

  Nov. 4, 2014

• Will Boehringer win an asthma indication for Spiriva Respimat?

  Nov. 4, 2014

• Feds probe whether US officials engaged in insider trading over Dendreon drug

  Nov. 3, 2014

• Scientists identify treasure trove of plasma-based cancer markers

  Nov. 3, 2014

• Express Scripts gearing up to snub Gilead in favor of AbbVie hep C drug

  Nov. 3, 2014

• Most UK diabetes patients fall short of evidence-based treatment goals

  Nov. 3, 2014

• FDA panel endorses approval of Daaichi's blood clot, stroke drug

  Nov. 3, 2014

• Scientists seek to make remote-controlled drug delivery device that works in space

  Oct. 31, 2014

• Abbott acquires heart-mapping company Topera for $250 million

  Oct. 31, 2014

• Sacked Sanofi chief's golden parachute more like a bronze parachute

  Oct. 31, 2014

• Pfizer's meningitis drug becomes first FDA-approved breakthrough therapy

  Oct. 31, 2014

• BMS's novel Opdivo exceeds expectations in late-stage lung cancer trials

  Oct. 31, 2014

• With Viehbacher gone, who will be the next Sanofi chief?

  Oct. 30, 2014

• US senators propose FDA vouchers to expedite Ebola drug development

  Oct. 30, 2014

• J&J to open major new Shanghai-based 'Asia Pacific Innovation Center'

  Oct. 30, 2014

• Diving into the future of fixed-dose combos

  Oct. 30, 2014

• India to ban use of plastic bottles for liquid drugs

  Oct. 30, 2014

• Cara Therapeutics' opioid alternative could be a true game changer

  Oct. 30, 2014

• Gilead shares fall on lower-than-expected Sovaldi sales

  Oct. 29, 2014

• Secretive Google[x] developing nano pill to detect cancer, monitor health

  Oct. 29, 2014

• UPDATED: Judge slashes Actos class action award from $9 billion to $36.8 million

  Oct. 29, 2014

• Cost-effectiveness: Treat prisoners with Sovaldi now, save money later

  Oct. 29, 2014

• Pfizer posts weaker-than-expected Q3 while Sanofi CEO gets the boot

  Oct. 29, 2014

• Pfizer pulls the plug on pain deal with Pain Therapeutics

  Oct. 28, 2014

• Novartis smashes in Q3 as earnings soar 45%

  Oct. 28, 2014

• Novartis sells off flu vaccines business to CSL for $275 million

  Oct. 28, 2014

• Sarepta's mega-orphan Duchenne's drug faces more roadblocks

  Oct. 28, 2014

• Roche to spend $3.2B on massive R&D cluster in Basel

  Oct. 28, 2014

• EU panel recommends approval of Clinuvel's sunburn-prevention drug

  Oct. 27, 2014

• Determined Shire ratchets up 2014 forecast, again

  Oct. 27, 2014

• FDA approves Baxter's hemophilia orphan drug

  Oct. 27, 2014

• EMA recommends approval of AZ's ovarian cancer drug

  Oct. 27, 2014

• EU reverses course, won't cede drug-related decisions to pharma

  Oct. 24, 2014

• EMA establishes expedited review framework for Ebola vaccines

  Oct. 24, 2014

• Actavis to cut more jobs, this time in New York

  Oct. 24, 2014

• Soliris sales drive Alexion's Q3 earnings beyond the loftiest expectations

  Oct. 24, 2014

• Biogen shares down as Tecfidera-treated patient dies from viral brain infection

  Oct. 23, 2014

• Anti-inflammatories may boost the effects of antidepressants

  Oct. 23, 2014

• UK patients rally online to demand lower price for Roche's Kadcyla

  Oct. 23, 2014

• WHO decries funding gap for tuberculosis R&D

  Oct. 23, 2014

• Is Regulus' injectable the next HCV blockbuster in the making?

  Oct. 23, 2014

• Best of BD: Biosimilars in China: The coming revolution

  Oct. 22, 2014

• Lilly, Boehringer fixed-dose diabetes combo could win FDA blessing soon

  Oct. 22, 2014

• Study: Parkinson's disease drugs make some patients want to party

  Oct. 22, 2014

• Glaxo, Abbott Q3 earnings best analyst expectations

  Oct. 22, 2014

• How the FDA plans to stop facilities from undermining inspections

  Oct. 22, 2014

• Mylan investor pulls $70 million as lethal injection controvery heats up

  Oct. 22, 2014

• Useful insights: Europe slow to embrace biosimilars of antibody-based drugs

  Oct. 21, 2014

• Study: Viagra could be used to protect against heart disease

  Oct. 21, 2014

• PhRMA fights back, blames insurance companies for drug access woes

  Oct. 21, 2014

• Genentech strikes rare $1.15B cancer pact with NewLink Genetics

  Oct. 20, 2014

• These anti-inflammatories may enhance the effects of schizophrenia treatment

  Oct. 20, 2014

• EMA approves J&J's Imbruvica for two rare blood cancers

  Oct. 20, 2014

• EU contemplates adaptive licensing in the face of Ebola threat

  Oct. 20, 2014

• US orders 3 state-of-the-art labs to ramp up Ebola drug ZMapp production

  Oct. 20, 2014

• Fearing creation of deadlier viruses, US tells scientists to halt bird flu research

  Oct. 20, 2014

• FDA approves Pfizer's addiction-fighting pain pill as US heroin deaths soar

  Oct. 20, 2014

• How new FDA flexibility in breast cancer trials can help high-risk patients

  Oct. 17, 2014

• HHS puts third Ebola vaccine on the fast-track

  Oct. 16, 2014

• New, top-shelf breast cancer drug sales lift Roche above Q3 expectations

  Oct. 16, 2014

• Potential Novartis psoriasis blockbuster inches closer to approval

  Oct. 16, 2014

• EMA considers relaxing clinical trial rules for rare-cancer patients

  Oct. 16, 2014

• FDA to generic drug makers: Looks matter

  Oct. 16, 2014

• FDA approves two competing 'breakthrough' IPF drugs in one day

  Oct. 16, 2014

• Astellas to collaborate with Harvard team on ophthalmological gene therapy

  Oct. 16, 2014

• Indian pharma: We're stymied by 'overzealous' drug regulators

  Oct. 16, 2014

• The Critical Path Initiative: 10 years later

  Oct. 16, 2014

• FDA approves telescope implant for younger end-stage AMD patients

  Oct. 15, 2014

• NICE to Celgene: We won't authorize NHS funding for Imnovid

  Oct. 15, 2014

• Pharma balks at new FDA final guidance on fixed-dose combinations

  Oct. 15, 2014

• FDA not likely to drop black box suicide warning for Pfizer's Chantix

  Oct. 15, 2014

• Patent battle brewing over Biogen's MS blockbuster Tecfidera

  Oct. 15, 2014

• Chinese pharma firm says it has an Ebola cure

  Oct. 14, 2014

• J&J forecast up big in Q3 on strong pharma sales

  Oct. 14, 2014

• Novartis may be fined $49M by Indian pricing authority

  Oct. 14, 2014

• Eisai/Helsinn's Akynzeo scores FDA approval for chemo-induced nausea

  Oct. 14, 2014

• Research, royalties, and recreation: What pharma paid docs in 2013

  Oct. 14, 2014

• Australian docs fight to ban meetings between physicians, pharma sales reps

  Oct. 13, 2014

• Study: Pricey specialty med costs worth it in the long run

  Oct. 13, 2014

• Severe asthma drug breathes new life into AstraZeneca pipeline

  Oct. 10, 2014

• Study: Lung cancer can hide out for 20 years

  Oct. 10, 2014

• Class-action gender discrimination suit against Merck to move forward

  Oct. 10, 2014

• Endo to buy Auxilium at a premium for $2.6 billion

  Oct. 10, 2014

• Here come the layoffs: Targacept-AstraZeneca R&D partnership nixed

  Oct. 10, 2014

• How 2 companies are revolutionizing flu vaccine manufacturing

  Oct. 10, 2014

• University of Utah scientists may have just discovered the key to an Ebola cure

  Oct. 9, 2014

• Cash for compliance: West Pharma, HealthPrize team up to boost drug adherence

  Oct. 9, 2014

• Groups urge stronger psych warnings for controversial Pfizer anti-smoking drug

  Oct. 9, 2014

• Flu vaccine development as a hotbed of innovation: Who knew?

  Oct. 9, 2014

• Look out, AbbVie: Here comes Amgen's Humira biosimilar

  Oct. 9, 2014

• Catalyst Pharma to ramp up hiring after impressive orphan drug trial

  Oct. 8, 2014

• Novare Pharmaceuticals launches in Boston

  Oct. 8, 2014

• Watching the 'Watchman:' Boston Scientific to face FDA over heart device today

  Oct. 8, 2014

• Tylenol for tots: FDA provides guidance on liquid acetaminophen for kids

  Oct. 8, 2014

• Sanofi faces bribery allegations in East African, Middle Eastern markets

  Oct. 8, 2014

• Acacia Pharma braces for approval of potential blockbuster post-op nausea drug

  Oct. 7, 2014

• British Medical Association to UK officials: Cancer, dementia treatment at risk

  Oct. 7, 2014

• Teva's downsizing efforts squeeze out women's health and cancer R&D

  Oct. 7, 2014

• First US Ebola patient being treated with experimental Chimerix antiviral

  Oct. 7, 2014

• Actavis shores up infectious disease franchise with Durata acquisition

  Oct. 7, 2014

• How pharma and patients can work together to improve drug access

  Oct. 6, 2014

• Baxter invests $45M in Rockwell Medical

  Oct. 6, 2014

• Nobel committee announces 2014 winners in Physiology or Medicine

  Oct. 6, 2014

• Novartis and BMS co-testing lung cancer therapies

  Oct. 6, 2014

• Optos to collaborate with UK government and universities

  Oct. 6, 2014

• Ascension Health bans Genentech sales reps from campus

  Oct. 6, 2014

• NICE rejects funding for Roche's leukemia drug

  Oct. 3, 2014

• Lilly abandons lupus drug after late-stage trial failures

  Oct. 3, 2014

• Study: NSAID-related GI bleeding risk increases with combo therapy

  Oct. 3, 2014

• Breast cancer drug sales to increase almost two-fold by 2023

  Oct. 3, 2014

• EMA expands clinical data access to researchers and public

  Oct. 3, 2014

• FDA issues final guidance on cybersecurity of medical devices

  Oct. 2, 2014

• Salud: NHS to endorse daily pill for heavy drinkers in England

  Oct. 2, 2014

• Specialty pharma ready to dispense Xtandi after expanded indication

  Oct. 2, 2014

• Pfizer, Kyowa Hakko Kirin partner on immuno-oncology study

  Oct. 2, 2014

• Bayer a top OTC player after $14.2B deal with Merck

  Oct. 2, 2014

• Open Payments: Pharma, device companies shelled out $3.5B in 5 months [CHART]

  Oct. 1, 2014

• BI spending $1.26 million to expand Respimat inhaler production

  Oct. 1, 2014

• UK shores up its stem cell banking system with non-profit support

  Oct. 1, 2014

• Acquisition update: J&J buys Alios for $1.75 billion

  Oct. 1, 2014

• Horizon hailed as 'world's leading gene-editing' company after acquiring Sage

  Sept. 30, 2014

• Report: 700-plus biosimilars in development worldwide

  Sept. 30, 2014

• Amag Pharma buys maternal health specialist Lumara in $1B deal

  Sept. 30, 2014

• Indian government: Major US think tank 'smeared' our pharma industry

  Sept. 30, 2014

• Access wanted: What it takes for patients to get the drugs they need

  Sept. 30, 2014

• Acquisition update: Daiichi Sankyo buys Ambit Biosciences for $410 million

  Sept. 30, 2014

• EU regulators to patients: Help us evaluate drugs

  Sept. 29, 2014

• Shareholders bullish on Nicox after phase III glaucoma trial

  Sept. 29, 2014

• AbbVie racks up another Humira approval from the FDA

  Sept. 29, 2014

• Merger Monday: Pfizer snaps up Innopharma in $360M deal

  Sept. 29, 2014

• 15 new medications headed toward EU approval

  Sept. 29, 2014

• Actavis to continue sales of cheaper Alzheimer's drug for 60 days

  Sept. 26, 2014

• Almirall, AZ big winners as key committee recommends COPD combo

  Sept. 26, 2014

• BI scores an FDA approval for mist-based COPD drug

  Sept. 26, 2014

• Novartis to seek approval for potential psoriatic arthritis blockbuster

  Sept. 26, 2014

• BI to cut up to 600 jobs in Germany

  Sept. 25, 2014

• Cost concerns drive UK authority to spurn popular ulcerative colitis drugs

  Sept. 25, 2014

• FDA approves Celgene's potential blockbuster Otezla for psoriasis

  Sept. 25, 2014

• India's drug-pricing authority drops price caps on nonessential drugs

  Sept. 25, 2014

• Innovators wanted: FDA issues $500K challenge for better food pathogen detection

  Sept. 24, 2014

• UK launches beta of transparency site MyNHS

  Sept. 24, 2014

• How the NIH is trying to get more women to participate in clinical trials

  Sept. 24, 2014

• Nigerian health minister declares Nigeria 'Ebola-free'

  Sept. 24, 2014

• CDC: Dire outlook for Ebola in West Africa

  Sept. 24, 2014

• Collaborating with Chinese pharma: Inside one company's success story

  Sept. 23, 2014

• Does this month mark the beginning of a new era in cancer care?

  Sept. 23, 2014

• Wales NHS approves Celgene's Abraxane for pancreatic cancer

  Sept. 23, 2014

• UK public health advocates: Boys need HPV vaccine, too

  Sept. 23, 2014

• Merck KGaA buys lab supplies manufacturer in major $17 billion deal

  Sept. 23, 2014

• Amgen seeks FDA approval for breakthrough orphan leukemia drug

  Sept. 23, 2014

• India's Sun Pharma, Merck pen unique $80M development deal

  Sept. 22, 2014

• Study: Just one dose of antidepressant changes brain connectivity

  Sept. 22, 2014

• AZ's new formulation performs well in phase III diabetes study

  Sept. 22, 2014

• Gilead's Zydelig approved in the EU for rare blood cancers

  Sept. 22, 2014

• Pharma breathes a sigh of relief as Scots say 'No' to independence

  Sept. 19, 2014

• President Obama issues Executive Order to combat antibiotic resistance

  Sept. 19, 2014

• NICE approves comprehensive funding for GSK melanoma drug Tafinlar

  Sept. 19, 2014

• NICE agrees to fund Janssen's Olysio for hep C

  Sept. 19, 2014

• Bayer to spin off material science division into separate company

  Sept. 19, 2014

• Pfizer nabs exclusive option for MedGenesis Parkinson's treatment

  Sept. 18, 2014

• Denovo snaps up Lilly's failed cancer drug for undisclosed price

  Sept. 18, 2014

• Endo bids $2.2 billion for Auxilium

  Sept. 18, 2014

• Sanofi, MyoKardia team up to take on cardiomyopathy

  Sept. 18, 2014

• Gilead's pancreatic cancer hopeful crashes in phase II

  Sept. 18, 2014

• ICYMI: How one Shanghai pharma became a model for malaria drug production

  Sept. 18, 2014

• EU approves updated and expanded Gardasil labeling

  Sept. 17, 2014

• UK approves first therapy under new fast-track access program

  Sept. 17, 2014

• AstraZeneca's opioid constipation drug wins US approval

  Sept. 17, 2014

• AstraZeneca, Lilly plan sprint to Alzheimer's drug development

  Sept. 17, 2014

• Recordati to market Plethora's premature ejaculation spray

  Sept. 17, 2014

• Shire's ADHD blockbuster Vyvanse scores priority review for binge eating disorder

  Sept. 16, 2014

• FDA panel recommends NPS Pharma's orphan drug Naptara

  Sept. 16, 2014

• Avanir Pharma soars to 8-year high on positive Alzheimer's drug results

  Sept. 16, 2014

• Roche starts phase III trials for advanced wet AMD drug

  Sept. 16, 2014

• Roche's cheaper vision loss drug just as effective as Novartis' Lucentis

  Sept. 16, 2014

• Asterias, Cancer Research UK to collaborate on lung cancer vaccine

  Sept. 15, 2014

• FDA panel recommendation paves way for Novo Nordisk obesity drug approval

  Sept. 15, 2014

• Dompé bullish on novel eye disease treatment

  Sept. 15, 2014

• Baxter's once-monthly Hyqvia for immune disorders wins FDA approval

  Sept. 15, 2014

• Advocates furious over EU decision to cede authority back to pharma

  Sept. 15, 2014

• R&D update: PhRMA and BHA provide insight into HIV/AIDS pipeline

  Sept. 12, 2014

• Genmab partners with Seattle Genetics for exclusive use of ADCs

  Sept. 12, 2014

• Report: Psoriatic arthritis market to cross $3.7 billion by 2023

  Sept. 12, 2014

• EMA approves first-ever insulin biosimilar, Lilly/BI's Abrasia

  Sept. 12, 2014

• FDA panel cautiously supports polypill

  Sept. 11, 2014

• FDA approves expanded use of Xtandi for prostate cancer

  Sept. 11, 2014

• NICE demands more transparency from pharma

  Sept. 11, 2014

• Severe misconduct: Hyperion and Evotec halt diabetes drug trial

  Sept. 11, 2014

• New statin guidelines: Thoughts from a physician on the front lines

  Sept. 11, 2014

• Pfizer and Astellas Pharma to no longer co-distribute Caduet in Japan

  Sept. 10, 2014

• A good deal for Roche just got better: Intermune reports new Esbriet data

  Sept. 10, 2014

• Astrazeneca not deterred when COPD drug fails to meet primary endpoints

  Sept. 10, 2014

• FTC files first-ever 'pay-for-delay' lawsuit against Teva, AbbVie

  Sept. 9, 2014

• NICE rejects Celgene's Abraxane for pancreatic cancer

  Sept. 9, 2014

• Advanced Cell Tech scores US patent for dendritic cell manufacturing

  Sept. 9, 2014

• BMS sues Merck over historic PD-1 cancer drug Keytruda

  Sept. 9, 2014

• Report: Government-supported cancer services at risk in the UK

  Sept. 9, 2014

• The statin stumper: Are new cholesterol guidelines prudent or overzealous?

  Sept. 9, 2014

• Wellspring acquires OTC motion sickness drug

  Sept. 8, 2014

• Game on: Novartis' COPD drug bests GSK blockbuster in phase III trials

  Sept. 8, 2014

• Servier slammed for withholding antidepressant trial data

  Sept. 8, 2014

• FDA gives a qualified 'yes' to Keryx's chronic kidney disease drug

  Sept. 8, 2014

• FDA approves first-ever kidney injury diagnostic NephroCheck

  Sept. 8, 2014

• AbbVie and Infinity to collaborate on blood cancer treatment

  Sept. 5, 2014

• History is made: FDA approves Merck's PD-1 inhibitor Keytruda for melanoma

  Sept. 5, 2014

• Teamwork: Pfizer to promote Novartis' COPD drugs in the UK

  Sept. 5, 2014

• Viiv's 3-in-1 HIV combo drug Triumeq nabs European marketing authorization

  Sept. 5, 2014

• Facing patent expirations, Teva launches patient-centric MS e-health site

  Sept. 5, 2014

• BMS opts out of RA drug deal with Alder Biopharmaceuticals

  Sept. 4, 2014

• AZ, RedX Pharma to collaborate on genetic oncology research

  Sept. 4, 2014

• NICE reverses course, says 'yes' to Alexion's pricey Soliris

  Sept. 4, 2014

• Roche cuts jobs in Spain in response to price controls

  Sept. 4, 2014

• EU expands use of Allergan's Ozurdex again

  Sept. 4, 2014

• AstraZeneca's Brilinta falls short in phase IV study

  Sept. 3, 2014

• Florida researchers: Marijuana may be key to Alzheimer's treatment

  Sept. 3, 2014

• Belgium-based Ablynx pens development deal with China's Eddingpharm

  Sept. 3, 2014

• BI's Ohio plant plagued by continuing woes

  Sept. 3, 2014

• Novo Nordisk walks away from inflammatory disease R&D

  Sept. 3, 2014

• Exelixis prostate cancer drug falls flat in trials, prompts massive layoffs

  Sept. 2, 2014

• AZ's PD-1 immunotherapy drug advances in colorectal cancer studies

  Sept. 2, 2014

• Novartis soars on groundbreaking heart failure drug trial results

  Sept. 2, 2014

• Sanofi, Regeneron reveal positive data from alirocumab cholesterol trials

  Sept. 2, 2014

• 10-year data show no link between Actos and bladder cancer risk

  Sept. 2, 2014

• Amgen files first-in-class cholesterol drug with FDA

  Aug. 29, 2014

• Amgen scores priority review for chronic heart failure drug

  Aug. 29, 2014

• Could low-dose aspirin be a cheaper alternative to anti-clotting drugs?

  Aug. 29, 2014

• Final guidance: NICE recommends Biogen Idec's Tecfidera for RRMS

  Aug. 29, 2014

• NICE sounds costs concerns over BI's Jardiance, requests more data

  Aug. 29, 2014

• The biosimilars are coming: Tackling uncertainty and interchangeability

  Aug. 28, 2014

• EU approves BMS's Daklinza for hep C combo therapy

  Aug. 28, 2014

• Does Gilead have its sights set on Achillion Pharma?

  Aug. 28, 2014

• Velphoro wins EU approval for treating hyperphosphalemia

  Aug. 28, 2014

• GSK's Promacta scores FDA approval for rare bone marrow disorder

  Aug. 28, 2014

• Alexion reprimanded for lax manufacturing practices

  Aug. 27, 2014

• The biosimilars are coming: Why Basaglar and Zarzio are harbingers of a new pharma landscape

  Aug. 27, 2014

• Pfizer, Merck team up to develop metastatic cancer immunotherapy

  Aug. 27, 2014

• AZ, Illumina join forces to develop companion diagnostic tests for cancer drugs

  Aug. 27, 2014

• FDA approves Iroko's Zorvolex for treatment of osteoarthritis pain

  Aug. 27, 2014

• MultiCell Tech scores patent for cancer-fighting immunotherapy platform

  Aug. 27, 2014

• Alexion vies to add another eculizumab indication with kidney graft trial

  Aug. 27, 2014

• Mylan introduces generic of Upsher-Smith's Klor-Con

  Aug. 26, 2014

• J&J's Janssen buys Covagen

  Aug. 26, 2014

• EMA prepares to review new Cubist antibiotic

  Aug. 26, 2014

• Merck, Advaxis partner up on prostate cancer research

  Aug. 26, 2014

• Actavis, UCB Pharma butt heads over generic Neupro

  Aug. 26, 2014

• Pfizer, GSK's Viiv Healthcare nabs FDA approval for 3-in-1 HIV drug

  Aug. 25, 2014

• Experts call for an end to alternative medicine clinical trials

  Aug. 25, 2014

• Auxilium's CCH reduces cellulite in phase IIa trial

  Aug. 25, 2014

• J&J pursues stem cell diabetes deal with ViaCyte

  Aug. 25, 2014

• Lilly's psoriasis drug scores big in phase III trials

  Aug. 25, 2014

• Migalastat generates positive phase III results in Fabry patients

  Aug. 22, 2014

• Novartis-funded study shows 75% of asthmatics are at risk

  Aug. 22, 2014

• Jordan-based Hikma Pharma posts strong results amidst regional turmoil

  Aug. 22, 2014

• Illumina to provide personalized oncology diagnostics for big-pharma studies

  Aug. 22, 2014

• Pfizer, BMS score FDA hat-trick with another Eliquis approval

  Aug. 22, 2014

• FDA approves GSK asthma inhaler Arnuity Ellipta

  Aug. 21, 2014

• Novartis buys stake in Israeli stem-cell company

  Aug. 21, 2014

• NICE reverses course, recommends Celgene's Revlimid for rare MDS form

  Aug. 21, 2014

• Apricus Biosciences launches topical ED treatment in Germany

  Aug. 20, 2014

• Amgen kidney drug for dialysis patients hits phase III targets again

  Aug. 20, 2014

• Lilly, Boehringer win tentative FDA approval for Sanofi diabetes biosimilar

  Aug. 20, 2014

• Novo hit with fine for stalling Tresiba rejection disclosure

  Aug. 20, 2014

• Analysts: Transition to generic antidepressants will be offset by new options

  Aug. 20, 2014

• Pfizer files NDA for breast cancer breakthrough therapy

  Aug. 19, 2014

• Sanofi gears up for mass production of malaria drug

  Aug. 19, 2014

• US Justice Department stops investigation of AstraZeneca's Brilinta trial

  Aug. 19, 2014

• Eisai files thyroid cancer drug in US, EU

  Aug. 19, 2014

• Advocates slam NICE, Janssen over prostate cancer drug 'fiasco'

  Aug. 19, 2014

• Jilting generics: Part 2 of an exclusive interview with GPhA CEO Ralph Neas

  Aug. 17, 2014

• FDA committee recommends approval of Boehringer COPD drug

  Aug. 17, 2014

• Turkish citizens arrested for selling fake cancer drugs

  Aug. 17, 2014

• Amgen's multiple myeloma drug fails in phase III single-drug study

  Aug. 15, 2014

• Word on the street: IPF drug maker InterMune is taking bids

  Aug. 15, 2014

• UK's NICE gives Gilead's Sovaldi a qualified 'yes'

  Aug. 15, 2014

• FDA approves Avastin for treatment of metastatic cervical cancer

  Aug. 15, 2014

• Debt-ridden Dendreon struggles to stay afloat

  Aug. 14, 2014

• AstraZeneca's severe asthma drug breezes into phase III trials

  Aug. 14, 2014

• Roche backs out of $600 million development deal with Chiasma

  Aug. 14, 2014

• Jilting generics: Part 1 of an exclusive interview with GPhA CEO Ralph Neas

  Aug. 14, 2014

• Pfizer, 23andMe team up to study the genetics of bowel disease

  Aug. 14, 2014

• Celltrion submits FDA filing for biosimilar Remicade

  Aug. 14, 2014

• AstraZeneca drug routs gout in phase III trials

  Aug. 13, 2014

• Indiana University research team discovers new heart molecule

  Aug. 13, 2014

• Falling sales, Sovaldi force Vertex to ditch hep C drug

  Aug. 13, 2014

• Boehringer to slash global workforce as earnings fall

  Aug. 13, 2014

• Intercept Pharma's shares fly high on positive liver drug results

  Aug. 12, 2014

• Boehringer sales fall, but long-term prospects look good

  Aug. 12, 2014

• Does faster regulatory approval translate into safety problems?

  Aug. 12, 2014

• FDA green lights J&J's 2-in-1 diabetes drug

  Aug. 12, 2014

• EU launches landmark decentralized generic drug approval pilot program

  Aug. 11, 2014

• UK regulators say Roche's Kadcyla is too expensive

  Aug. 11, 2014

• Astellas, Cancer Research Technology team up for pancreatic cancer research

  Aug. 11, 2014

• Sex, drugs, and bribes: More on GSK's Chinese misadventures

  Aug. 11, 2014

• Another perspective on Sovaldi: Spend more now, save much more later

  Aug. 8, 2014

• EMA green lights Pfizer bid to broaden pneumonia vaccine use

  Aug. 8, 2014

• Sarepta Therapeutics urges government to approve its Ebola drug

  Aug. 8, 2014

• AbbVie-Shire, other inversions on the chopping block as government mulls action

  Aug. 8, 2014

• FDA approves another antibacterial drug for skin infections

  Aug. 8, 2014

• Actelion focusing on patient experience through PatientsLikeMe initiative

  Aug. 7, 2014

• Cytori's stock plummets as stem-cell clinical trials are halted

  Aug. 7, 2014

• Pfizer to pay $35 million in Rapamune settlement

  Aug. 7, 2014

• Pfizer's Enbrel approved in the EU for rare inflammatory disease

  Aug. 7, 2014

• EU approves Avastin for recurrent ovarian cancer

  Aug. 7, 2014

• Can an aspirin a day keep the cancers away?

  Aug. 6, 2014

• Australia's drug regulator says Pradaxa safety advice will not change

  Aug. 6, 2014

• Roche to buy Santaris, add gene-silencing research to its portfolio

  Aug. 6, 2014

• UK to fund Roche's cash-saving cancer injection

  Aug. 6, 2014

• AbbVie's glioblastoma drug granted orphan status in US, EU

  Aug. 6, 2014

• Prevention efforts critical as HIV stigma falls

  Aug. 5, 2014

• Pfizer locks out workers at Indian manufacturing plant

  Aug. 5, 2014

• Amgen's multiple myeloma drug meets phase III targets

  Aug. 5, 2014

• Analysts: Pfizer may have its sights set on GSK

  Aug. 5, 2014

• EU broadens target population for life-saving cystic fibrosis drug

  Aug. 5, 2014

• BMS and Allied Minds team up to turn academic research into a clinical reality

  Aug. 5, 2014

• Postdoctoral fellow admits to faking Novartis brain tumor study results

  Aug. 4, 2014

• High-dose estrogen birth control may increase breast cancer risk, study finds

  Aug. 4, 2014

• FDA expands use of Genzyme's Pompe disease treatment for young children

  Aug. 4, 2014

• FDA approves Boehringer/Eli Lilly Alliance type 2 diabetes drug

  Aug. 4, 2014

• NICE gives Celgene's myeloma treatment the cold shoulder

  July 31, 2014

• PCI to acquire Penn Pharma

  July 31, 2014

• Gilead scores exclusive licensing rights for Theraclone's HIV antibodies

  July 31, 2014

• Adamis tries to make its mark with low-cost epinephrine injector

  July 31, 2014

• Sunshine Biopharma seeks global market through new Canadian subsidiary

  July 31, 2014

• AZ buys rights to Almirall's respiratory portfolio in $2.1 billion deal

  July 31, 2014

• GSK's once-weekly diabetes injection launches in U.S. pharmacies

  July 31, 2014

• FDA approves Eylea for treatment of DME

  July 31, 2014

• Merck outperforms second-quarter expectations as earnings surge

  July 30, 2014

• Pfizer's Q2 earnings-per-share rise despite plummeting revenues

  July 30, 2014

• Novartis' Simbrinza approved for glaucoma treatment in the EU

  July 30, 2014

• Generic drug use is saving UK's NHS $21 billion per year

  July 30, 2014

• US-based Alimera Sciences gets approval to market Iluvien in Norway

  July 30, 2014